{
  "questions": [
    {
      "id": "65d3715b1930410b13000046",
      "type": "yesno",
      "body": "Is Durvalumab effective for locally advanced cervical cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
        "http://www.ncbi.nlm.nih.gov/pubmed/37445743",
        "http://www.ncbi.nlm.nih.gov/pubmed/32447296",
        "http://www.ncbi.nlm.nih.gov/pubmed/32774270",
        "http://www.ncbi.nlm.nih.gov/pubmed/25033678",
        "http://www.ncbi.nlm.nih.gov/pubmed/11176235",
        "http://www.ncbi.nlm.nih.gov/pubmed/16093801",
        "http://www.ncbi.nlm.nih.gov/pubmed/35142642",
        "http://www.ncbi.nlm.nih.gov/pubmed/36640944",
        "http://www.ncbi.nlm.nih.gov/pubmed/32522774"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
          "text": "INTERPRETATION: Durvalumab concurrent with chemoradiotherapy was well tolerated in participants with locally advanced cervical cancer, however it did not significantly improve progression-free survival in a biomarker unselected, all-comers population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 3283,
          "endSection": "abstract",
          "offsetInEndSection": 3534
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37445743",
          "text": "This phase 1b trial demonstrates the safety of combining chemo-CIRT and durvalumab for locally advanced cervical cancer in the early phase. Further research is required as only three patients were included in this study.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1117,
          "endSection": "abstract",
          "offsetInEndSection": 1337
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
          "text": "Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 137
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
          "text": "We assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 334,
          "endSection": "abstract",
          "offsetInEndSection": 472
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
          "text": "We assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer. METHODS\nThe CALLA randomised, double-blind, phase 3 trial included 105 hospitals across 15 countries.",
          "beginSection": "abstract",
          "offsetInBeginSection": 334,
          "endSection": "abstract",
          "offsetInEndSection": 576
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37445743",
          "text": "Patients with newly diagnosed histologically proven locally advanced cervical cancer were enrolled. All patients received 74.4 Gy of CIRT in 20 fractions and concurrent weekly cisplatin (chemo-CIRT) at a dose of 40 mg/m2. Durvalumab was administered (1500 mg/body) at weeks two and six.",
          "beginSection": "abstract",
          "offsetInBeginSection": 255,
          "endSection": "abstract",
          "offsetInEndSection": 541
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
          "text": "INTERPRETATION\nDurvalumab concurrent with chemoradiotherapy was well tolerated in participants with locally advanced cervical cancer, however it did not significantly improve progression-free survival in a biomarker unselected, all-comers population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 3289,
          "endSection": "abstract",
          "offsetInEndSection": 3539
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37445743",
          "text": "All three patients achieved complete responses within the CIRT region concerning treatment efficacy. This phase 1b trial demonstrates the safety of combining chemo-CIRT and durvalumab for locally advanced cervical cancer in the early phase. Further research is required as only three patients were included in this study.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1016,
          "endSection": "abstract",
          "offsetInEndSection": 1337
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37445743",
          "text": "This phase 1b trial demonstrates the safety of combining chemo-CIRT and durvalumab for locally advanced cervical cancer in the early phase.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1117,
          "endSection": "abstract",
          "offsetInEndSection": 1256
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
          "text": "We assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer. METHODS\nThe CALLA randomised, double-blind, phase 3 trial included 105 hospitals across 15 countries. Patients aged at least 18 years with previously untreated locally advanced cervical cancer (adenocarcinoma, squamous, or adenosquamous; International Federation of Gynaecology and Obstetrics [FIGO] 2009 stage IB2-IIB lymph node positive, stage ≥III any lymph node status) and WHO or Eastern Cooperative Oncology Group performance status of 0 or 1 were randomly assigned (1:1) through an interactive web response system using a permuted block size of 4 to receive durvalumab (1500 mg intravenously once every 4 weeks) or placebo with and following chemoradiotherapy, for up to 24 cycles.",
          "beginSection": "abstract",
          "offsetInBeginSection": 334,
          "endSection": "abstract",
          "offsetInEndSection": 1163
        }
      ],
      "ideal_answer": "No, Durvalumab is not effective for locally advanced cervical cancer. The CALLA randomised, double-blind, phase 3 trial found that Durvalumab concurrent with chemoradiotherapy was well tolerated in participants with locally advanced cervical cancer, however it did not significantly improve progression-free survival in a biomarker unselected, all-comers population.",
      "exact_answer": "no"
    },
    {
      "id": "66099c57fdcbea915f000025",
      "type": "list",
      "body": "What clinical conditions influence the prognostic after the liver metastasis resection from colorectal cancer patients?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/10493478",
        "http://www.ncbi.nlm.nih.gov/pubmed/18953839",
        "http://www.ncbi.nlm.nih.gov/pubmed/26421789",
        "http://www.ncbi.nlm.nih.gov/pubmed/23979110",
        "http://www.ncbi.nlm.nih.gov/pubmed/26404693",
        "http://www.ncbi.nlm.nih.gov/pubmed/27621747",
        "http://www.ncbi.nlm.nih.gov/pubmed/15029391",
        "http://www.ncbi.nlm.nih.gov/pubmed/3386073",
        "http://www.ncbi.nlm.nih.gov/pubmed/14598428",
        "http://www.ncbi.nlm.nih.gov/pubmed/19366082"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23979110",
          "text": "PURPOSE\nWe investigated the predictive indicator for a good prognosis of surgical resection for liver metastasis of colorectal cancer. METHOD\nBetween 1990 and 2009 at our institute, 117 patients underwent 132 hepatic resections for liver metastasis of colorectal cancer. The clinical, pathological, and outcome parameters affecting their prognoses were analyzed.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 364
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23979110",
          "text": "METHOD\nBetween 1990 and 2009 at our institute, 117 patients underwent 132 hepatic resections for liver metastasis of colorectal cancer. The clinical, pathological, and outcome parameters affecting their prognoses were analyzed.",
          "beginSection": "abstract",
          "offsetInBeginSection": 137,
          "endSection": "abstract",
          "offsetInEndSection": 364
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421789",
          "text": "Prognostic Factors after Liver Resection for Colorectal Liver Metastasis.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 73
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421789",
          "text": "Although many studies have been performed to determine prognostic factors for tumor recurrence and survival after resection of colorectal liver metastases, there are few prognostic scoring systems stratifying patients undergoing surgery for colorectal liver metastases into risk group models.",
          "beginSection": "abstract",
          "offsetInBeginSection": 160,
          "endSection": "abstract",
          "offsetInEndSection": 452
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23979110",
          "text": "Prognostic indicator for the resection of liver metastasis of colorectal cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 80
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421789",
          "text": "Although many studies have been performed to determine prognostic factors for tumor recurrence and survival after resection of colorectal liver metastases, there are few prognostic scoring systems stratifying patients undergoing surgery for colorectal liver metastases into risk group models. OBJECTIVES\nTo identify, evaluate and compare the existing prognostic scores for survival after surgery for resection of colorectal liver metastases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 160,
          "endSection": "abstract",
          "offsetInEndSection": 603
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18953839",
          "text": "[Prognostic factors of colorectal cancer patients with synchronous liver metastasis treated with simultaneous liver and colorectal resection].",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 142
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23979110",
          "text": "PURPOSE\nWe investigated the predictive indicator for a good prognosis of surgical resection for liver metastasis of colorectal cancer. METHOD\nBetween 1990 and 2009 at our institute, 117 patients underwent 132 hepatic resections for liver metastasis of colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 272
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26404693",
          "text": "[Analysis of treatment and prognostic factors in colorectal cancer liver metastasis].",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 85
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26404693",
          "text": "OBJECTIVE\nTo investigate the prognostic factors of colorectal cancer patients with liver metastasis in order to provide reference for clinical practice. METHODS\nClinicopathological and follow-up data of 264 cases of colorectal liver metastasis in our department from January 1997 to January 2012 were analyzed retrospectively.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 328
        }
      ],
      "ideal_answer": "Clinical conditions that influence the prognostic after the liver metastasis resection from colorectal cancer patients include synchronous liver metastasis and tumor recurrence.",
      "exact_answer": [
        [
          "synchronous liver metastasis"
        ],
        [
          "tumor recurrence"
        ],
        [
          "survival"
        ]
      ]
    },
    {
      "id": "661be07748a2c27714000002",
      "type": "summary",
      "body": "What is Lennox-Gastaut syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37353676",
        "http://www.ncbi.nlm.nih.gov/pubmed/37054522",
        "http://www.ncbi.nlm.nih.gov/pubmed/36700706",
        "http://www.ncbi.nlm.nih.gov/pubmed/11918467",
        "http://www.ncbi.nlm.nih.gov/pubmed/11952036",
        "http://www.ncbi.nlm.nih.gov/pubmed/28689466",
        "http://www.ncbi.nlm.nih.gov/pubmed/3071644",
        "http://www.ncbi.nlm.nih.gov/pubmed/3742825",
        "http://www.ncbi.nlm.nih.gov/pubmed/8029151",
        "http://www.ncbi.nlm.nih.gov/pubmed/8174524"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37353676",
          "text": "Lennox-Gastaut syndrome is a severe drug-resistant developmental and epileptic encephalopathy with slow spike and wave on EEG (DEE-SSW) composing about 1-2% of epilepsy patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 178
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37353676",
          "text": "Lennox-Gastaut syndrome is a severe drug-resistant developmental and epileptic encephalopathy with slow spike and wave on EEG (DEE-SSW) composing about 1-2% of epilepsy patients. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 179
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37353676",
          "text": "Lennox-Gastaut syndrome is a severe drug-resistant developmental and epileptic encephalopathy with slow spike and wave on EEG (DEE-SSW) composing about 1-2% of epilepsy patients. Seizures in DEE-SSW are caused by a variety of etiologies, and there is a large unmet treatment need as seizures are usually treatment-resistant and individuals are often unable to function independently.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 383
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37353676",
          "text": "Lennox-Gastaut syndrome is a severe drug-resistant developmental and epileptic encephalopathy with slow spike and wave on EEG (DEE-SSW) composing about 1-2% of epilepsy patients. Seizures in DEE-SSW are caused by a variety of etiologies, and there is a large unmet treatment need as seizures are usually treatment-resistant and individuals are often unable to function independently. The updated definition by the International League Against Epilepsy has established formal diagnostic criteria allowing for more uniform diagnosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 531
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28689466",
          "text": "Lennox-Gastaut syndrome (LGS) is a severe form of childhood-onset epilepsy associated with high morbidity and mortality. The peak period for manifestations of Lennox-Gastaut syndrome is between ages 3 and 5 years, a time of critical brain development and corresponding vulnerability to the electroclinical dysfunction arising from Lennox-Gastaut syndrome. Diagnosis is based on a triad of symptoms: multiple seizure types, cognitive impairment, and slow spike-and-wave pattern on electroencephalography.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 503
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28689466",
          "text": "Lennox-Gastaut syndrome (LGS) is a severe form of childhood-onset epilepsy associated with high morbidity and mortality. The peak period for manifestations of Lennox-Gastaut syndrome is between ages 3 and 5 years, a time of critical brain development and corresponding vulnerability to the electroclinical dysfunction arising from Lennox-Gastaut syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 355
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28689466",
          "text": "Lennox-Gastaut syndrome (LGS) is a severe form of childhood-onset epilepsy associated with high morbidity and mortality.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 120
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11918467",
          "text": "Lennox-Gastaut syndrome is a type of childhood epilepsy that has enormous detrimental effects on the patient's physical and developmental health and can also take a dramatic toll on the well-being of the patient's family. Lennox-Gastaut syndrome is characterized by variable etiology, multiple types of intractable seizures, and cognitive impairment in most patients. It is one of the most difficult epilepsy syndromes to treat and is frequently resistant to treatment with standard antiepilepsy drugs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 502
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11918467",
          "text": "Lennox-Gastaut syndrome is a type of childhood epilepsy that has enormous detrimental effects on the patient's physical and developmental health and can also take a dramatic toll on the well-being of the patient's family. Lennox-Gastaut syndrome is characterized by variable etiology, multiple types of intractable seizures, and cognitive impairment in most patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 367
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11918467",
          "text": "Lennox-Gastaut syndrome is characterized by variable etiology, multiple types of intractable seizures, and cognitive impairment in most patients. It is one of the most difficult epilepsy syndromes to treat and is frequently resistant to treatment with standard antiepilepsy drugs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 222,
          "endSection": "abstract",
          "offsetInEndSection": 502
        }
      ],
      "ideal_answer": "Lennox-Gastaut syndrome (LGS) is a severe, drug-resistant developmental and epileptic encephalopathy that affects about 1-2% of epilepsy patients. It is characterized by slow spike and wave patterns on EEG and is often associated with a range of underlying aetiologies, making it a'secondary network epilepsy'.",
      "exact_answer": "n/a"
    },
    {
      "id": "6616547dfdcbea915f00004f",
      "type": "factoid",
      "body": "What is the prevalence of neurofibromatosis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37710322",
        "http://www.ncbi.nlm.nih.gov/pubmed/1523507",
        "http://www.ncbi.nlm.nih.gov/pubmed/24659732",
        "http://www.ncbi.nlm.nih.gov/pubmed/22832780",
        "http://www.ncbi.nlm.nih.gov/pubmed/27519821",
        "http://www.ncbi.nlm.nih.gov/pubmed/37816254",
        "http://www.ncbi.nlm.nih.gov/pubmed/24065580",
        "http://www.ncbi.nlm.nih.gov/pubmed/25208116",
        "http://www.ncbi.nlm.nih.gov/pubmed/2518509",
        "http://www.ncbi.nlm.nih.gov/pubmed/9880138"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37816254",
          "text": "In adult patients with neurofibromatosis, 46.5% were found to have at least one psychiatric comorbid diagnosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1338,
          "endSection": "abstract",
          "offsetInEndSection": 1449
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27519821",
          "text": "Prevalence of neurofibromatosis type 1 in congenital pseudarthrosis of the tibia.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 81
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27519821",
          "text": "• Literature focus is mainly on treatment and little epidemiologic research is available. What is New: • Prevalence of neurofibromatosis type 1 in patient with congenital pseudarthrosis of the tibia might be higher than what is reported until now.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1271,
          "endSection": "abstract",
          "offsetInEndSection": 1518
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27519821",
          "text": "What is New: • Prevalence of neurofibromatosis type 1 in patient with congenital pseudarthrosis of the tibia might be higher than what is reported until now.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1361,
          "endSection": "abstract",
          "offsetInEndSection": 1518
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1523507",
          "text": "Prevalence of scoliosis in neurofibromatosis.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 45
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37816254",
          "text": "In adult patients with neurofibromatosis, 46.5% were found to have at least one psychiatric comorbid diagnosis. The most frequent psychiatric comorbid disorders were mood disorders and anxiety disorders. Female sex and non-White race predicted a lower likelihood of having a psychiatric disorder.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1338,
          "endSection": "abstract",
          "offsetInEndSection": 1634
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37816254",
          "text": "In adult patients with neurofibromatosis, 46.5% were found to have at least one psychiatric comorbid diagnosis. The most frequent psychiatric comorbid disorders were mood disorders and anxiety disorders.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1338,
          "endSection": "abstract",
          "offsetInEndSection": 1541
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1523507",
          "text": "The authors believe that 10% is representative of the true prevalence of spinal deformity in an otherwise unselected cross section of neurofibromatosis patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 763,
          "endSection": "abstract",
          "offsetInEndSection": 924
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37816254",
          "text": "To assess the prevalence of psychiatric comorbidities in patients with neurofibromatosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 89
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27519821",
          "text": "What is New: • Prevalence of neurofibromatosis type 1 in patient with congenital pseudarthrosis of the tibia might be higher than what is reported until now. • A multidisciplinary approach with meticulous clinical examination and genetic counseling might lead to an earlier diagnosis of neurofibromatosis type 1 in patients with congenital pseudarthrosis of the tibia.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1361,
          "endSection": "abstract",
          "offsetInEndSection": 1729
        }
      ],
      "ideal_answer": "The prevalence of neurofibromatosis is estimated to be around 10% in the general population.",
      "exact_answer": [
        "10%"
      ]
    },
    {
      "id": "661d96c9eac11fad33000028",
      "type": "factoid",
      "body": "What is the key transcription factor for melanocyte development and differentiation?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
        "http://www.ncbi.nlm.nih.gov/pubmed/16140982",
        "http://www.ncbi.nlm.nih.gov/pubmed/18703590",
        "http://www.ncbi.nlm.nih.gov/pubmed/11851873",
        "http://www.ncbi.nlm.nih.gov/pubmed/7478537",
        "http://www.ncbi.nlm.nih.gov/pubmed/30515787",
        "http://www.ncbi.nlm.nih.gov/pubmed/15250933",
        "http://www.ncbi.nlm.nih.gov/pubmed/19081068",
        "http://www.ncbi.nlm.nih.gov/pubmed/10080955",
        "http://www.ncbi.nlm.nih.gov/pubmed/9012511"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
          "text": "Microphthalmia-associated transcription factor (MITF) is a key transcription factor for melanocyte development and differentiation. MITF regulates expression of numerous pigmentation genes to promote melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis, including genes encoding proteins involved in apoptosis (eg, BCL2) and the cell cycle (eg, CDK2).",
          "beginSection": "abstract",
          "offsetInBeginSection": 141,
          "endSection": "abstract",
          "offsetInEndSection": 529
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
          "text": "Microphthalmia-associated transcription factor (MITF) is a key transcription factor for melanocyte development and differentiation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 141,
          "endSection": "abstract",
          "offsetInEndSection": 272
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
          "text": "Certain transcription factors have vital roles in lineage development, including specification of cell types and control of differentiation. Microphthalmia-associated transcription factor (MITF) is a key transcription factor for melanocyte development and differentiation. MITF regulates expression of numerous pigmentation genes to promote melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis, including genes encoding proteins involved in apoptosis (eg, BCL2) and the cell cycle (eg, CDK2).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 529
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
          "text": "Certain transcription factors have vital roles in lineage development, including specification of cell types and control of differentiation. Microphthalmia-associated transcription factor (MITF) is a key transcription factor for melanocyte development and differentiation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 272
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16140982",
          "text": "Microphthalmia-associated transcription factor (MITF) M-form is a melanocyte-specific transcription factor that plays a key role in melanocyte development, survival, and differentiation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 186
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
          "text": "Microphthalmia-associated transcription factor (MITF) is a key transcription factor for melanocyte development and differentiation. MITF regulates expression of numerous pigmentation genes to promote melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis, including genes encoding proteins involved in apoptosis (eg, BCL2) and the cell cycle (eg, CDK2). Loss-of-function mutations of MITF cause Waardenburg syndrome type IIA, whose phenotypes include depigmentation due to melanocyte loss, whereas amplification or specific mutation of MITF can be an oncogenic event that is seen in a subset of familial or sporadic melanomas.",
          "beginSection": "abstract",
          "offsetInBeginSection": 141,
          "endSection": "abstract",
          "offsetInEndSection": 802
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18703590",
          "text": "The transcription factor Sox5 modulates Sox10 function during melanocyte development.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 85
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16140982",
          "text": "Microphthalmia-associated transcription factor (MITF) M-form is a melanocyte-specific transcription factor that plays a key role in melanocyte development, survival, and differentiation. Here, we identified MITF as a new substrate of caspases and we characterized the cleavage site after Asp 345 in the C-terminal domain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 321
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7478537",
          "text": "Given the role of octamer-binding proteins in cell differentiation and development, the role this factor is a key issue in understanding melanocyte differentiation and transformation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 93,
          "endSection": "abstract",
          "offsetInEndSection": 276
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16140982",
          "text": "Microphthalmia-associated transcription factor (MITF) M-form is a melanocyte-specific transcription factor that plays a key role in melanocyte development, survival, and differentiation. Here, we identified MITF as a new substrate of caspases and we characterized the cleavage site after Asp 345 in the C-terminal domain. We show that expression of a noncleavable form of MITF renders melanoma cells resistant to apoptotic stimuli, and we found that the C-terminal fragment generated upon caspase cleavage is endowed with a proapoptotic activity that sensitizes melanoma cells to death signals.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 594
        }
      ],
      "ideal_answer": "Microphthalmia-associated transcription factor (MITF) is the key transcription factor for melanocyte development and differentiation.",
      "exact_answer": [
        "Microphthalmia-associated transcription factor"
      ]
    },
    {
      "id": "661d48a2eac11fad33000018",
      "type": "factoid",
      "body": "What is the cause of Phenylketonuria (PKU)?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35356682",
        "http://www.ncbi.nlm.nih.gov/pubmed/27014571",
        "http://www.ncbi.nlm.nih.gov/pubmed/33806544",
        "http://www.ncbi.nlm.nih.gov/pubmed/1677790",
        "http://www.ncbi.nlm.nih.gov/pubmed/3308176",
        "http://www.ncbi.nlm.nih.gov/pubmed/30364670",
        "http://www.ncbi.nlm.nih.gov/pubmed/1915521",
        "http://www.ncbi.nlm.nih.gov/pubmed/3310139",
        "http://www.ncbi.nlm.nih.gov/pubmed/1959225",
        "http://www.ncbi.nlm.nih.gov/pubmed/15370336"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27014571",
          "text": "Phenylketonuria (PKU) is a rare metabolic disorder characterized by impaired conversion of phenylalanine (Phe) to tyrosine. If left untreated, the resultant accumulation of excess blood Phe can cause physiological, neurological, and intellectual disabilities.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 259
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27014571",
          "text": "Phenylketonuria (PKU) is a rare metabolic disorder characterized by impaired conversion of phenylalanine (Phe) to tyrosine. If left untreated, the resultant accumulation of excess blood Phe can cause physiological, neurological, and intellectual disabilities. The National PKU Alliance (NPKUA) conducted a survey of its membership to assess current health status and interest in new treatments for PKU.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 402
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27014571",
          "text": "Phenylketonuria (PKU) is a rare metabolic disorder characterized by impaired conversion of phenylalanine (Phe) to tyrosine.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 123
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1677790",
          "text": "In phenylketonuria (PKU) usually there is a defect in the phenylalanine hydroxylase (PAH) gene.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 95
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33806544",
          "text": "Phenylketonuria (PKU) is an inborn error of phenylalanine metabolism primarily treated through a phenylalanine-restrictive diet that is frequently supplemented with an amino acid formula to maintain proper nutrition. Little is known of the effects of these dietary interventions on the gut microbiome of PKU patients, particularly in adults.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 341
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33806544",
          "text": "Phenylketonuria (PKU) is an inborn error of phenylalanine metabolism primarily treated through a phenylalanine-restrictive diet that is frequently supplemented with an amino acid formula to maintain proper nutrition.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 216
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33806544",
          "text": "Phenylketonuria (PKU) is an inborn error of phenylalanine metabolism primarily treated through a phenylalanine-restrictive diet that is frequently supplemented with an amino acid formula to maintain proper nutrition. Little is known of the effects of these dietary interventions on the gut microbiome of PKU patients, particularly in adults. In this study, we sequenced the V4 region of the 16S rRNA gene from stool samples collected from adults with PKU (n = 11) and non-PKU controls (n = 21).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 494
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1677790",
          "text": "In phenylketonuria (PKU) usually there is a defect in the phenylalanine hydroxylase (PAH) gene. Eight restriction fragment length polymorfisms (RFLP's) in the PAH gene together constitute the haplotype. A considerable number of mutations, responsible for the gene defect, some of which are rather frequent, have been described.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 327
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1677790",
          "text": "In phenylketonuria (PKU) usually there is a defect in the phenylalanine hydroxylase (PAH) gene. Eight restriction fragment length polymorfisms (RFLP's) in the PAH gene together constitute the haplotype.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 202
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3308176",
          "text": "This review points out the very high incidence of damage to the fetus in untreated maternal phenylketonuria (PKU). In classical cases, 92% of the offspring are mentally retarded, 73% have microcephaly, 40% are growth retarded at birth, and 12% have congenital anomalies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 270
        }
      ],
      "ideal_answer": "Phenylketonuria (PKU) is caused by a defect in the PAH gene, which impairs the conversion of phenylalanine (Phe) to tyrosine.",
      "exact_answer": [
        "defect in PAH gene"
      ]
    },
    {
      "id": "65cebc0c1930410b13000003",
      "type": "factoid",
      "body": "Which disease is treated with nirsevimab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36577878",
        "http://www.ncbi.nlm.nih.gov/pubmed/36634694",
        "http://www.ncbi.nlm.nih.gov/pubmed/36599520",
        "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
        "http://www.ncbi.nlm.nih.gov/pubmed/37466917",
        "http://www.ncbi.nlm.nih.gov/pubmed/37095249",
        "http://www.ncbi.nlm.nih.gov/pubmed/37616235",
        "http://www.ncbi.nlm.nih.gov/pubmed/35235726",
        "http://www.ncbi.nlm.nih.gov/pubmed/32726528",
        "http://www.ncbi.nlm.nih.gov/pubmed/37901217"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
          "text": "INTRODUCTION\nNirsevimab, a monoclonal antibody for the prevention of disease caused by respiratory syncytial virus (RSV), has recently been approved for use in Europe and Spain. OBJECTIVES\nTo provide recommendations for the administration of nirsevimab for prevention of RSV disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 285
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
          "text": "INTRODUCTION\nNirsevimab, a monoclonal antibody for the prevention of disease caused by respiratory syncytial virus (RSV), has recently been approved for use in Europe and Spain. OBJECTIVES\nTo provide recommendations for the administration of nirsevimab for prevention of RSV disease. METHODS\nThe approach chosen to develop these recommendations involved a critical review of the literature and the use of the Delphi and GRADE methods.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 438
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
          "text": "INTRODUCTION\nNirsevimab, a monoclonal antibody for the prevention of disease caused by respiratory syncytial virus (RSV), has recently been approved for use in Europe and Spain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 177
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37616235",
          "text": "Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 200
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37616235",
          "text": "Nirsevimab can prevent severe RSV disease among infants and young children at increased risk for severe RSV disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 958,
          "endSection": "abstract",
          "offsetInEndSection": 1074
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
          "text": "RESULTS\nIn the general neonatal population, routine administration of nirsevimab is recommended to reduce the frequency of illness and hospitalisation for bronchiolitis and RSV lower respiratory tract infection.",
          "beginSection": "abstract",
          "offsetInBeginSection": 647,
          "endSection": "abstract",
          "offsetInEndSection": 858
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37616235",
          "text": "In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting monoclonal antibody, for passive immunization to prevent RSV-associated lower respiratory tract infection among infants and young children.",
          "beginSection": "abstract",
          "offsetInBeginSection": 94,
          "endSection": "abstract",
          "offsetInEndSection": 315
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
          "text": "OBJECTIVES\nTo provide recommendations for the administration of nirsevimab for prevention of RSV disease. METHODS\nThe approach chosen to develop these recommendations involved a critical review of the literature and the use of the Delphi and GRADE methods.",
          "beginSection": "abstract",
          "offsetInBeginSection": 180,
          "endSection": "abstract",
          "offsetInEndSection": 438
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36577878",
          "text": "Nirsevimab was approved in the EU on 3 November 2022 and in the UK on 7 November 2022 for the prevention of RSV lower respiratory tract disease in neonates and infants during their first RSV season.",
          "beginSection": "abstract",
          "offsetInBeginSection": 495,
          "endSection": "abstract",
          "offsetInEndSection": 693
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
          "text": "OBJECTIVES\nTo provide recommendations for the administration of nirsevimab for prevention of RSV disease. METHODS\nThe approach chosen to develop these recommendations involved a critical review of the literature and the use of the Delphi and GRADE methods. An expert group was formed.",
          "beginSection": "abstract",
          "offsetInBeginSection": 180,
          "endSection": "abstract",
          "offsetInEndSection": 466
        }
      ],
      "ideal_answer": "Respiratory syncytial virus (RSV) disease is treated with nirsevimab.",
      "exact_answer": [
        "RSV"
      ]
    },
    {
      "id": "660998ecfdcbea915f000014",
      "type": "summary",
      "body": "Why does rectal cancer have worse prognosis than other colon tumors?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30200215",
        "http://www.ncbi.nlm.nih.gov/pubmed/27497831",
        "http://www.ncbi.nlm.nih.gov/pubmed/24265711",
        "http://www.ncbi.nlm.nih.gov/pubmed/30577807",
        "http://www.ncbi.nlm.nih.gov/pubmed/29156800",
        "http://www.ncbi.nlm.nih.gov/pubmed/18334831",
        "http://www.ncbi.nlm.nih.gov/pubmed/20577916",
        "http://www.ncbi.nlm.nih.gov/pubmed/8664045",
        "http://www.ncbi.nlm.nih.gov/pubmed/8425421",
        "http://www.ncbi.nlm.nih.gov/pubmed/22071131"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265711",
          "text": "CONCLUSION\nThis was a population-based study. The prognosis of rectal cancer was not worse than that of colon cancer. Local advanced colorectal cancer had a poorer prognosis than local regional lymph node metastasis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1355,
          "endSection": "abstract",
          "offsetInEndSection": 1571
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265711",
          "text": "The prognosis of rectal cancer was not worse than that of colon cancer. Local advanced colorectal cancer had a poorer prognosis than local regional lymph node metastasis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1401,
          "endSection": "abstract",
          "offsetInEndSection": 1571
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265711",
          "text": "The prognosis of rectal cancer was not worse than that of colon cancer. Local advanced colorectal cancer had a poorer prognosis than local regional lymph node metastasis. Stage IIB might require more aggressive chemotherapy, and no less than that for stage III.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1401,
          "endSection": "abstract",
          "offsetInEndSection": 1662
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265711",
          "text": "CONCLUSION\nThis was a population-based study. The prognosis of rectal cancer was not worse than that of colon cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1355,
          "endSection": "abstract",
          "offsetInEndSection": 1472
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265711",
          "text": "The prognosis of rectal cancer was not worse than that of colon cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1401,
          "endSection": "abstract",
          "offsetInEndSection": 1472
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29156800",
          "text": "Tumor sidedness has emerged as an important prognostic and predictive factor in the treatment of colorectal cancer. Recent studies demonstrate that patients with advanced right-sided colon cancers have a worse prognosis than those with left-sided colon or rectal cancers, and these patient subgroups respond differently to biological therapies. Historically, management of patients with metastatic colon and rectal cancers has been similar, and colon and rectal cancer patients have been grouped together in large clinical trials.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 530
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29156800",
          "text": "Recent studies demonstrate that patients with advanced right-sided colon cancers have a worse prognosis than those with left-sided colon or rectal cancers, and these patient subgroups respond differently to biological therapies. Historically, management of patients with metastatic colon and rectal cancers has been similar, and colon and rectal cancer patients have been grouped together in large clinical trials.",
          "beginSection": "abstract",
          "offsetInBeginSection": 116,
          "endSection": "abstract",
          "offsetInEndSection": 530
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29156800",
          "text": "Recent studies demonstrate that patients with advanced right-sided colon cancers have a worse prognosis than those with left-sided colon or rectal cancers, and these patient subgroups respond differently to biological therapies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 116,
          "endSection": "abstract",
          "offsetInEndSection": 344
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265711",
          "text": "In stage IIIC and stage IV, rectal cancer patients had better survival than colon cancer patients, by about 3 months. Stage IIB colorectal cancer patients had a poorer prognosis than those with stage IIIA and IIIB colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 854,
          "endSection": "abstract",
          "offsetInEndSection": 1086
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265711",
          "text": "Among them, colon cancer patients had better survival than those with rectal cancer, by a margin of 4 months in stage IIB. In stage IIIC and stage IV, rectal cancer patients had better survival than colon cancer patients, by about 3 months. Stage IIB colorectal cancer patients had a poorer prognosis than those with stage IIIA and IIIB colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 731,
          "endSection": "abstract",
          "offsetInEndSection": 1086
        }
      ],
      "ideal_answer": "Rectal cancer does not have worse prognosis than other colon tumors. Recent studies show that patients with advanced right-sided colon cancers have a worse prognosis than those with left-sided colon or rectal cancers. In stages IIIC and IV, rectal cancer patients had better survival than colon cancer patients, by about 3 months.",
      "exact_answer": "n/a"
    },
    {
      "id": "661a6733fdcbea915f00005c",
      "type": "yesno",
      "body": "Is Loeys-Dietz syndrome (LDS) associated with Aortic Aneurysm?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37823753",
        "http://www.ncbi.nlm.nih.gov/pubmed/37916856",
        "http://www.ncbi.nlm.nih.gov/pubmed/37755470",
        "http://www.ncbi.nlm.nih.gov/pubmed/33487195",
        "http://www.ncbi.nlm.nih.gov/pubmed/37876949",
        "http://www.ncbi.nlm.nih.gov/pubmed/31724649",
        "http://www.ncbi.nlm.nih.gov/pubmed/29687491",
        "http://www.ncbi.nlm.nih.gov/pubmed/30534260",
        "http://www.ncbi.nlm.nih.gov/pubmed/21801912",
        "http://www.ncbi.nlm.nih.gov/pubmed/20662229"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31724649",
          "text": "Loeys-Dietz syndrome (LDS) is a recently reported autosomal dominant aortic aneurysm syndrome with widespread systemic involvement.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 131
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37876949",
          "text": "Loeys-Dietz syndrome (LDS) is less commonly seen as a cause of ascending aortic aneurysms in children. In this case report, we describe pediatric Bentall procedure, which we successfully performed to a child with LDS (Type I) with giant ascending aortic enlargement and significant aortic regurgitation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 171,
          "endSection": "abstract",
          "offsetInEndSection": 474
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37876949",
          "text": "Loeys-Dietz syndrome (LDS) is less commonly seen as a cause of ascending aortic aneurysms in children.",
          "beginSection": "abstract",
          "offsetInBeginSection": 171,
          "endSection": "abstract",
          "offsetInEndSection": 273
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21801912",
          "text": "BACKGROUND\nLoeys-Dietz syndrome (LDS) is a recently recognized aggressive aortic disorder characterized by root aneurysm, arterial tortuosity, hypertelorism, and bifid uvula or cleft palate.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 190
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20662229",
          "text": "After the 1st operation, she was diagnosed with Loeys-Dietz syndrome (LDS), which is recently described as an autosomal dominant aortic aneurysm syndrome caused by heterozygous mutations in the transforming growth factor-beta receptor type 1 and 2 genes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 299,
          "endSection": "abstract",
          "offsetInEndSection": 553
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31724649",
          "text": "Loeys-Dietz syndrome (LDS) is a recently reported autosomal dominant aortic aneurysm syndrome with widespread systemic involvement. Although connective tissue diseases carry a theoretical risk of aneurysmal degeneration in vein grafts, there are no reports of vein graft aneurysm (VGA) in patients with connective tissue disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 329
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20662229",
          "text": "After the 1st operation, she was diagnosed with Loeys-Dietz syndrome (LDS), which is recently described as an autosomal dominant aortic aneurysm syndrome caused by heterozygous mutations in the transforming growth factor-beta receptor type 1 and 2 genes. Only 2 months after the 1st operation, she developed heart failure due to recurrence of aortic regurgitation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 299,
          "endSection": "abstract",
          "offsetInEndSection": 663
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33487195",
          "text": "Loeys-Dietz syndrome is a connective tissue disorder known to cause aggressive aortopathy in paediatric patients, but it is extremely rare for cardiovascular events to present during infancy. We report the first successful aortic repair in a neonate with LDS presenting in extremis with an early onset, massive aortic aneurysm.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 327
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31724649",
          "text": "Loeys-Dietz syndrome (LDS) is a recently reported autosomal dominant aortic aneurysm syndrome with widespread systemic involvement. Although connective tissue diseases carry a theoretical risk of aneurysmal degeneration in vein grafts, there are no reports of vein graft aneurysm (VGA) in patients with connective tissue disease. We herein report the first case of a giant VGA that was manifested 5 years after the reconstruction of a popliteal artery aneurysm associated with LDS.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 481
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20662229",
          "text": "She underwent a valve sparing operation with graft replacement of the ascending aorta and the proximal portion of the aortic arch. After the 1st operation, she was diagnosed with Loeys-Dietz syndrome (LDS), which is recently described as an autosomal dominant aortic aneurysm syndrome caused by heterozygous mutations in the transforming growth factor-beta receptor type 1 and 2 genes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 168,
          "endSection": "abstract",
          "offsetInEndSection": 553
        }
      ],
      "ideal_answer": "Yes, Loeys-Dietz syndrome (LDS) is associated with Aortic Aneurysm.",
      "exact_answer": "yes"
    },
    {
      "id": "66150366fdcbea915f000046",
      "type": "summary",
      "body": "What is borderline personality disorder?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29795363",
        "http://www.ncbi.nlm.nih.gov/pubmed/35166488",
        "http://www.ncbi.nlm.nih.gov/pubmed/21195251",
        "http://www.ncbi.nlm.nih.gov/pubmed/21686143",
        "http://www.ncbi.nlm.nih.gov/pubmed/21462898",
        "http://www.ncbi.nlm.nih.gov/pubmed/17409055",
        "http://www.ncbi.nlm.nih.gov/pubmed/15863787",
        "http://www.ncbi.nlm.nih.gov/pubmed/15939918",
        "http://www.ncbi.nlm.nih.gov/pubmed/9418746",
        "http://www.ncbi.nlm.nih.gov/pubmed/17671917"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35166488",
          "text": "Borderline personality disorder is a psychological disorder characterized by a pervasive pattern of instability in affect regulation, impulse control, interpersonal relationships, and self-image. Borderline personality disorder may be present in up to 6.4% of adult primary care visits, which is fourfold higher than in the general population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 343
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35166488",
          "text": "Borderline personality disorder is a psychological disorder characterized by a pervasive pattern of instability in affect regulation, impulse control, interpersonal relationships, and self-image. Borderline personality disorder may be present in up to 6.4% of adult primary care visits, which is fourfold higher than in the general population. Borderline personality disorder is underdiagnosed and most patients who have it also have additional psychiatric conditions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 468
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795363",
          "text": "Caretakers are often intimidated or alienated by patients with borderline personality disorder (BPD), compounding the clinical challenges posed by the severe morbidity, high social costs and substantial prevalence of this disorder in many health-care settings. BPD is found in ∼1.7% of the general population but in 15-28% of patients in psychiatric clinics or hospitals and in a large proportion of individuals seeking help for psychological problems in general health facilities. BPD is characterized by extreme sensitivity to perceived interpersonal slights, an unstable sense of self, intense and volatile emotionality and impulsive behaviours that are often self-destructive.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 680
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795363",
          "text": "Caretakers are often intimidated or alienated by patients with borderline personality disorder (BPD), compounding the clinical challenges posed by the severe morbidity, high social costs and substantial prevalence of this disorder in many health-care settings. BPD is found in ∼1.7% of the general population but in 15-28% of patients in psychiatric clinics or hospitals and in a large proportion of individuals seeking help for psychological problems in general health facilities.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 481
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795363",
          "text": "Caretakers are often intimidated or alienated by patients with borderline personality disorder (BPD), compounding the clinical challenges posed by the severe morbidity, high social costs and substantial prevalence of this disorder in many health-care settings.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 260
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15939918",
          "text": "Borderline personality disorder is a chronic psychiatric disorder characterized by marked impulsivity, instability of mood and interpersonal relationships, and suicidal behaviour that can complicate medical care.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 212
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15939918",
          "text": "Borderline personality disorder is a chronic psychiatric disorder characterized by marked impulsivity, instability of mood and interpersonal relationships, and suicidal behaviour that can complicate medical care. Identifying this diagnosis is important for treatment planning.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 276
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795363",
          "text": "Borderline personality disorder.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 32
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35166488",
          "text": "Borderline Personality Disorder.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 32
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15939918",
          "text": "Borderline personality disorder is a chronic psychiatric disorder characterized by marked impulsivity, instability of mood and interpersonal relationships, and suicidal behaviour that can complicate medical care. Identifying this diagnosis is important for treatment planning. Although the cause of borderline personality disorder is uncertain, most patients improve with time.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 377
        }
      ],
      "ideal_answer": "Borderline personality disorder (BPD) is a mental health condition characterized by extreme sensitivity to perceived interpersonal slights, an unstable sense of self, intense and volatile emotionality, impulsive behaviors that are often self-destructive, and persistent social disabilities related to depression or self-harming behaviors. It is found in approximately 1.7% of the general population, but its prevalence is significantly higher in psychiatric clinics, hospitals, and general health facilities.",
      "exact_answer": "n/a"
    },
    {
      "id": "661d9cc3eac11fad33000029",
      "type": "summary",
      "body": "What is the role of the FOXA1 transcription factor in estrogen-receptor-positive (ER+) breast cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37467106",
        "http://www.ncbi.nlm.nih.gov/pubmed/22649425",
        "http://www.ncbi.nlm.nih.gov/pubmed/21503684",
        "http://www.ncbi.nlm.nih.gov/pubmed/25707489",
        "http://www.ncbi.nlm.nih.gov/pubmed/22476979",
        "http://www.ncbi.nlm.nih.gov/pubmed/17163418",
        "http://www.ncbi.nlm.nih.gov/pubmed/27791031",
        "http://www.ncbi.nlm.nih.gov/pubmed/23771556",
        "http://www.ncbi.nlm.nih.gov/pubmed/22577344",
        "http://www.ncbi.nlm.nih.gov/pubmed/21984487"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37467106",
          "text": "We demonstrate that ectopic high FOXA1 (H-FOXA1) expression promotes estrogen receptor-positive (ER+) breast cancer (BC) metastasis in a xenograft mouse model. Mechanistically, H-FOXA1 reprograms ER-chromatin binding to elicit a core gene signature (CGS) enriched in ER+ endocrine-resistant (EndoR) cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 166,
          "endSection": "abstract",
          "offsetInEndSection": 471
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37467106",
          "text": "However, the key mediators of high FOXA1 signaling remain elusive. We demonstrate that ectopic high FOXA1 (H-FOXA1) expression promotes estrogen receptor-positive (ER+) breast cancer (BC) metastasis in a xenograft mouse model. Mechanistically, H-FOXA1 reprograms ER-chromatin binding to elicit a core gene signature (CGS) enriched in ER+ endocrine-resistant (EndoR) cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 99,
          "endSection": "abstract",
          "offsetInEndSection": 471
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37467106",
          "text": "We demonstrate that ectopic high FOXA1 (H-FOXA1) expression promotes estrogen receptor-positive (ER+) breast cancer (BC) metastasis in a xenograft mouse model.",
          "beginSection": "abstract",
          "offsetInBeginSection": 166,
          "endSection": "abstract",
          "offsetInEndSection": 325
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37467106",
          "text": "However, the key mediators of high FOXA1 signaling remain elusive. We demonstrate that ectopic high FOXA1 (H-FOXA1) expression promotes estrogen receptor-positive (ER+) breast cancer (BC) metastasis in a xenograft mouse model.",
          "beginSection": "abstract",
          "offsetInBeginSection": 99,
          "endSection": "abstract",
          "offsetInEndSection": 325
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37467106",
          "text": "We demonstrate that ectopic high FOXA1 (H-FOXA1) expression promotes estrogen receptor-positive (ER+) breast cancer (BC) metastasis in a xenograft mouse model. Mechanistically, H-FOXA1 reprograms ER-chromatin binding to elicit a core gene signature (CGS) enriched in ER+ endocrine-resistant (EndoR) cells. We identify Secretome14, a CGS subset encoding ER-dependent cancer secretory proteins, as a strong predictor for poor outcomes of ER+ BC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 166,
          "endSection": "abstract",
          "offsetInEndSection": 609
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37467106",
          "text": "Aberrant activation of the forkhead protein FOXA1 is observed in advanced hormone-related cancers. However, the key mediators of high FOXA1 signaling remain elusive. We demonstrate that ectopic high FOXA1 (H-FOXA1) expression promotes estrogen receptor-positive (ER+) breast cancer (BC) metastasis in a xenograft mouse model.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 325
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37467106",
          "text": "Aberrant activation of the forkhead protein FOXA1 is observed in advanced hormone-related cancers. However, the key mediators of high FOXA1 signaling remain elusive. We demonstrate that ectopic high FOXA1 (H-FOXA1) expression promotes estrogen receptor-positive (ER+) breast cancer (BC) metastasis in a xenograft mouse model. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 326
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22649425",
          "text": "FoxA1 acts as a pioneer factor for both androgen receptor (AR) and estrogen receptor-α (ER), dictating the binding location, and therefore function of these transcription factors. It is an essential protein for the transcriptional activity of both ER and AR, yet it has distinct roles with the two different nuclear receptors. In both malignancies, FoxA1 plays a pivotal role from early stage cancer through to drug resistant and metastatic disease. Due to this key role in mediating ER and AR function, FoxA1 is not only an attractive therapeutic target but could potentially function as a novel biomarker.",
          "beginSection": "abstract",
          "offsetInBeginSection": 120,
          "endSection": "abstract",
          "offsetInEndSection": 727
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22649425",
          "text": "FoxA1 acts as a pioneer factor for both androgen receptor (AR) and estrogen receptor-α (ER), dictating the binding location, and therefore function of these transcription factors. It is an essential protein for the transcriptional activity of both ER and AR, yet it has distinct roles with the two different nuclear receptors. In both malignancies, FoxA1 plays a pivotal role from early stage cancer through to drug resistant and metastatic disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 120,
          "endSection": "abstract",
          "offsetInEndSection": 569
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22649425",
          "text": "It is an essential protein for the transcriptional activity of both ER and AR, yet it has distinct roles with the two different nuclear receptors. In both malignancies, FoxA1 plays a pivotal role from early stage cancer through to drug resistant and metastatic disease. Due to this key role in mediating ER and AR function, FoxA1 is not only an attractive therapeutic target but could potentially function as a novel biomarker.",
          "beginSection": "abstract",
          "offsetInBeginSection": 300,
          "endSection": "abstract",
          "offsetInEndSection": 727
        }
      ],
      "ideal_answer": "The FOXA1 transcription factor plays a pivotal role in estrogen-receptor-positive (ER+) breast cancer, from early stage cancer through to drug resistant and metastatic disease. It is an attractive therapeutic target and could potentially function as a novel biomarker. Ectopic high FOXA1 expression promotes ER+ breast cancer metastasis in a xenograft mouse model.",
      "exact_answer": "n/a"
    },
    {
      "id": "661d62dceac11fad33000026",
      "type": "summary",
      "body": "How is Huntington's Disease inherited?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35829908",
        "http://www.ncbi.nlm.nih.gov/pubmed/14960907",
        "http://www.ncbi.nlm.nih.gov/pubmed/16925544",
        "http://www.ncbi.nlm.nih.gov/pubmed/17293170",
        "http://www.ncbi.nlm.nih.gov/pubmed/26439718",
        "http://www.ncbi.nlm.nih.gov/pubmed/15381897",
        "http://www.ncbi.nlm.nih.gov/pubmed/34636452",
        "http://www.ncbi.nlm.nih.gov/pubmed/1387416",
        "http://www.ncbi.nlm.nih.gov/pubmed/12531930",
        "http://www.ncbi.nlm.nih.gov/pubmed/17156701"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16925544",
          "text": "Huntington disease (HD) is a dominantly inherited neurodegenerative disorder related to expansion of a triplet repeat sequence in the huntington gene on chromosome 4.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 166
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16925544",
          "text": "Huntington disease (HD) is a dominantly inherited neurodegenerative disorder related to expansion of a triplet repeat sequence in the huntington gene on chromosome 4. Adult HD usually presents with chorea and personality changes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 229
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15381897",
          "text": "Huntington disease is a dominantly inherited, neurodegenerative disease characterized by choreiform movement disturbances and dementia, usually with adult onset.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 161
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34636452",
          "text": "Huntington disease is an autosomal dominant inherited brain disorder that typically becomes manifest in adulthood.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 114
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34636452",
          "text": "Huntington disease is an autosomal dominant inherited brain disorder that typically becomes manifest in adulthood. Juvenile-onset Huntington disease refers to approximately 5% of patients with symptom onset before the age of 21 years. The causal factor is a pathologically expanded CAG repeat in the Huntingtin gene.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 316
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16925544",
          "text": "Huntington disease (HD) is a dominantly inherited neurodegenerative disorder related to expansion of a triplet repeat sequence in the huntington gene on chromosome 4. Adult HD usually presents with chorea and personality changes. Juvenile HD is far less common and presents with parkinsonism, dystonia and seizures.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 315
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15381897",
          "text": "Huntington disease is a dominantly inherited, neurodegenerative disease characterized by choreiform movement disturbances and dementia, usually with adult onset. The rare juvenile-onset Huntington disease differs from the adult phenotype.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 238
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34636452",
          "text": "Huntington disease is an autosomal dominant inherited brain disorder that typically becomes manifest in adulthood. Juvenile-onset Huntington disease refers to approximately 5% of patients with symptom onset before the age of 21 years.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 234
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16925544",
          "text": "Juvenile Huntington disease.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 28
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15381897",
          "text": "Huntington disease is a dominantly inherited, neurodegenerative disease characterized by choreiform movement disturbances and dementia, usually with adult onset. The rare juvenile-onset Huntington disease differs from the adult phenotype. A case presenting twice, at age 10 with all the signs of a major depression and age 14 with mutism and rigidity, is reported.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 364
        }
      ],
      "ideal_answer": "Huntington's Disease is inherited in an autosomal dominant manner, meaning that a child of an affected parent has a 50% chance of inheriting the disease-causing mutation.",
      "exact_answer": "n/a"
    },
    {
      "id": "65cfcd541930410b13000019",
      "type": "factoid",
      "body": "Burrow Ink Test can be used to diagnose which disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23205026",
        "http://www.ncbi.nlm.nih.gov/pubmed/8308357",
        "http://www.ncbi.nlm.nih.gov/pubmed/23904181",
        "http://www.ncbi.nlm.nih.gov/pubmed/21268539",
        "http://www.ncbi.nlm.nih.gov/pubmed/35244292",
        "http://www.ncbi.nlm.nih.gov/pubmed/34317837",
        "http://www.ncbi.nlm.nih.gov/pubmed/34580363",
        "http://www.ncbi.nlm.nih.gov/pubmed/15961128",
        "http://www.ncbi.nlm.nih.gov/pubmed/37875158",
        "http://www.ncbi.nlm.nih.gov/pubmed/14555736"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35244292",
          "text": "The ink test may provide a useful technique to enhance FP visualization and support a diagnosis of extragenital LS, thereby avoiding diagnostic delays or biopsy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 300,
          "endSection": "abstract",
          "offsetInEndSection": 461
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35244292",
          "text": "Ink test: A useful technique to enhance extragenital lichen sclerosus diagnosis.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 80
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35244292",
          "text": "Histopathology is the gold standard for diagnosis. Dermoscopy is a useful tool when follicular plugs (FP) are observed, though FP are sometimes hard to recognize. The ink test may provide a useful technique to enhance FP visualization and support a diagnosis of extragenital LS, thereby avoiding diagnostic delays or biopsy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 137,
          "endSection": "abstract",
          "offsetInEndSection": 461
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35244292",
          "text": "Dermoscopy is a useful tool when follicular plugs (FP) are observed, though FP are sometimes hard to recognize. The ink test may provide a useful technique to enhance FP visualization and support a diagnosis of extragenital LS, thereby avoiding diagnostic delays or biopsy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 188,
          "endSection": "abstract",
          "offsetInEndSection": 461
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34580363",
          "text": "(4) The latency to reseal the burrow showed no obvious differences between each treatment both in the laboratory and in the field.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1460,
          "endSection": "abstract",
          "offsetInEndSection": 1590
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34317837",
          "text": "OBJECTIVE\nWe assessed the long-term outcomes of the loop technique with the ink-dot marking test, an alternative to the ink test for aligning the mitral valve (MV) leaflet height, during MV repair. METHODS\nWe retrospectively reviewed 351 patients who underwent MV repair with the loop technique via median sternotomy or right mini-thoracotomy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 345
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34580363",
          "text": "(2) Burrow-sealing behavior in response to each treatment did not differ significantly between males and females in the laboratory experiment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 975,
          "endSection": "abstract",
          "offsetInEndSection": 1117
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34580363",
          "text": "In this study, we selected a subterranean rodent, plateau zokor (Myospalax fontanieri), as a species to investigate (both in the laboratory and in the field) the possible factors responsible for burrow-sealing behavior.",
          "beginSection": "abstract",
          "offsetInBeginSection": 375,
          "endSection": "abstract",
          "offsetInEndSection": 594
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37875158",
          "text": "Our goal was to test this hypothesis by exploring the burrow-site selection of different-sized desert isopods (Hemilepistus reaumuri) near and away from a scorpion burrow.",
          "beginSection": "abstract",
          "offsetInBeginSection": 277,
          "endSection": "abstract",
          "offsetInEndSection": 448
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34317837",
          "text": "OBJECTIVE\nWe assessed the long-term outcomes of the loop technique with the ink-dot marking test, an alternative to the ink test for aligning the mitral valve (MV) leaflet height, during MV repair. METHODS\nWe retrospectively reviewed 351 patients who underwent MV repair with the loop technique via median sternotomy or right mini-thoracotomy. The ink-dot marking test involves creation of a dotted line between the rough and clear zones in the anterior leaflet and the center of the posterior leaflet by gentian violet.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 522
        }
      ],
      "ideal_answer": "The Burrow Ink Test can be used to diagnose extragenital lichen sclerosus.",
      "exact_answer": [
        "extragenital lichen sclerosus"
      ]
    },
    {
      "id": "6609994bfdcbea915f000017",
      "type": "list",
      "body": "What drugs are effective for the treatment of EGFR inhibitors skin rash?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32609305",
        "http://www.ncbi.nlm.nih.gov/pubmed/20142600",
        "http://www.ncbi.nlm.nih.gov/pubmed/19229368",
        "http://www.ncbi.nlm.nih.gov/pubmed/18192159",
        "http://www.ncbi.nlm.nih.gov/pubmed/30232957",
        "http://www.ncbi.nlm.nih.gov/pubmed/25039761",
        "http://www.ncbi.nlm.nih.gov/pubmed/25670908",
        "http://www.ncbi.nlm.nih.gov/pubmed/33026750",
        "http://www.ncbi.nlm.nih.gov/pubmed/33910927",
        "http://www.ncbi.nlm.nih.gov/pubmed/22271877"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19229368",
          "text": "The EGFR inhibitors (EGFRIS) approved in Canada include the tyrosine kinase inhibitors erlotinib and gefitinib (in selected cases), and the monoclonal antibodies (mAbs) panitumumab and cetuximab. Although EGFRIS have been proven effective in the treatment of a variety of malignancies, the entire class of agents is associated with a high prevalence of dermatologic side effects, most commonly skin rash. This reversible condition requires intervention in approximately one third of patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 346,
          "endSection": "abstract",
          "offsetInEndSection": 838
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19229368",
          "text": "The EGFR inhibitors (EGFRIS) approved in Canada include the tyrosine kinase inhibitors erlotinib and gefitinib (in selected cases), and the monoclonal antibodies (mAbs) panitumumab and cetuximab. Although EGFRIS have been proven effective in the treatment of a variety of malignancies, the entire class of agents is associated with a high prevalence of dermatologic side effects, most commonly skin rash.",
          "beginSection": "abstract",
          "offsetInBeginSection": 346,
          "endSection": "abstract",
          "offsetInEndSection": 750
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19229368",
          "text": "Agents targeting the EGFR-mediated signalling pathway are increasingly part of the therapeutic armamentarium for the treatment of advanced lung, head-and-neck, and colorectal carcinoma. The EGFR inhibitors (EGFRIS) approved in Canada include the tyrosine kinase inhibitors erlotinib and gefitinib (in selected cases), and the monoclonal antibodies (mAbs) panitumumab and cetuximab. Although EGFRIS have been proven effective in the treatment of a variety of malignancies, the entire class of agents is associated with a high prevalence of dermatologic side effects, most commonly skin rash.",
          "beginSection": "abstract",
          "offsetInBeginSection": 160,
          "endSection": "abstract",
          "offsetInEndSection": 750
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18192159",
          "text": "Clinical approaches to minimize rash associated with EGFR inhibitors.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 69
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19229368",
          "text": "The present article focuses on EGFR-targeted mAbs for the treatment of gi malignancy, addressing the pathophysiology, clinical presentation, and incidence of skin rash caused by this class of agents. Recommendations aimed at establishing a framework for consistent, proactive management of skin rash in the Canadian setting are presented.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1216,
          "endSection": "abstract",
          "offsetInEndSection": 1554
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18192159",
          "text": "CONCLUSIONS\nUsing the approach described in this article to treat the rash associated with the use of EGFR inhibitors, nurses can lessen patient discomfort and help ensure that patients will continue cancer treatment for as long as necessary. IMPLICATIONS FOR NURSING\nThe approach described in this article should help nurses to recognize, grade, and treat the skin rash associated with EGFR inhibitors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 699,
          "endSection": "abstract",
          "offsetInEndSection": 1104
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19229368",
          "text": "The present article focuses on EGFR-targeted mAbs for the treatment of gi malignancy, addressing the pathophysiology, clinical presentation, and incidence of skin rash caused by this class of agents.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1216,
          "endSection": "abstract",
          "offsetInEndSection": 1415
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19229368",
          "text": "Although EGFRIS have been proven effective in the treatment of a variety of malignancies, the entire class of agents is associated with a high prevalence of dermatologic side effects, most commonly skin rash. This reversible condition requires intervention in approximately one third of patients. A proactive, multidisciplinary approach to management can help to improve skin rash and optimize clinical outcomes by preventing EGFRI dose reduction or discontinuation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 542,
          "endSection": "abstract",
          "offsetInEndSection": 1008
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19229368",
          "text": "Although EGFRIS have been proven effective in the treatment of a variety of malignancies, the entire class of agents is associated with a high prevalence of dermatologic side effects, most commonly skin rash.",
          "beginSection": "abstract",
          "offsetInBeginSection": 542,
          "endSection": "abstract",
          "offsetInEndSection": 750
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19229368",
          "text": "Although EGFRIS have been proven effective in the treatment of a variety of malignancies, the entire class of agents is associated with a high prevalence of dermatologic side effects, most commonly skin rash. This reversible condition requires intervention in approximately one third of patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 542,
          "endSection": "abstract",
          "offsetInEndSection": 838
        }
      ],
      "ideal_answer": "Minocycline, tetracycline, doxycycline, isotretinoin, and corticosteroids are effective for the treatment of EGFR inhibitors skin rash.",
      "exact_answer": [
        [
          "minocycline"
        ],
        [
          "tetracycline"
        ],
        [
          "doxycycline"
        ],
        [
          "isotretinoin"
        ],
        [
          "corticosteroids"
        ]
      ]
    },
    {
      "id": "660810a0fdcbea915f000005",
      "type": "yesno",
      "body": "Is MIRPE, also known as the Nuss procedure, considered to be an very invasive form of surgical treatment?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36881966",
        "http://www.ncbi.nlm.nih.gov/pubmed/34743569",
        "http://www.ncbi.nlm.nih.gov/pubmed/36935229",
        "http://www.ncbi.nlm.nih.gov/pubmed/35455522",
        "http://www.ncbi.nlm.nih.gov/pubmed/30214110",
        "http://www.ncbi.nlm.nih.gov/pubmed/27458490",
        "http://www.ncbi.nlm.nih.gov/pubmed/14725098",
        "http://www.ncbi.nlm.nih.gov/pubmed/29473012",
        "http://www.ncbi.nlm.nih.gov/pubmed/16982197",
        "http://www.ncbi.nlm.nih.gov/pubmed/23545345"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36881966",
          "text": "The minimally invasive repair of pectus excavatum (MIRPE), or Nuss procedure, is regarded as the gold standard technique for the treatment of symptomatic pectus excavatum. Minimally invasive repair of pectus excavatum is regarded as a low-risk operation with a reported life-threatening complication rate estimated at around 0.1%.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 330
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36881966",
          "text": "The minimally invasive repair of pectus excavatum (MIRPE), or Nuss procedure, is regarded as the gold standard technique for the treatment of symptomatic pectus excavatum. Minimally invasive repair of pectus excavatum is regarded as a low-risk operation with a reported life-threatening complication rate estimated at around 0.1%. Presented are three cases of right internal mammary artery injury (RIMA) after MIRPE resulting in massive hemorrhage in both the acute and chronic postoperative setting and subsequent management strategies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 537
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36881966",
          "text": "The minimally invasive repair of pectus excavatum (MIRPE), or Nuss procedure, is regarded as the gold standard technique for the treatment of symptomatic pectus excavatum.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 171
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36881966",
          "text": "The minimally invasive repair of pectus excavatum (MIRPE), or Nuss procedure, is regarded as the gold standard technique for the treatment of symptomatic pectus excavatum",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 170
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34743569",
          "text": "INTRODUCTION\nSurgical correction of pectus excavatum by Nuss procedure, commonly referred to as minimally invasive repair of pectus excavatum (MIRPE), often results in significant postoperative pain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 199
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34743569",
          "text": "Surgical correction of pectus excavatum by Nuss procedure, commonly referred to as minimally invasive repair of pectus excavatum (MIRPE), often results in significant postoperative pain. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 14,
          "endSection": "abstract",
          "offsetInEndSection": 201
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34743569",
          "text": "INTRODUCTION\nSurgical correction of pectus excavatum by Nuss procedure, commonly referred to as minimally invasive repair of pectus excavatum (MIRPE), often results in significant postoperative pain. This study investigated whether adding intraoperative methadone would reduce the postoperative opioid requirement during admission for patients undergoing MIRPE.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 361
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34743569",
          "text": "INTRODUCTION\nSurgical correction of pectus excavatum by Nuss procedure, commonly referred to as minimally invasive repair of pectus excavatum (MIRPE), often results in significant postoperative pain. This study investigated whether adding intraoperative methadone would reduce the postoperative opioid requirement during admission for patients undergoing MIRPE. METHODS\nA retrospective cohort chart review was conducted for 40 MIRPE patients between 2018 and 2020.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 466
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30214110",
          "text": "The Nuss technique includes using temporary metallic bars without costochondral resection to correct the chest wall deformity. Modified MIRPE can be learned easily and performed safely with few complications. There are no reports of successful MIRPE in Iran, although the Ravitch technique is well known.",
          "beginSection": "abstract",
          "offsetInBeginSection": 227,
          "endSection": "abstract",
          "offsetInEndSection": 531
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35455522",
          "text": "However, the widespread use of the minimally invasive repair of pectus excavatum (MIRPE) procedure has been associated with a significant number of serious complications.",
          "beginSection": "abstract",
          "offsetInBeginSection": 854,
          "endSection": "abstract",
          "offsetInEndSection": 1024
        }
      ],
      "ideal_answer": "No, MIRPE is not considered to be a very invasive form of surgical treatment. It is regarded as a low-risk operation with a reported life-threatening complication rate estimated at around 0.1%.",
      "exact_answer": "no"
    },
    {
      "id": "66154a32fdcbea915f00004b",
      "type": "list",
      "body": "What are major complications of mastoiditis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31563751",
        "http://www.ncbi.nlm.nih.gov/pubmed/32073562",
        "http://www.ncbi.nlm.nih.gov/pubmed/37056111",
        "http://www.ncbi.nlm.nih.gov/pubmed/18260229",
        "http://www.ncbi.nlm.nih.gov/pubmed/19504555",
        "http://www.ncbi.nlm.nih.gov/pubmed/10767461",
        "http://www.ncbi.nlm.nih.gov/pubmed/26221557",
        "http://www.ncbi.nlm.nih.gov/pubmed/21926622",
        "http://www.ncbi.nlm.nih.gov/pubmed/31475649",
        "http://www.ncbi.nlm.nih.gov/pubmed/30915252"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18260229",
          "text": "Complete resolution was achieved in all cases. CONCLUSION\nThe persistent othorrea, otalgia and headache, prolonged high fever, neurological signs were the most common symptoms associated with the development of intracranial complications of acute mastoiditis in children.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1463,
          "endSection": "abstract",
          "offsetInEndSection": 1736
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18260229",
          "text": "Intracranial complications occurred in 29 (21.4%) of acute mastoiditis cases and facial paralysis was the commonest one in 14 (40.0%) cases, followed by sigmoid sinus thrombosis and perisinus abscess.",
          "beginSection": "abstract",
          "offsetInBeginSection": 945,
          "endSection": "abstract",
          "offsetInEndSection": 1145
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18260229",
          "text": "Intracranial complications occurred in 29 (21.4%) of acute mastoiditis cases and facial paralysis was the commonest one in 14 (40.0%) cases, followed by sigmoid sinus thrombosis and perisinus abscess. Ear cultures grew in patients with otogenic complications, the most often Staphylococcus aureus, Streptococcus sp.",
          "beginSection": "abstract",
          "offsetInBeginSection": 945,
          "endSection": "abstract",
          "offsetInEndSection": 1260
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18260229",
          "text": "Intracranial complications occurred in 29 (21.4%) of acute mastoiditis cases and facial paralysis was the commonest one in 14 (40.0%) cases, followed by sigmoid sinus thrombosis and perisinus abscess. Ear cultures grew in patients with otogenic complications, the most often Staphylococcus aureus, Streptococcus sp. and Pseudomonas aeruginosa were found.",
          "beginSection": "abstract",
          "offsetInBeginSection": 945,
          "endSection": "abstract",
          "offsetInEndSection": 1299
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18260229",
          "text": "[Complications of acute mastoiditis in children].",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 49
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18260229",
          "text": "RESULTS\nExtracranial complications occurred in 41 (30.4%) of treated acute mastoiditis cases, and subperiostal abscess was the commonest one in 37 (90.2%) patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 780,
          "endSection": "abstract",
          "offsetInEndSection": 944
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18260229",
          "text": "Complete resolution was achieved in all cases. CONCLUSION\nThe persistent othorrea, otalgia and headache, prolonged high fever, neurological signs were the most common symptoms associated with the development of intracranial complications of acute mastoiditis in children. Computed tomography and MRI are necessary tools for diagnosis and surgery planning in every case of latent mastoiditis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1463,
          "endSection": "abstract",
          "offsetInEndSection": 1856
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19504555",
          "text": "Advanced pediatric mastoiditis with and without intracranial complications.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 75
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18260229",
          "text": "CONCLUSION\nThe persistent othorrea, otalgia and headache, prolonged high fever, neurological signs were the most common symptoms associated with the development of intracranial complications of acute mastoiditis in children.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1512,
          "endSection": "abstract",
          "offsetInEndSection": 1736
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18260229",
          "text": "CONCLUSION\nThe persistent othorrea, otalgia and headache, prolonged high fever, neurological signs were the most common symptoms associated with the development of intracranial complications of acute mastoiditis in children. Computed tomography and MRI are necessary tools for diagnosis and surgery planning in every case of latent mastoiditis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1512,
          "endSection": "abstract",
          "offsetInEndSection": 1856
        }
      ],
      "ideal_answer": "Major complications of mastoiditis include facial paralysis, sigmoid sinus thrombosis, and perisinus abscess.",
      "exact_answer": [
        [
          "facial paralysis"
        ],
        [
          "sigmoid sinus thrombosis"
        ],
        [
          "perisinus abscess"
        ]
      ]
    },
    {
      "id": "661c41d448a2c27714000009",
      "type": "list",
      "body": "Which DNA language models currently exist to model the human genome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37873118",
        "http://www.ncbi.nlm.nih.gov/pubmed/37883436",
        "http://www.ncbi.nlm.nih.gov/pubmed/33538820",
        "http://www.ncbi.nlm.nih.gov/pubmed/37426456",
        "http://www.ncbi.nlm.nih.gov/pubmed/37090673",
        "http://www.ncbi.nlm.nih.gov/pubmed/35536244",
        "http://www.ncbi.nlm.nih.gov/pubmed/3748365",
        "http://www.ncbi.nlm.nih.gov/pubmed/35389869",
        "http://www.ncbi.nlm.nih.gov/pubmed/37173156",
        "http://www.ncbi.nlm.nih.gov/pubmed/37489753"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37873118",
          "text": "To address this challenge, we here introduce GPN-MSA, a novel framework for DNA language models that leverages whole-genome sequence alignments across multiple species and takes only a few hours to train. Across several benchmarks on clinical databases (ClinVar, COSMIC, and OMIM) and population genomic data (gnomAD), our model for the human genome achieves outstanding performance on deleteriousness prediction for both coding and non-coding variants.",
          "beginSection": "abstract",
          "offsetInBeginSection": 282,
          "endSection": "abstract",
          "offsetInEndSection": 735
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37873118",
          "text": "Whereas protein language models have demonstrated remarkable efficacy in predicting the effects of missense variants, DNA counterparts have not yet achieved a similar competitive edge for genome-wide variant effect predictions, especially in complex genomes such as that of humans. To address this challenge, we here introduce GPN-MSA, a novel framework for DNA language models that leverages whole-genome sequence alignments across multiple species and takes only a few hours to train. Across several benchmarks on clinical databases (ClinVar, COSMIC, and OMIM) and population genomic data (gnomAD), our model for the human genome achieves outstanding performance on deleteriousness prediction for both coding and non-coding variants.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 735
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37883436",
          "text": "DNA language models are powerful predictors of genome-wide variant effects.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 75
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35536244",
          "text": "Here, we present LOGO (Language of Genome), a self-attention based contextualized pre-trained language model containing only two self-attention layers with 1 million parameters as a substantially light architecture that applies self-supervision techniques to learn bidirectional representations of the unlabelled human reference genome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 281,
          "endSection": "abstract",
          "offsetInEndSection": 617
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3748365",
          "text": "Three models of human language.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 31
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35536244",
          "text": "Deep learning based computational approaches emerge recently to help interpret non-coding regions. Here, we present LOGO (Language of Genome), a self-attention based contextualized pre-trained language model containing only two self-attention layers with 1 million parameters as a substantially light architecture that applies self-supervision techniques to learn bidirectional representations of the unlabelled human reference genome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 182,
          "endSection": "abstract",
          "offsetInEndSection": 617
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37873118",
          "text": "Whereas protein language models have demonstrated remarkable efficacy in predicting the effects of missense variants, DNA counterparts have not yet achieved a similar competitive edge for genome-wide variant effect predictions, especially in complex genomes such as that of humans.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 281
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37873118",
          "text": "Whereas protein language models have demonstrated remarkable efficacy in predicting the effects of missense variants, DNA counterparts have not yet achieved a similar competitive edge for genome-wide variant effect predictions, especially in complex genomes such as that of humans. To address this challenge, we here introduce GPN-MSA, a novel framework for DNA language models that leverages whole-genome sequence alignments across multiple species and takes only a few hours to train.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 486
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3748365",
          "text": "Three models of human language processing can be discerned in contemporary neurobiology: the Wernicke-Broca model, primarily derived from studies of stroke and other brain lesions; the model developed by Dr. George Ojemann from electrical stimulation mapping of the cerebral cortex; and the linguistic model, evolved from Noam Chomsky's linguistic theories.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 357
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35536244",
          "text": "Interpretation of non-coding genome remains an unsolved challenge in human genetics due to impracticality of exhaustively annotating biochemically active elements in all conditions. Deep learning based computational approaches emerge recently to help interpret non-coding regions. Here, we present LOGO (Language of Genome), a self-attention based contextualized pre-trained language model containing only two self-attention layers with 1 million parameters as a substantially light architecture that applies self-supervision techniques to learn bidirectional representations of the unlabelled human reference genome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 617
        }
      ],
      "ideal_answer": "Currently, GPN-MSA and LOGO are two DNA language models that exist to model the human genome.",
      "exact_answer": [
        [
          "GPN-MSA"
        ],
        [
          "LOGO"
        ]
      ]
    },
    {
      "id": "661d1d2deac11fad33000015",
      "type": "list",
      "body": "What biomarkers are used for the identification of neonatal sepsis in low-income countries?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36649385",
        "http://www.ncbi.nlm.nih.gov/pubmed/32070161",
        "http://www.ncbi.nlm.nih.gov/pubmed/35299860",
        "http://www.ncbi.nlm.nih.gov/pubmed/35427523",
        "http://www.ncbi.nlm.nih.gov/pubmed/33782558",
        "http://www.ncbi.nlm.nih.gov/pubmed/29027207",
        "http://www.ncbi.nlm.nih.gov/pubmed/24367543",
        "http://www.ncbi.nlm.nih.gov/pubmed/34582466",
        "http://www.ncbi.nlm.nih.gov/pubmed/32401160",
        "http://www.ncbi.nlm.nih.gov/pubmed/23198116"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36649385",
          "text": "Systematic review and meta-analysis of the diagnostic value of four biomarkers in detecting neonatal sepsis in low- and middle-income countries.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 144
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36649385",
          "text": "BACKGROUND\nBiomarkers may enhance diagnostic capability for common paediatric infections, especially in low- and middle-income countries (LMICs) where standard diagnostic modalities are frequently unavailable, but disease burden is high. A comprehensive understanding of the diagnostic capability of commonly available biomarkers for neonatal sepsis in LMICs is lacking. Our objective was to systematically review evidence on biomarkers to understand their diagnostic performance for neonatal sepsis in LMICs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 509
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36649385",
          "text": "BACKGROUND\nBiomarkers may enhance diagnostic capability for common paediatric infections, especially in low- and middle-income countries (LMICs) where standard diagnostic modalities are frequently unavailable, but disease burden is high. A comprehensive understanding of the diagnostic capability of commonly available biomarkers for neonatal sepsis in LMICs is lacking.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 370
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36649385",
          "text": "A comprehensive understanding of the diagnostic capability of commonly available biomarkers for neonatal sepsis in LMICs is lacking.",
          "beginSection": "abstract",
          "offsetInBeginSection": 238,
          "endSection": "abstract",
          "offsetInEndSection": 370
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32070161",
          "text": "Neonatal sepsis in low-income countries: epidemiology, diagnosis and prevention.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 80
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36649385",
          "text": "ESR and WBC demonstrated poor discrimination for neonatal sepsis in LMICs. Future studies may incorporate biomarkers into clinical evaluation in LMICs to diagnose neonatal sepsis more accurately.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1552,
          "endSection": "abstract",
          "offsetInEndSection": 1747
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36649385",
          "text": "A comprehensive understanding of the diagnostic capability of commonly available biomarkers for neonatal sepsis in LMICs is lacking. Our objective was to systematically review evidence on biomarkers to understand their diagnostic performance for neonatal sepsis in LMICs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 238,
          "endSection": "abstract",
          "offsetInEndSection": 509
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36649385",
          "text": "Future studies may incorporate biomarkers into clinical evaluation in LMICs to diagnose neonatal sepsis more accurately.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1627,
          "endSection": "abstract",
          "offsetInEndSection": 1747
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36649385",
          "text": "A comprehensive understanding of the diagnostic capability of commonly available biomarkers for neonatal sepsis in LMICs is lacking. Our objective was to systematically review evidence on biomarkers to understand their diagnostic performance for neonatal sepsis in LMICs. METHODS\nWe conducted a systematic review and meta-analysis of studies published in English, Spanish, French, German, Dutch, and Arabic reporting the diagnostic performance of C reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cell count (WBC) and procalcitonin (PCT) for neonatal sepsis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 238,
          "endSection": "abstract",
          "offsetInEndSection": 824
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36649385",
          "text": "ESR and WBC demonstrated poor discrimination for neonatal sepsis in LMICs. Future studies may incorporate biomarkers into clinical evaluation in LMICs to diagnose neonatal sepsis more accurately. PROSPERO REGISTRATION NUMBER\nCRD42020188680.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1552,
          "endSection": "abstract",
          "offsetInEndSection": 1794
        }
      ],
      "ideal_answer": "CRP and PCT are used for the identification of neonatal sepsis in low-income countries.",
      "exact_answer": [
        [
          "CRP"
        ],
        [
          "PCT"
        ]
      ]
    },
    {
      "id": "65cfdd9c1930410b13000027",
      "type": "summary",
      "body": "What is the mechanism of action of Mirikizumab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37389706",
        "http://www.ncbi.nlm.nih.gov/pubmed/37379135",
        "http://www.ncbi.nlm.nih.gov/pubmed/37465925",
        "http://www.ncbi.nlm.nih.gov/pubmed/37069321",
        "http://www.ncbi.nlm.nih.gov/pubmed/37594044",
        "http://www.ncbi.nlm.nih.gov/pubmed/34748774",
        "http://www.ncbi.nlm.nih.gov/pubmed/30734266",
        "http://www.ncbi.nlm.nih.gov/pubmed/37993033",
        "http://www.ncbi.nlm.nih.gov/pubmed/37610533",
        "http://www.ncbi.nlm.nih.gov/pubmed/37057827"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37465925",
          "text": "Mirikizumab is a humanized IgG4 monoclonal antibody against the p19 subunit of IL-23, dosed intravenously during induction and subcutaneously during maintenance.",
          "beginSection": "abstract",
          "offsetInBeginSection": 289,
          "endSection": "abstract",
          "offsetInEndSection": 450
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37465925",
          "text": "Mirikizumab is a humanized IgG4 monoclonal antibody against the p19 subunit of IL-23, dosed intravenously during induction and subcutaneously during maintenance. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 289,
          "endSection": "abstract",
          "offsetInEndSection": 451
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37465925",
          "text": "Mirikizumab is a humanized IgG4 monoclonal antibody against the p19 subunit of IL-23, dosed intravenously during induction and subcutaneously during maintenance. It is effective for the induction and maintenance of remission in moderately to severely active UC, including patients with prior failure of biological or tofacitinib therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 289,
          "endSection": "abstract",
          "offsetInEndSection": 626
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37465925",
          "text": "Mirikizumab is a humanized IgG4 monoclonal antibody against the p19 subunit of IL-23, dosed intravenously during induction and subcutaneously during maintenance. It is effective for the induction and maintenance of remission in moderately to severely active UC, including patients with prior failure of biological or tofacitinib therapy. Like other IL-23 antagonists, mirikizumab has a favorable safety profile.",
          "beginSection": "abstract",
          "offsetInBeginSection": 289,
          "endSection": "abstract",
          "offsetInEndSection": 700
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37465925",
          "text": "The IL-23 pathway has emerged as an important therapeutic target for UC. Mirikizumab is a humanized IgG4 monoclonal antibody against the p19 subunit of IL-23, dosed intravenously during induction and subcutaneously during maintenance. It is effective for the induction and maintenance of remission in moderately to severely active UC, including patients with prior failure of biological or tofacitinib therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 216,
          "endSection": "abstract",
          "offsetInEndSection": 626
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37465925",
          "text": "The IL-23 pathway has emerged as an important therapeutic target for UC. Mirikizumab is a humanized IgG4 monoclonal antibody against the p19 subunit of IL-23, dosed intravenously during induction and subcutaneously during maintenance.",
          "beginSection": "abstract",
          "offsetInBeginSection": 216,
          "endSection": "abstract",
          "offsetInEndSection": 450
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37465925",
          "text": "Despite a growing number of available therapeutic options for ulcerative colitis (UC), up to 50% of patients do not respond to initial treatment or lose response over time, highlighting the need for novel therapies. The IL-23 pathway has emerged as an important therapeutic target for UC. Mirikizumab is a humanized IgG4 monoclonal antibody against the p19 subunit of IL-23, dosed intravenously during induction and subcutaneously during maintenance.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 450
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37389706",
          "text": "Mirikizumab (Omvoh®), a humanized IgG4 anti-human IL-23p19 monoclonal antibody, is being developed by Eli Lilly and Company Ltd for the treatment of ulcerative colitis and Crohn's disease. Mirikizumab was approved in March 2023 in Japan for use as induction and maintenance therapy in patients with moderate to severe ulcerative colitis who have an inadequate response to conventional therapy or therapies and is the first IL-23p19 inhibitor to be approved for this indication.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 477
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37389706",
          "text": "Mirikizumab (Omvoh®), a humanized IgG4 anti-human IL-23p19 monoclonal antibody, is being developed by Eli Lilly and Company Ltd for the treatment of ulcerative colitis and Crohn's disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 188
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37389706",
          "text": "Mirikizumab (Omvoh®), a humanized IgG4 anti-human IL-23p19 monoclonal antibody, is being developed by Eli Lilly and Company Ltd for the treatment of ulcerative colitis and Crohn's disease. Mirikizumab was approved in March 2023 in Japan for use as induction and maintenance therapy in patients with moderate to severe ulcerative colitis who have an inadequate response to conventional therapy or therapies and is the first IL-23p19 inhibitor to be approved for this indication. Mirikizumab was granted a positive opinion in the EU in March 2023 for the treatment of adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 753
        }
      ],
      "ideal_answer": "Mirikizumab is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of IL-23, inhibiting its interaction with the IL-23 receptor and thereby preventing the downstream inflammatory cascade.",
      "exact_answer": "n/a"
    },
    {
      "id": "66099c30fdcbea915f000024",
      "type": "list",
      "body": "What clinical indications does the self-expanding colon stent have in colorectal cancer patients?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26798442",
        "http://www.ncbi.nlm.nih.gov/pubmed/26064818",
        "http://www.ncbi.nlm.nih.gov/pubmed/30445358",
        "http://www.ncbi.nlm.nih.gov/pubmed/30550698",
        "http://www.ncbi.nlm.nih.gov/pubmed/11182388",
        "http://www.ncbi.nlm.nih.gov/pubmed/25731261",
        "http://www.ncbi.nlm.nih.gov/pubmed/12833730",
        "http://www.ncbi.nlm.nih.gov/pubmed/17784867",
        "http://www.ncbi.nlm.nih.gov/pubmed/26805137",
        "http://www.ncbi.nlm.nih.gov/pubmed/22500788"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30550698",
          "text": "Colon stent self-expanding metallic stents(SEMS) are useful for obstructive colorectal cancers (CRC). SEMS placement has indicated in the palliation of malignant colorectal obstruc- tion, and bridge to elective surgery for resectable colorectal cancers. SEMS can reduce the risk of early complications, mortality, stoma creation rate, and shorten hospital stay.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 361
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30550698",
          "text": "Colon stent self-expanding metallic stents(SEMS) are useful for obstructive colorectal cancers (CRC). SEMS placement has indicated in the palliation of malignant colorectal obstruc- tion, and bridge to elective surgery for resectable colorectal cancers.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 253
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30445358",
          "text": "INTRODUCTION\nThe self-expanding metal stent (SEMS) has been used in malignant colorectal obstruction as a bridge to surgery or for palliative treatment. We report a case of obstructive descending colon diverticulitis in-stent restenosis, which is difficult to distinguish from colon cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 290
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30445358",
          "text": "INTRODUCTION\nThe self-expanding metal stent (SEMS) has been used in malignant colorectal obstruction as a bridge to surgery or for palliative treatment. We report a case of obstructive descending colon diverticulitis in-stent restenosis, which is difficult to distinguish from colon cancer. PRESENTATION OF CASE\nA 48-year-old man presented with abdominal pain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 362
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30550698",
          "text": "Colon stent self-expanding metallic stents(SEMS) are useful for obstructive colorectal cancers (CRC).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 101
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30550698",
          "text": "Self-expanding metallic stent for unresectable obstructive colorectal cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 77
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30445358",
          "text": "Self-expanding metal stent restenosis in obstructive colon diverticulitis mimicking colon cancer: A case report.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 112
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11182388",
          "text": "PURPOSE\nThis report describes our experience with the use of self-expanding metallic stents (SEMS) in the management of obstructing colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 150
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30445358",
          "text": "INTRODUCTION\nThe self-expanding metal stent (SEMS) has been used in malignant colorectal obstruction as a bridge to surgery or for palliative treatment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 152
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11182388",
          "text": "PURPOSE\nThis report describes our experience with the use of self-expanding metallic stents (SEMS) in the management of obstructing colorectal cancer. METHODS\nA retrospective chart review of all patients undergoing placement of SEMS between May 1997 and January 2000 was performed. RESULTS\nInsertion of SEMS was attempted in 12 patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 341
        }
      ],
      "ideal_answer": "The self-expanding colon stent is indicated for palliation and as a bridge to elective surgery in patients with obstructive colorectal cancers. It can reduce the risk of early complications, mortality, stoma creation rate, and shorten hospital stay.",
      "exact_answer": [
        [
          "palliation"
        ],
        [
          "bridge to elective surgery"
        ],
        [
          "resectable colorectal cancers"
        ],
        [
          "obstructive colorectal cancers"
        ]
      ]
    },
    {
      "id": "661a624bfdcbea915f00005b",
      "type": "list",
      "body": "List the cells which have CD21 on the surface.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27010233",
        "http://www.ncbi.nlm.nih.gov/pubmed/11367532",
        "http://www.ncbi.nlm.nih.gov/pubmed/28449602",
        "http://www.ncbi.nlm.nih.gov/pubmed/28061947",
        "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
        "http://www.ncbi.nlm.nih.gov/pubmed/7691616",
        "http://www.ncbi.nlm.nih.gov/pubmed/30046318",
        "http://www.ncbi.nlm.nih.gov/pubmed/23266128",
        "http://www.ncbi.nlm.nih.gov/pubmed/3278912",
        "http://www.ncbi.nlm.nih.gov/pubmed/9250823"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
          "text": "CD21 is primarily expressed on B lymphocytes and follicular dendritic cells, but has also been reported on T cells. We established a semi-quantitative PCR and compared the CD21 mRNA levels of B and T lymphocytes with the expression of the CD21 glycoprotein on the surface of the respective cells by flow cytometry. The B cell lines Raji and Ramos and the T cell lines Jurkat and Molt4 expressed equal amounts of CD21 mRNA, but differed in surface staining.",
          "beginSection": "abstract",
          "offsetInBeginSection": 420,
          "endSection": "abstract",
          "offsetInEndSection": 876
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
          "text": "Nevertheless only B cells, but not CD4+ or CD8+ T cells, expressed detectable amounts of CD21 on their cell surface. Expression of the CD21 exon 11 has been reported being restricted to follicular dendritic cells only. To the contrary, we found that both purified B and T cell subpopulations expressed CD21 mRNA with and without exon 11.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1189,
          "endSection": "abstract",
          "offsetInEndSection": 1526
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
          "text": "Nevertheless only B cells, but not CD4+ or CD8+ T cells, expressed detectable amounts of CD21 on their cell surface. Expression of the CD21 exon 11 has been reported being restricted to follicular dendritic cells only.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1189,
          "endSection": "abstract",
          "offsetInEndSection": 1407
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
          "text": "Nevertheless only B cells, but not CD4+ or CD8+ T cells, expressed detectable amounts of CD21 on their cell surface.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1189,
          "endSection": "abstract",
          "offsetInEndSection": 1305
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
          "text": "CD21 is primarily expressed on B lymphocytes and follicular dendritic cells, but has also been reported on T cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 420,
          "endSection": "abstract",
          "offsetInEndSection": 535
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
          "text": "B lymphocytes and CD4+ or CD8+ T cells expressed similar amounts of CD21 mRNA. Nevertheless only B cells, but not CD4+ or CD8+ T cells, expressed detectable amounts of CD21 on their cell surface. Expression of the CD21 exon 11 has been reported being restricted to follicular dendritic cells only.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1110,
          "endSection": "abstract",
          "offsetInEndSection": 1407
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27010233",
          "text": "Although CD21 is important, B cells that express low amounts or lack surface CD21 (CD21(-/low) ) are increased in conditions with chronic inflammation, e.g.",
          "beginSection": "abstract",
          "offsetInBeginSection": 218,
          "endSection": "abstract",
          "offsetInEndSection": 374
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27010233",
          "text": "Although CD21 is important, B cells that express low amounts or lack surface CD21 (CD21(-/low) ) are increased in conditions with chronic inflammation, e.g. autoimmune diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 218,
          "endSection": "abstract",
          "offsetInEndSection": 395
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
          "text": "The B cell lines Raji and Ramos and the T cell lines Jurkat and Molt4 expressed equal amounts of CD21 mRNA, but differed in surface staining.",
          "beginSection": "abstract",
          "offsetInBeginSection": 735,
          "endSection": "abstract",
          "offsetInEndSection": 876
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
          "text": "B lymphocytes and CD4+ or CD8+ T cells expressed similar amounts of CD21 mRNA. Nevertheless only B cells, but not CD4+ or CD8+ T cells, expressed detectable amounts of CD21 on their cell surface.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1110,
          "endSection": "abstract",
          "offsetInEndSection": 1305
        }
      ],
      "ideal_answer": "B lymphocytes and follicular dendritic cells have CD21 on the surface.",
      "exact_answer": [
        [
          "B lymphocytes"
        ],
        [
          "follicular dendritic cells"
        ]
      ]
    },
    {
      "id": "6616a250fdcbea915f000059",
      "type": "yesno",
      "body": "Do PPIs increase the risk of gastric cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34226290",
        "http://www.ncbi.nlm.nih.gov/pubmed/37505975",
        "http://www.ncbi.nlm.nih.gov/pubmed/37326271",
        "http://www.ncbi.nlm.nih.gov/pubmed/29852782",
        "http://www.ncbi.nlm.nih.gov/pubmed/36585832",
        "http://www.ncbi.nlm.nih.gov/pubmed/37655427",
        "http://www.ncbi.nlm.nih.gov/pubmed/37882179",
        "http://www.ncbi.nlm.nih.gov/pubmed/18636786",
        "http://www.ncbi.nlm.nih.gov/pubmed/31206764",
        "http://www.ncbi.nlm.nih.gov/pubmed/33975680"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36585832",
          "text": "BACKGROUND\nProton-pump inhibitors (PPIs) are suspected to increase the risk of gastric cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 94
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29852782",
          "text": "Recently, two epidemiological studies showed that long-term treatment with proton pump inhibitors (PPIs) increased the risk of gastric cancer. It is well known that hypergastrinemia predisposes to gastric neoplasia in animals as well as man.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 241
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29852782",
          "text": "Recently, two epidemiological studies showed that long-term treatment with proton pump inhibitors (PPIs) increased the risk of gastric cancer. It is well known that hypergastrinemia predisposes to gastric neoplasia in animals as well as man. Recently a study showed that hypergastrinemic patients had an increased risk of gastric cancer when followed for about 25 years.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 370
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29852782",
          "text": "Recently, two epidemiological studies showed that long-term treatment with proton pump inhibitors (PPIs) increased the risk of gastric cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 142
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29852782",
          "text": "Recently a study showed that hypergastrinemic patients had an increased risk of gastric cancer when followed for about 25 years. It is likely that hypergastrinemia is the pathogenic factor for gastric carcinogenesis due to PPI.",
          "beginSection": "abstract",
          "offsetInBeginSection": 242,
          "endSection": "abstract",
          "offsetInEndSection": 469
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36585832",
          "text": "BACKGROUND\nProton-pump inhibitors (PPIs) are suspected to increase the risk of gastric cancer. AIM\nTo assess the risk of gastric cancer associated with the use of PPIs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 170
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36585832",
          "text": "BACKGROUND\nProton-pump inhibitors (PPIs) are suspected to increase the risk of gastric cancer. AIM\nTo assess the risk of gastric cancer associated with the use of PPIs. METHODS\nWe systematically searched Medline/PubMed, Embase and Scopus databases (until June 1, 2022) for randomised and non-randomised studies (NRS) of the association between PPIs and gastric cancer having considered Histamine-2 receptor antagonists (H2RAs) users as controls.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 449
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29852782",
          "text": "Recently a study showed that hypergastrinemic patients had an increased risk of gastric cancer when followed for about 25 years. It is likely that hypergastrinemia is the pathogenic factor for gastric carcinogenesis due to PPI. PPI are the only group of drugs that causes long-term hypergastrinemia in the doses used in a clinical setting.",
          "beginSection": "abstract",
          "offsetInBeginSection": 242,
          "endSection": "abstract",
          "offsetInEndSection": 581
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37326271",
          "text": "PPIs and gastric cancer: any causal relationship?",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 49
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29852782",
          "text": "Proton pump inhibitors (PPIs) may cause gastric cancer - clinical consequences.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 79
        }
      ],
      "ideal_answer": "Yes, long-term use of proton-pump inhibitors (PPIs) may increase the risk of gastric cancer, possibly due to hypergastrinemia.",
      "exact_answer": "yes"
    },
    {
      "id": "661c414d48a2c27714000007",
      "type": "yesno",
      "body": "Can enhancers act as promoters?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29378788",
        "http://www.ncbi.nlm.nih.gov/pubmed/31605096",
        "http://www.ncbi.nlm.nih.gov/pubmed/22264824",
        "http://www.ncbi.nlm.nih.gov/pubmed/3016550",
        "http://www.ncbi.nlm.nih.gov/pubmed/35803216",
        "http://www.ncbi.nlm.nih.gov/pubmed/26984057",
        "http://www.ncbi.nlm.nih.gov/pubmed/36167150",
        "http://www.ncbi.nlm.nih.gov/pubmed/26317464",
        "http://www.ncbi.nlm.nih.gov/pubmed/34473698",
        "http://www.ncbi.nlm.nih.gov/pubmed/22508764"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22264824",
          "text": "In mammals there are more enhancers than promoters which are distributed both between and within genes. Here we show that activated, intragenic enhancers frequently act as alternative tissue-specific promoters producing a class of abundant, spliced, multiexonic poly(A)(+) RNAs (meRNAs) which reflect the host gene's structure.",
          "beginSection": "abstract",
          "offsetInBeginSection": 151,
          "endSection": "abstract",
          "offsetInEndSection": 478
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22264824",
          "text": "Intragenic enhancers act as alternative promoters.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 50
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36167150",
          "text": "Enhancers and promoters are cis-regulatory elements that control gene expression. Enhancers are activated in a cell type-, tissue-, and condition-specific manner to stimulate promoter function and transcription.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 211
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36167150",
          "text": "Enhancers and promoters are cis-regulatory elements that control gene expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 81
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3016550",
          "text": "Enhancers are DNA sequences that stimulate transcription from eukaryotic promoters. This stimulatory effect can be exerted over large distances and from a position either 5' or 3' of a promoter.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 194
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22264824",
          "text": "Here we show that activated, intragenic enhancers frequently act as alternative tissue-specific promoters producing a class of abundant, spliced, multiexonic poly(A)(+) RNAs (meRNAs) which reflect the host gene's structure.",
          "beginSection": "abstract",
          "offsetInBeginSection": 255,
          "endSection": "abstract",
          "offsetInEndSection": 478
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3016550",
          "text": "Enhancers are DNA sequences that stimulate transcription from eukaryotic promoters. This stimulatory effect can be exerted over large distances and from a position either 5' or 3' of a promoter. Enhancers have been found in the genomes of many viruses, and in some cellular genes such as those encoding immunoglobulin heavy chain and kappa light chain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 352
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36167150",
          "text": "Enhancers are activated in a cell type-, tissue-, and condition-specific manner to stimulate promoter function and transcription.",
          "beginSection": "abstract",
          "offsetInBeginSection": 82,
          "endSection": "abstract",
          "offsetInEndSection": 211
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3016550",
          "text": "Enhancers are DNA sequences that stimulate transcription from eukaryotic promoters.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 83
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35803216",
          "text": "Two recent reports (Martinez-Ara et al., 2022; Bergman et al., 2022) explore the compatibility between enhancers and promoters and find that enhancers preferentially activate promoters with low intrinsic activity rather than favoring housekeeping or cell-type-specific promoters.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 279
        }
      ],
      "ideal_answer": "Yes, enhancers can act as promoters, specifically activated intragenic enhancers can act as alternative tissue-specific promoters producing a class of abundant, spliced, multiexonic poly(A)(+) RNAs (meRNAs) which reflect the host gene's structure.",
      "exact_answer": "yes"
    },
    {
      "id": "661d575eeac11fad33000020",
      "type": "summary",
      "body": "How is pain treated in patients with Ehlers-Danlos Syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36305215",
        "http://www.ncbi.nlm.nih.gov/pubmed/10906878",
        "http://www.ncbi.nlm.nih.gov/pubmed/31328377",
        "http://www.ncbi.nlm.nih.gov/pubmed/22616833",
        "http://www.ncbi.nlm.nih.gov/pubmed/3983062",
        "http://www.ncbi.nlm.nih.gov/pubmed/30214474",
        "http://www.ncbi.nlm.nih.gov/pubmed/30512708",
        "http://www.ncbi.nlm.nih.gov/pubmed/34845584",
        "http://www.ncbi.nlm.nih.gov/pubmed/7455751",
        "http://www.ncbi.nlm.nih.gov/pubmed/16600507"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22616833",
          "text": "Questions from patients about pain conditions and analgesic pharmacotherapy and responses from authors are presented to help educate patients and make them more effective self-advocates. The topics addressed in this issue are Ehlers-Danlos syndrome and associated chronic pain; the information is meant to help readers understand the mechanisms for pain in this connective tissue disorder as well as general treatment principles for chronic pain management.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 457
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22616833",
          "text": "The topics addressed in this issue are Ehlers-Danlos syndrome and associated chronic pain; the information is meant to help readers understand the mechanisms for pain in this connective tissue disorder as well as general treatment principles for chronic pain management.",
          "beginSection": "abstract",
          "offsetInBeginSection": 187,
          "endSection": "abstract",
          "offsetInEndSection": 457
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10906878",
          "text": "Thirty patients with Type III Ehlers-Danlos syndrome reported joint pain more frequently than did patients with Types I, II, or IV. Ambulation was impaired significantly in patients with Type III disorder as a whole, as was functional hand strength and upper extremity function.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1014,
          "endSection": "abstract",
          "offsetInEndSection": 1292
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10906878",
          "text": "Thirty patients with Type III Ehlers-Danlos syndrome reported joint pain more frequently than did patients with Types I, II, or IV.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1014,
          "endSection": "abstract",
          "offsetInEndSection": 1145
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22616833",
          "text": "Ehlers-Danlos syndrome and chronic pain.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 40
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30512708",
          "text": "Ehlers-Danlos syndrome do not have any specific etiological treatment. The management is poorly systematized due to the absence of controlled clinical trials or good clinical practice recommendations. Patients should be seen in a department of genetics, physical medicine and rehabilitation or rheumatology to avoid the diagnostic odyssey and help preventing disease complications.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1203,
          "endSection": "abstract",
          "offsetInEndSection": 1584
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10906878",
          "text": "Thirty patients with Type III Ehlers-Danlos syndrome reported joint pain more frequently than did patients with Types I, II, or IV. Ambulation was impaired significantly in patients with Type III disorder as a whole, as was functional hand strength and upper extremity function. Back or neck pain was a common (67.2%) report among patients with all types of disease but did not correlate with the presence or absence of spinal deformity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1014,
          "endSection": "abstract",
          "offsetInEndSection": 1451
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3983062",
          "text": "This is a previously unrecorded complication of Ehlers-Danlos syndrome and should be considered in the differential diagnosis of chest and abdominal pain in patients with this condition.",
          "beginSection": "abstract",
          "offsetInBeginSection": 172,
          "endSection": "abstract",
          "offsetInEndSection": 358
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30512708",
          "text": "Ehlers-Danlos syndrome do not have any specific etiological treatment. The management is poorly systematized due to the absence of controlled clinical trials or good clinical practice recommendations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1203,
          "endSection": "abstract",
          "offsetInEndSection": 1403
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10906878",
          "text": "Musculoskeletal problems include joint pain, swelling and instability, and spinal deformity. This study was undertaken to assess functional orthopaedic problems of patients with Ehlers-Danlos syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 86,
          "endSection": "abstract",
          "offsetInEndSection": 287
        }
      ],
      "ideal_answer": "Pain in patients with Ehlers-Danlos Syndrome is treated with general chronic pain management principles, as there is no specific etiological treatment for the condition. Patients should be seen in a department of genetics, physical medicine and rehabilitation or rheumatology to avoid the diagnostic odyssey and help preventing disease complications.",
      "exact_answer": "n/a"
    },
    {
      "id": "65cfa6201930410b1300000e",
      "type": "yesno",
      "body": "Is Patisiran used for Transthyretin Cardiac Amyloidosis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37888916",
        "http://www.ncbi.nlm.nih.gov/pubmed/36336119",
        "http://www.ncbi.nlm.nih.gov/pubmed/37288260",
        "http://www.ncbi.nlm.nih.gov/pubmed/37599395",
        "http://www.ncbi.nlm.nih.gov/pubmed/33841597",
        "http://www.ncbi.nlm.nih.gov/pubmed/30644768",
        "http://www.ncbi.nlm.nih.gov/pubmed/37456349",
        "http://www.ncbi.nlm.nih.gov/pubmed/32519928",
        "http://www.ncbi.nlm.nih.gov/pubmed/31309347",
        "http://www.ncbi.nlm.nih.gov/pubmed/30480471"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37888916",
          "text": "Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 71
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33841597",
          "text": "Patisiran might be a promising disease-modifying drug for hereditary transthyretin cardiac amyloidosis even in its advanced stage, although further evaluation in a large cohort is warranted.",
          "beginSection": "abstract",
          "offsetInBeginSection": 351,
          "endSection": "abstract",
          "offsetInEndSection": 541
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33841597",
          "text": "We experienced a 78-year-old woman who was diagnosed with hereditary transthyretin cardiac amyloidosis and administered patisiran for advanced heart failure refractory to tafamidis. The levels of N-terminal pro B-type natriuretic peptide and left ventricular mass index decreased following the six-month patisiran treatment without any complications. Patisiran might be a promising disease-modifying drug for hereditary transthyretin cardiac amyloidosis even in its advanced stage, although further evaluation in a large cohort is warranted.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 541
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33841597",
          "text": "Patisiran for advanced heart failure with hereditary transthyretin cardiac amyloidosis.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 87
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33841597",
          "text": "We experienced a 78-year-old woman who was diagnosed with hereditary transthyretin cardiac amyloidosis and administered patisiran for advanced heart failure refractory to tafamidis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 181
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37456349",
          "text": "Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 86
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33841597",
          "text": "We experienced a 78-year-old woman who was diagnosed with hereditary transthyretin cardiac amyloidosis and administered patisiran for advanced heart failure refractory to tafamidis. The levels of N-terminal pro B-type natriuretic peptide and left ventricular mass index decreased following the six-month patisiran treatment without any complications.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 350
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30644768",
          "text": "Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 77
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30644768",
          "text": "Expert Commentary: Patisiran offers a new treatment option for patients with hereditary transthyretin-mediated amyloidosis. Patisiran can significantly reduce the TTR level and improve patient's neuropathy and quality of life. The common adverse reactions were upper respiratory tract infections and infusion-related reactions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 446,
          "endSection": "abstract",
          "offsetInEndSection": 773
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33841597",
          "text": "The levels of N-terminal pro B-type natriuretic peptide and left ventricular mass index decreased following the six-month patisiran treatment without any complications. Patisiran might be a promising disease-modifying drug for hereditary transthyretin cardiac amyloidosis even in its advanced stage, although further evaluation in a large cohort is warranted.",
          "beginSection": "abstract",
          "offsetInBeginSection": 182,
          "endSection": "abstract",
          "offsetInEndSection": 541
        }
      ],
      "ideal_answer": "Yes, Patisiran is used for Transthyretin Cardiac Amyloidosis. It is a promising disease-modifying drug for hereditary transthyretin cardiac amyloidosis even in its advanced stage. It can significantly reduce the TTR level and improve patient's neuropathy and quality of life. The common adverse reactions are upper respiratory tract infections and infusion-related reactions.",
      "exact_answer": "yes"
    },
    {
      "id": "65f77a32c4010b4d7800003a",
      "type": "list",
      "body": "What are the molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32175278",
        "http://www.ncbi.nlm.nih.gov/pubmed/29184575",
        "http://www.ncbi.nlm.nih.gov/pubmed/19381027",
        "http://www.ncbi.nlm.nih.gov/pubmed/20087037",
        "http://www.ncbi.nlm.nih.gov/pubmed/21368463",
        "http://www.ncbi.nlm.nih.gov/pubmed/16724868",
        "http://www.ncbi.nlm.nih.gov/pubmed/15612152",
        "http://www.ncbi.nlm.nih.gov/pubmed/19942597",
        "http://www.ncbi.nlm.nih.gov/pubmed/30253191",
        "http://www.ncbi.nlm.nih.gov/pubmed/19152449"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19381027",
          "text": "The prognosis of advanced colorectal cancer has been improved by introduction of molecular targeting agents, such as bevacizumab and cetuximab.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 143
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21368463",
          "text": "PURPOSE\nThe aim of this study was to retrospectively assess if arterial hypertension induced during treatment with bevacizumab was associated with the clinical outcome in advanced, recurrent colorectal cancer patients treated with first-line bevacizumab. SUBJECTS\n13 patients( 7 men and 6 women) with advanced, recurrent colorectal cancer were treated by mFOLFOX6 regimen with first-line bevacizumab from August 2008 to July 2009.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 432
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21368463",
          "text": "Patients with hypertension tended to have a better response rate and disease control rate than patients without hypertension. CONCLUSION\nBevacizumab-induced hypertension may represent a prognostic factor for clinical outcome in advanced, recurrent colorectal cancer patients treated with first-line bevacizumab.",
          "beginSection": "abstract",
          "offsetInBeginSection": 822,
          "endSection": "abstract",
          "offsetInEndSection": 1135
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16724868",
          "text": "Bevacizumab has acceptable tolerability in patients with advanced colorectal cancer, breast cancer, or NSCLC, with the majority of adverse events being generally mild and clinically manageable.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1107,
          "endSection": "abstract",
          "offsetInEndSection": 1300
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21368463",
          "text": "SUBJECTS\n13 patients( 7 men and 6 women) with advanced, recurrent colorectal cancer were treated by mFOLFOX6 regimen with first-line bevacizumab from August 2008 to July 2009.",
          "beginSection": "abstract",
          "offsetInBeginSection": 257,
          "endSection": "abstract",
          "offsetInEndSection": 432
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16724868",
          "text": "Bevacizumab has acceptable tolerability in patients with advanced colorectal cancer, breast cancer, or NSCLC, with the majority of adverse events being generally mild and clinically manageable. Thus, bevacizumab provides a highly effective addition to standard chemotherapeutic regimens for advanced colorectal cancer, breast cancer, and NSCLC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1107,
          "endSection": "abstract",
          "offsetInEndSection": 1451
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16724868",
          "text": "In the second-line treatment of advanced colorectal cancer, patients who received bevacizumab in combination with a fluorouracil/leucovorin plus oxaliplatin (FOLFOX4) regimen had an overall survival time that was 2 months longer than that in patients receiving FOLFOX4.",
          "beginSection": "abstract",
          "offsetInBeginSection": 426,
          "endSection": "abstract",
          "offsetInEndSection": 695
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21368463",
          "text": "PURPOSE\nThe aim of this study was to retrospectively assess if arterial hypertension induced during treatment with bevacizumab was associated with the clinical outcome in advanced, recurrent colorectal cancer patients treated with first-line bevacizumab.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 254
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19381027",
          "text": "The prognosis of advanced colorectal cancer has been improved by introduction of molecular targeting agents, such as bevacizumab and cetuximab. Several clinical trials revealed a median survival time of more than 2 years.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 221
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19381027",
          "text": "Although the mechanisms of the resistance of molecular targeting agents for colorectal cancer are still unclear, the inherent resistance to cetuximab or panitumumab by why of expression of KRAS mutation is the first breakthrough in this field.",
          "beginSection": "abstract",
          "offsetInBeginSection": 834,
          "endSection": "abstract",
          "offsetInEndSection": 1077
        }
      ],
      "ideal_answer": "Secondary resistance to Bevacizumab in advanced colorectal cancer patients is unclear, but the inherent resistance to cetuximab or panitumumab by why of expression of KRAS mutation is a known mechanism of resistance to molecular targeting agents in colorectal cancer.",
      "exact_answer": [
        [
          "vascular endothelial growth factor inhibition"
        ],
        [
          "tumor angiogenesis"
        ]
      ]
    },
    {
      "id": "661a6a67fdcbea915f00005d",
      "type": "yesno",
      "body": "Does early stage oral squamous cell carcinoma have  good survival rates?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37356209",
        "http://www.ncbi.nlm.nih.gov/pubmed/37779502",
        "http://www.ncbi.nlm.nih.gov/pubmed/36891418",
        "http://www.ncbi.nlm.nih.gov/pubmed/36688107",
        "http://www.ncbi.nlm.nih.gov/pubmed/37294162",
        "http://www.ncbi.nlm.nih.gov/pubmed/33648813",
        "http://www.ncbi.nlm.nih.gov/pubmed/8699569",
        "http://www.ncbi.nlm.nih.gov/pubmed/22349276",
        "http://www.ncbi.nlm.nih.gov/pubmed/28638410",
        "http://www.ncbi.nlm.nih.gov/pubmed/15792612"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8699569",
          "text": "[A study on survival rates of oral squamous cell carcinoma].",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 60
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33648813",
          "text": "Treatment delay in early-stage oral squamous cell carcinoma and its relation to survival.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 89
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33648813",
          "text": "For patients with early-stage disease, a treatment delay of 20 days is critical regarding overall survival (p = 0.011). For patients with advanced-stage disease, no significant differences have been observed. As patients with early-stage oral squamous cell carcinoma profit from early treatment initiation, we suggest an acceptable maximum treatment delay of no more than 20 days in the surgical management of these patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1361,
          "endSection": "abstract",
          "offsetInEndSection": 1786
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33648813",
          "text": "For patients with advanced-stage disease, no significant differences have been observed. As patients with early-stage oral squamous cell carcinoma profit from early treatment initiation, we suggest an acceptable maximum treatment delay of no more than 20 days in the surgical management of these patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1481,
          "endSection": "abstract",
          "offsetInEndSection": 1786
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33648813",
          "text": "As patients with early-stage oral squamous cell carcinoma profit from early treatment initiation, we suggest an acceptable maximum treatment delay of no more than 20 days in the surgical management of these patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1570,
          "endSection": "abstract",
          "offsetInEndSection": 1786
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33648813",
          "text": "The aim of this study was to investigate the impact of a prolonged treatment delay on survival in patients with primary oral squamous cell carcinoma. The investigators hypothesized that treatment delay affects survival, supposing a poor outcome in patients with prolonged treatment initiation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 293
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33648813",
          "text": "The aim of this study was to investigate the impact of a prolonged treatment delay on survival in patients with primary oral squamous cell carcinoma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 149
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8699569",
          "text": "Oral squamous cell carcinoma is seen predominantly after the fourth decade of life.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 83
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8699569",
          "text": "Oral squamous cell carcinoma is seen predominantly after the fourth decade of life. We have retrospectively reviewed 103 patients (92 males and 11 females) with squamous cell carcinoma, which were confirmed by histopathologic examination and treated by surgical excision at Kaohsiung Medical College Hospital from 1987 to 1991. The age of the patients ranged from 23 to 87 years.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 379
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8699569",
          "text": "Oral squamous cell carcinoma is seen predominantly after the fourth decade of life. We have retrospectively reviewed 103 patients (92 males and 11 females) with squamous cell carcinoma, which were confirmed by histopathologic examination and treated by surgical excision at Kaohsiung Medical College Hospital from 1987 to 1991.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 327
        }
      ],
      "ideal_answer": "Yes, early stage oral squamous cell carcinoma has good survival rates, but early treatment initiation is crucial for optimal outcomes.",
      "exact_answer": "yes"
    },
    {
      "id": "65f85fdbc4010b4d78000054",
      "type": "factoid",
      "body": "What is the technique of choice to perform a caesarean section?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32760792",
        "http://www.ncbi.nlm.nih.gov/pubmed/19110959",
        "http://www.ncbi.nlm.nih.gov/pubmed/11359321",
        "http://www.ncbi.nlm.nih.gov/pubmed/12521877",
        "http://www.ncbi.nlm.nih.gov/pubmed/12521878",
        "http://www.ncbi.nlm.nih.gov/pubmed/12804476",
        "http://www.ncbi.nlm.nih.gov/pubmed/16867092",
        "http://www.ncbi.nlm.nih.gov/pubmed/14626783",
        "http://www.ncbi.nlm.nih.gov/pubmed/12037415",
        "http://www.ncbi.nlm.nih.gov/pubmed/25328165"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12804476",
          "text": "BACKGROUND\nCaesarean section is a common operation with no agreed standard on operative techniques and materials to use. The skin layer can be repaired by sub cuticular stitch immediately below the skin layer, an interrupted stitch or with skin staples. A great variety of materials and techniques are used for skin closure after caesarean section and there is a need to identify which provide the best outcomes for women.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 422
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12804476",
          "text": "BACKGROUND\nCaesarean section is a common operation with no agreed standard on operative techniques and materials to use. The skin layer can be repaired by sub cuticular stitch immediately below the skin layer, an interrupted stitch or with skin staples.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 253
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19110959",
          "text": "Currently, caesarean section is the most commonly indicated procedure.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 70
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19110959",
          "text": "Currently, caesarean section is the most commonly indicated procedure. The proportion of caesarean deliveries continues to rise.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 128
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19110959",
          "text": "Currently, caesarean section is the most commonly indicated procedure. The proportion of caesarean deliveries continues to rise. And the spectrum of surgical indications has dramatically broadened.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 197
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12804476",
          "text": "BACKGROUND\nCaesarean section is a common operation with no agreed standard on operative techniques and materials to use.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 120
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19110959",
          "text": "Thus making it ethical and professionally acceptable to perform a caesarean section based on the wish of a competent and well-informed pregnant woman.",
          "beginSection": "abstract",
          "offsetInBeginSection": 681,
          "endSection": "abstract",
          "offsetInEndSection": 831
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12521878",
          "text": "Elective caesarean section--the patient's choice?",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 49
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12521877",
          "text": "The aim of this survey, carried out prospectively, was to find out whether patients' requests for caesarean section are contributing significantly to the rise in the section rate, by attempting to actually quantify the influence of patients' choice on the decision to perform a caesarean section. The results showed that it is possible to quantify this influence, and that maternal request does play a major role in the decision-making process.",
          "beginSection": "abstract",
          "offsetInBeginSection": 309,
          "endSection": "abstract",
          "offsetInEndSection": 753
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19110959",
          "text": "[Caesarean section--indication or choice?].",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 43
        }
      ],
      "ideal_answer": "The technique of choice to perform a caesarean section is not specified in the given context. The skin layer can be repaired by sub cuticular stitch immediately below the skin layer, an interrupted stitch or with skin staples. The context focuses on the rising rate of caesarean sections and the influence of patients' choice on the decision to perform a caesarean section.",
      "exact_answer": [
        "caesarean section"
      ]
    },
    {
      "id": "661d9e79fe9d0b3967000001",
      "type": "list",
      "body": "Which cell states can exist in melanomas?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32753671",
        "http://www.ncbi.nlm.nih.gov/pubmed/34874265",
        "http://www.ncbi.nlm.nih.gov/pubmed/16230395",
        "http://www.ncbi.nlm.nih.gov/pubmed/7607797",
        "http://www.ncbi.nlm.nih.gov/pubmed/9648905",
        "http://www.ncbi.nlm.nih.gov/pubmed/19437352",
        "http://www.ncbi.nlm.nih.gov/pubmed/15967921",
        "http://www.ncbi.nlm.nih.gov/pubmed/8304780",
        "http://www.ncbi.nlm.nih.gov/pubmed/24682564",
        "http://www.ncbi.nlm.nih.gov/pubmed/26485776"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16230395",
          "text": "Here, we test whether stem cell-like populations exist in human melanomas. In approximately 20% of the metastatic melanomas cultured in growth medium suitable for human embryonic stem cells, we found a subpopulation of cells propagating as nonadherent spheres, whereas in standard medium, adherent monolayer cultures were established. Individual cells from melanoma spheres (melanoma spheroid cells) could differentiate under appropriate conditions into multiple cell lineages, such as melanocytic, adipocytic, osteocytic, and chondrocytic lineages, which recapitulates the plasticity of neural crest stem cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 248,
          "endSection": "abstract",
          "offsetInEndSection": 860
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16230395",
          "text": "Here, we test whether stem cell-like populations exist in human melanomas. In approximately 20% of the metastatic melanomas cultured in growth medium suitable for human embryonic stem cells, we found a subpopulation of cells propagating as nonadherent spheres, whereas in standard medium, adherent monolayer cultures were established.",
          "beginSection": "abstract",
          "offsetInBeginSection": 248,
          "endSection": "abstract",
          "offsetInEndSection": 582
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16230395",
          "text": "CSCs have been identified in several malignancies, including those of blood, brain, and breast. Here, we test whether stem cell-like populations exist in human melanomas. In approximately 20% of the metastatic melanomas cultured in growth medium suitable for human embryonic stem cells, we found a subpopulation of cells propagating as nonadherent spheres, whereas in standard medium, adherent monolayer cultures were established.",
          "beginSection": "abstract",
          "offsetInBeginSection": 152,
          "endSection": "abstract",
          "offsetInEndSection": 582
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16230395",
          "text": "Based on these findings, we propose that melanomas can contain a subpopulation of stem cells that contribute to heterogeneity and tumorigenesis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1252,
          "endSection": "abstract",
          "offsetInEndSection": 1396
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16230395",
          "text": "Here, we test whether stem cell-like populations exist in human melanomas.",
          "beginSection": "abstract",
          "offsetInBeginSection": 248,
          "endSection": "abstract",
          "offsetInEndSection": 322
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16230395",
          "text": "Based on these findings, we propose that melanomas can contain a subpopulation of stem cells that contribute to heterogeneity and tumorigenesis. Targeting this population may lead to effective treatments for melanomas.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1252,
          "endSection": "abstract",
          "offsetInEndSection": 1470
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16230395",
          "text": "CSCs have been identified in several malignancies, including those of blood, brain, and breast. Here, we test whether stem cell-like populations exist in human melanomas.",
          "beginSection": "abstract",
          "offsetInBeginSection": 152,
          "endSection": "abstract",
          "offsetInEndSection": 322
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16230395",
          "text": "Individual cells from melanoma spheres (melanoma spheroid cells) could differentiate under appropriate conditions into multiple cell lineages, such as melanocytic, adipocytic, osteocytic, and chondrocytic lineages, which recapitulates the plasticity of neural crest stem cells. Multipotent melanoma spheroid cells persisted after serial cloning in vitro and transplantation in vivo, indicating their ability to self-renew.",
          "beginSection": "abstract",
          "offsetInBeginSection": 583,
          "endSection": "abstract",
          "offsetInEndSection": 1005
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16230395",
          "text": "Individual cells from melanoma spheres (melanoma spheroid cells) could differentiate under appropriate conditions into multiple cell lineages, such as melanocytic, adipocytic, osteocytic, and chondrocytic lineages, which recapitulates the plasticity of neural crest stem cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 583,
          "endSection": "abstract",
          "offsetInEndSection": 860
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9648905",
          "text": "Depending on the content of the balloon cells, these melanomas are best categorized as either glycogen-rich malignant melanomas or glycogen-rich balloon cell malignant melanomas.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1334,
          "endSection": "abstract",
          "offsetInEndSection": 1512
        }
      ],
      "ideal_answer": "Melanomas can exist in a stem cell-like state, which can differentiate into multiple cell lineages, such as melanocytic, adipocytic, osteocytic, and chondrocytic lineages.",
      "exact_answer": [
        [
          "melanocytic"
        ],
        [
          "adipocytic"
        ],
        [
          "osteocytic"
        ],
        [
          "chondrocytic"
        ]
      ]
    },
    {
      "id": "661d1c3ceac11fad33000012",
      "type": "yesno",
      "body": "Are there any molecular signatures identified for the differentiation between bacterial and viral infections?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34166284",
        "http://www.ncbi.nlm.nih.gov/pubmed/34912024",
        "http://www.ncbi.nlm.nih.gov/pubmed/21517122",
        "http://www.ncbi.nlm.nih.gov/pubmed/37081881",
        "http://www.ncbi.nlm.nih.gov/pubmed/35184750",
        "http://www.ncbi.nlm.nih.gov/pubmed/32712106",
        "http://www.ncbi.nlm.nih.gov/pubmed/33008730",
        "http://www.ncbi.nlm.nih.gov/pubmed/24034494",
        "http://www.ncbi.nlm.nih.gov/pubmed/36543117",
        "http://www.ncbi.nlm.nih.gov/pubmed/32359149"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21517122",
          "text": "Differentiation between viral and bacterial acute infections using chemiluminescent signatures of circulating phagocytes.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 121
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34912024",
          "text": "Transcript host-RNA signatures are a new tool used to differentiate viral from bacterial infections by analyzing the transcriptional biosignatures of RNA in host leukocytes. In this systematic review, we evaluate the efficacy and the possible application of this new diagnostic method in febrile children, along with challenges in its implementation. Our review support the growing evidence that the application of these new tools can improve the characterization of the spectrum of bacterial and viral infections and optimize the use of antibiotics in children.",
          "beginSection": "abstract",
          "offsetInBeginSection": 793,
          "endSection": "abstract",
          "offsetInEndSection": 1355
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34912024",
          "text": "Transcript host-RNA signatures are a new tool used to differentiate viral from bacterial infections by analyzing the transcriptional biosignatures of RNA in host leukocytes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 793,
          "endSection": "abstract",
          "offsetInEndSection": 966
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34912024",
          "text": "Transcript host-RNA signatures are a new tool used to differentiate viral from bacterial infections by analyzing the transcriptional biosignatures of RNA in host leukocytes. In this systematic review, we evaluate the efficacy and the possible application of this new diagnostic method in febrile children, along with challenges in its implementation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 793,
          "endSection": "abstract",
          "offsetInEndSection": 1143
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21517122",
          "text": "Oftentimes the etiological diagnostic differentiation between viral and bacterial infections is problematic, while clinical management decisions need to be made promptly upon admission. Thus, alternative rapid and sensitive diagnostic approaches need to be developed.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 267
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21517122",
          "text": "Oftentimes the etiological diagnostic differentiation between viral and bacterial infections is problematic, while clinical management decisions need to be made promptly upon admission.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 185
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35184750",
          "text": "We did not observe classification differences based on illness severity as defined by ICU admission for bacterial or viral infections. The median AUC across all signatures for COVID-19 classification was 0.80 compared to 0.83 for viral classification in the same datasets. CONCLUSIONS\nIn this systematic comparison of 28 host gene expression signatures, we observed differences based on a signature's size and characteristics of the validation population, including age and infection type.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1501,
          "endSection": "abstract",
          "offsetInEndSection": 1992
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34912024",
          "text": "This is the first review on the use of transcript RNA signatures in febrile children to distinguish viral from bacterial infections. Our review identified a wide variability of target populations and gold standards used to define sepsis and SBIs, limiting the generalization of our findings.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1615,
          "endSection": "abstract",
          "offsetInEndSection": 1906
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34912024",
          "text": "This approach has an adverse effect on costs, antibiotic resistance, and pediatric microbiota. Transcript host-RNA signatures are a new tool used to differentiate viral from bacterial infections by analyzing the transcriptional biosignatures of RNA in host leukocytes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 698,
          "endSection": "abstract",
          "offsetInEndSection": 966
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34912024",
          "text": "This is the first review on the use of transcript RNA signatures in febrile children to distinguish viral from bacterial infections.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1615,
          "endSection": "abstract",
          "offsetInEndSection": 1747
        }
      ],
      "ideal_answer": "Yes, there are molecular signatures identified for the differentiation between bacterial and viral infections. These include chemiluminescent signatures of circulating phagocytes and transcript host-RNA signatures in host leukocytes.",
      "exact_answer": "yes"
    },
    {
      "id": "65d1369c1930410b1300003b",
      "type": "list",
      "body": "What are active ingredients of Xacduro?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37523122",
        "http://www.ncbi.nlm.nih.gov/pubmed/22149076",
        "http://www.ncbi.nlm.nih.gov/pubmed/15197461",
        "http://www.ncbi.nlm.nih.gov/pubmed/18269361",
        "http://www.ncbi.nlm.nih.gov/pubmed/34813665",
        "http://www.ncbi.nlm.nih.gov/pubmed/28933116",
        "http://www.ncbi.nlm.nih.gov/pubmed/16955533",
        "http://www.ncbi.nlm.nih.gov/pubmed/22126064",
        "http://www.ncbi.nlm.nih.gov/pubmed/20120121",
        "http://www.ncbi.nlm.nih.gov/pubmed/1292492"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28933116",
          "text": "In the present experiment, the contents of active ingredients including quercetin, tricine, kaempferol, catechin, ferulic acid and inactive ingredients including 5-hydroxymethyl furfural, acrylamide in frying process were determined by HPLC. The dynamic change rules of active ingredient and inactive ingredients in the frying process were investigated by HCA, PCA and PLS-DA analysis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 220,
          "endSection": "abstract",
          "offsetInEndSection": 605
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28933116",
          "text": "In the present experiment, the contents of active ingredients including quercetin, tricine, kaempferol, catechin, ferulic acid and inactive ingredients including 5-hydroxymethyl furfural, acrylamide in frying process were determined by HPLC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 220,
          "endSection": "abstract",
          "offsetInEndSection": 461
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28933116",
          "text": "In the present experiment, the contents of active ingredients including quercetin, tricine, kaempferol, catechin, ferulic acid and inactive ingredients including 5-hydroxymethyl furfural, acrylamide in frying process were determined by HPLC. The dynamic change rules of active ingredient and inactive ingredients in the frying process were investigated by HCA, PCA and PLS-DA analysis. The results showed that the Fructus Hordei Germinatus samples with different frying temperatures were classified into 4 groups by HCA and PCA analysis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 220,
          "endSection": "abstract",
          "offsetInEndSection": 757
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28933116",
          "text": "It is not scientific to explain that fried Fructus Hordei Germinatus is more effective than row Fructus Hordei Germinatus in resolving food stagnation from the aspects of amylase, tricine and other \"active ingredients\". In the present experiment, the contents of active ingredients including quercetin, tricine, kaempferol, catechin, ferulic acid and inactive ingredients including 5-hydroxymethyl furfural, acrylamide in frying process were determined by HPLC. The dynamic change rules of active ingredient and inactive ingredients in the frying process were investigated by HCA, PCA and PLS-DA analysis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 605
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22149076",
          "text": "Encapsulation of new active ingredients.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 40
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28933116",
          "text": "The dynamic change rules of active ingredient and inactive ingredients in the frying process were investigated by HCA, PCA and PLS-DA analysis. The results showed that the Fructus Hordei Germinatus samples with different frying temperatures were classified into 4 groups by HCA and PCA analysis. PLS-DA analysis showed that frying temperature mainly impacted the contents of inactive ingredients including 5-hydroxymethyl furfural and acrylamide, with less effects on the contents of active ingredients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 462,
          "endSection": "abstract",
          "offsetInEndSection": 965
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15197461",
          "text": "[Active ingredients in dermatocosmetics].",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 41
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28933116",
          "text": "It is not scientific to explain that fried Fructus Hordei Germinatus is more effective than row Fructus Hordei Germinatus in resolving food stagnation from the aspects of amylase, tricine and other \"active ingredients\". In the present experiment, the contents of active ingredients including quercetin, tricine, kaempferol, catechin, ferulic acid and inactive ingredients including 5-hydroxymethyl furfural, acrylamide in frying process were determined by HPLC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 461
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34813665",
          "text": "The clinical studies regarding the active ingredients used in these products remain sparse and lack methodological quality. Among the top ingredients, niacinamide, panthenol and acetyl dipeptide-1 cetyl ester were the only ones studied on volunteers having sensitive skin, while acetyl dipeptide-1 cetyl ester and palmitoyl tripeptide-8 were designed to act on the molecular targets involved in this condition. CONCLUSION\nThis study reveals the most used active ingredients in cosmetic products for sensitive skin, as well as the scientific evidence supporting their efficacy and the mechanisms of action.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1103,
          "endSection": "abstract",
          "offsetInEndSection": 1710
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34813665",
          "text": "The clinical studies regarding the active ingredients used in these products remain sparse and lack methodological quality. Among the top ingredients, niacinamide, panthenol and acetyl dipeptide-1 cetyl ester were the only ones studied on volunteers having sensitive skin, while acetyl dipeptide-1 cetyl ester and palmitoyl tripeptide-8 were designed to act on the molecular targets involved in this condition.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1103,
          "endSection": "abstract",
          "offsetInEndSection": 1513
        }
      ],
      "ideal_answer": "The active ingredients of Xacduro are quercetin, tricine, kaempferol, catechin, and ferulic acid.",
      "exact_answer": [
        [
          "quercetin"
        ],
        [
          "tricine"
        ],
        [
          "kaempferol"
        ],
        [
          "catechin"
        ],
        [
          "ferulic acid"
        ]
      ]
    },
    {
      "id": "66099967fdcbea915f000018",
      "type": "factoid",
      "body": "What is the faster length time for oxaliplatin infusion?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
        "http://www.ncbi.nlm.nih.gov/pubmed/37525581",
        "http://www.ncbi.nlm.nih.gov/pubmed/14968944",
        "http://www.ncbi.nlm.nih.gov/pubmed/10213210",
        "http://www.ncbi.nlm.nih.gov/pubmed/32451327",
        "http://www.ncbi.nlm.nih.gov/pubmed/24423955",
        "http://www.ncbi.nlm.nih.gov/pubmed/35125319",
        "http://www.ncbi.nlm.nih.gov/pubmed/19352593",
        "http://www.ncbi.nlm.nih.gov/pubmed/32075507",
        "http://www.ncbi.nlm.nih.gov/pubmed/17823107"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37525581",
          "text": "PURPOSE\nThe National Comprehensive Cancer Network guidelines state that the oxaliplatin dose of 85 mg/m2 used in various gastrointestinal cancer regimens may be infused over a rapid rate of 85 min instead of the standard time of 120 min. We evaluated the safety outcomes of rapid administration of oxaliplatin compared to standard infusion. METHODS\nWe performed a retrospective, cohort study by chart review.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 410
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37525581",
          "text": "PURPOSE\nThe National Comprehensive Cancer Network guidelines state that the oxaliplatin dose of 85 mg/m2 used in various gastrointestinal cancer regimens may be infused over a rapid rate of 85 min instead of the standard time of 120 min. We evaluated the safety outcomes of rapid administration of oxaliplatin compared to standard infusion.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 340
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37525581",
          "text": "PURPOSE\nThe National Comprehensive Cancer Network guidelines state that the oxaliplatin dose of 85 mg/m2 used in various gastrointestinal cancer regimens may be infused over a rapid rate of 85 min instead of the standard time of 120 min.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 237
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10213210",
          "text": "Oxaliplatin pharmacokinetics during a four-hour infusion.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 57
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32451327",
          "text": "In this retrospective cohort study we compared the incidence of infusion-related pain in patients treated with oxaliplatin with or without simultaneous fluid infusion (FI) (800 mL glucose 5% in 2 hours).",
          "beginSection": "abstract",
          "offsetInBeginSection": 211,
          "endSection": "abstract",
          "offsetInEndSection": 414
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14968944",
          "text": "Median time to progression was 4.7 (2.6-7.6) months and median survival was 7.4 (6.0-11.3) months. Sixteen patients had neuropathy grade 1, four patients grade 2 and two patients grade 3. Short-time infusion of oxaliplatin and capecitabine is an active and convenient second-line regimen with a safety profile similar to that of other oxaliplatin schedules.",
          "beginSection": "abstract",
          "offsetInBeginSection": 717,
          "endSection": "abstract",
          "offsetInEndSection": 1074
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32451327",
          "text": "A known side effect of oxaliplatin administration via a peripheral vein is infusion-related pain. In this retrospective cohort study we compared the incidence of infusion-related pain in patients treated with oxaliplatin with or without simultaneous fluid infusion (FI) (800 mL glucose 5% in 2 hours).",
          "beginSection": "abstract",
          "offsetInBeginSection": 113,
          "endSection": "abstract",
          "offsetInEndSection": 414
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10213210",
          "text": "This study extensively analyzes the pharmacokinetics of both ultrafiltrable (free) and protein-bound platin in 13 patients receiving 130 mg/m2 oxaliplatin as a 4-h infusion in combination with 375 mg/m2 5-fluorouracil as a 24-h infusion for advanced colorectal carcinomas. The interpatient variability was very low for all parameters analyzed. The levels of free platin decreased triphasically, with a mean terminal half-life of 27.3+/-10.6 h. The area under the time-concentration curve was 20.17+/-6.97 microg.h/ml and the total and renal clearances amounted to 222+/-65 and 121+/-56 ml/min, respectively.",
          "beginSection": "abstract",
          "offsetInBeginSection": 170,
          "endSection": "abstract",
          "offsetInEndSection": 777
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14968944",
          "text": "Short-time infusion of oxaliplatin and capecitabine is an active and convenient second-line regimen with a safety profile similar to that of other oxaliplatin schedules.",
          "beginSection": "abstract",
          "offsetInBeginSection": 905,
          "endSection": "abstract",
          "offsetInEndSection": 1074
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32451327",
          "text": "OBJECTIVE\nOxaliplatin is a cytotoxic agent frequently used in the treatment of gastrointestinal cancer patients. A known side effect of oxaliplatin administration via a peripheral vein is infusion-related pain. In this retrospective cohort study we compared the incidence of infusion-related pain in patients treated with oxaliplatin with or without simultaneous fluid infusion (FI) (800 mL glucose 5% in 2 hours).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 414
        }
      ],
      "ideal_answer": "The faster length time for oxaliplatin infusion is 85 minutes.",
      "exact_answer": [
        "85 minutes"
      ]
    },
    {
      "id": "661be55f48a2c27714000003",
      "type": "factoid",
      "body": "What disease is treated by Callosotomy",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36435385",
        "http://www.ncbi.nlm.nih.gov/pubmed/36637309",
        "http://www.ncbi.nlm.nih.gov/pubmed/37303192",
        "http://www.ncbi.nlm.nih.gov/pubmed/10449075",
        "http://www.ncbi.nlm.nih.gov/pubmed/18539083",
        "http://www.ncbi.nlm.nih.gov/pubmed/25692412",
        "http://www.ncbi.nlm.nih.gov/pubmed/8029136",
        "http://www.ncbi.nlm.nih.gov/pubmed/31835250",
        "http://www.ncbi.nlm.nih.gov/pubmed/10612336",
        "http://www.ncbi.nlm.nih.gov/pubmed/32554339"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25692412",
          "text": "The purpose of this review is to summarize the studies of callosotomy in the past years as a treatment for severe drug-resistant epilepsy with traumatizing drop attacks, mostly in children and also in some adults. The aim is also to discuss knowledge gaps and suggest how these could be addressed. RECENT FINDINGS\nLately, a number of callosotomy series, mostly retrospective and single center, have included 289 operated patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 116,
          "endSection": "abstract",
          "offsetInEndSection": 548
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25692412",
          "text": "The purpose of this review is to summarize the studies of callosotomy in the past years as a treatment for severe drug-resistant epilepsy with traumatizing drop attacks, mostly in children and also in some adults. The aim is also to discuss knowledge gaps and suggest how these could be addressed.",
          "beginSection": "abstract",
          "offsetInBeginSection": 116,
          "endSection": "abstract",
          "offsetInEndSection": 413
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25692412",
          "text": "The purpose of this review is to summarize the studies of callosotomy in the past years as a treatment for severe drug-resistant epilepsy with traumatizing drop attacks, mostly in children and also in some adults.",
          "beginSection": "abstract",
          "offsetInBeginSection": 116,
          "endSection": "abstract",
          "offsetInEndSection": 329
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8029136",
          "text": "These patients were treated surgically with anterior callosotomy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 369,
          "endSection": "abstract",
          "offsetInEndSection": 434
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18539083",
          "text": "Corpus callosotomy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 19
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8029136",
          "text": "These patients were treated surgically with anterior callosotomy. Small number of patients and relatively short period of the follow-up do not allow more general conclusions to be drawn. However, in 3 out of 4 operated patients an improvement was noted within one year or more, including one case of significant improvement.",
          "beginSection": "abstract",
          "offsetInBeginSection": 369,
          "endSection": "abstract",
          "offsetInEndSection": 693
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18539083",
          "text": "Hence, callosotomy is justified as a therapy for appropriate patients with intractable epilepsy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 735,
          "endSection": "abstract",
          "offsetInEndSection": 831
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25692412",
          "text": "PURPOSE OF REVIEW\nCorpus callosotomy is a palliative surgical treatment modality that has gone in and out of favor. The purpose of this review is to summarize the studies of callosotomy in the past years as a treatment for severe drug-resistant epilepsy with traumatizing drop attacks, mostly in children and also in some adults. The aim is also to discuss knowledge gaps and suggest how these could be addressed.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 413
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25692412",
          "text": "PURPOSE OF REVIEW\nCorpus callosotomy is a palliative surgical treatment modality that has gone in and out of favor. The purpose of this review is to summarize the studies of callosotomy in the past years as a treatment for severe drug-resistant epilepsy with traumatizing drop attacks, mostly in children and also in some adults.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 329
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8029136",
          "text": "These patients were treated surgically with anterior callosotomy. Small number of patients and relatively short period of the follow-up do not allow more general conclusions to be drawn.",
          "beginSection": "abstract",
          "offsetInBeginSection": 369,
          "endSection": "abstract",
          "offsetInEndSection": 555
        }
      ],
      "ideal_answer": "Epilepsy is treated by Callosotomy.",
      "exact_answer": [
        "epilepsy"
      ]
    },
    {
      "id": "6614fe3dfdcbea915f000045",
      "type": "yesno",
      "body": "Is there an approved vaccine to prevent Zika virus infection during pregnancy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36690159",
        "http://www.ncbi.nlm.nih.gov/pubmed/37058415",
        "http://www.ncbi.nlm.nih.gov/pubmed/36762592",
        "http://www.ncbi.nlm.nih.gov/pubmed/28939807",
        "http://www.ncbi.nlm.nih.gov/pubmed/34461793",
        "http://www.ncbi.nlm.nih.gov/pubmed/28594787",
        "http://www.ncbi.nlm.nih.gov/pubmed/35087081",
        "http://www.ncbi.nlm.nih.gov/pubmed/27902933",
        "http://www.ncbi.nlm.nih.gov/pubmed/29523447",
        "http://www.ncbi.nlm.nih.gov/pubmed/30429338"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28594787",
          "text": "There is currently no vaccine or intervention to prevent the adverse effects of Zika virus infection during pregnancy; therefore, prevention has been the focus of public health activities, especially for pregnant women (3).",
          "beginSection": "abstract",
          "offsetInBeginSection": 358,
          "endSection": "abstract",
          "offsetInEndSection": 581
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28594787",
          "text": "There is currently no vaccine or intervention to prevent the adverse effects of Zika virus infection during pregnancy; therefore, prevention has been the focus of public health activities, especially for pregnant women (3). CDC and the Puerto Rico Department of Health analyzed data from the Pregnancy Risk Assessment Monitoring System Zika Postpartum Emergency Response (PRAMS-ZPER) survey conducted from August through December 2016 among Puerto Rico residents with a live birth.",
          "beginSection": "abstract",
          "offsetInBeginSection": 358,
          "endSection": "abstract",
          "offsetInEndSection": 839
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28939807",
          "text": "A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 99
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35087081",
          "text": "Efficacy of an inactivated Zika vaccine against virus infection during pregnancy in mice and marmosets.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 103
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35087081",
          "text": "The utmost goal of ZIKV vaccines is to prevent both maternal-fetal infection and congenital Zika syndrome. A Zika purified inactivated virus (ZPIV) was previously shown to be protective in non-pregnant mice and rhesus macaques. In this study, we further examined the efficacy of ZPIV against ZIKV infection during pregnancy in immunocompetent C57BL6 mice and common marmoset monkeys (Callithrix jacchus).",
          "beginSection": "abstract",
          "offsetInBeginSection": 96,
          "endSection": "abstract",
          "offsetInEndSection": 500
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28939807",
          "text": "Here we demonstrate that live-attenuated Zika virus vaccine candidates containing deletions in the 3' untranslated region of the Zika virus genome (ZIKV-3'UTR-LAV) prevent viral transmission during pregnancy and testis damage in mice, as well as infection of nonhuman primates.",
          "beginSection": "abstract",
          "offsetInBeginSection": 187,
          "endSection": "abstract",
          "offsetInEndSection": 464
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28939807",
          "text": "Here Shan et al. show that a single dose of a live-attenuated Zika vaccine prevents infection, testis damage and transmission to the fetus during pregnancy in different animal models.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1232,
          "endSection": "abstract",
          "offsetInEndSection": 1415
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28594787",
          "text": "There is currently no vaccine or intervention to prevent the adverse effects of Zika virus infection during pregnancy; therefore, prevention has been the focus of public health activities, especially for pregnant women (3). CDC and the Puerto Rico Department of Health analyzed data from the Pregnancy Risk Assessment Monitoring System Zika Postpartum Emergency Response (PRAMS-ZPER) survey conducted from August through December 2016 among Puerto Rico residents with a live birth. Most women (98.1%) reported using at least one measure to avoid mosquitos in their home environment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 358,
          "endSection": "abstract",
          "offsetInEndSection": 940
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28594787",
          "text": "Measures Taken to Prevent Zika Virus Infection During Pregnancy - Puerto Rico, 2016.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 84
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28939807",
          "text": "Here we demonstrate that live-attenuated Zika virus vaccine candidates containing deletions in the 3' untranslated region of the Zika virus genome (ZIKV-3'UTR-LAV) prevent viral transmission during pregnancy and testis damage in mice, as well as infection of nonhuman primates. After a single-dose vaccination, pregnant mice challenged with Zika virus at embryonic day 6 and evaluated at embryonic day 13 show markedly diminished levels of viral RNA in maternal, placental, and fetal tissues.",
          "beginSection": "abstract",
          "offsetInBeginSection": 187,
          "endSection": "abstract",
          "offsetInEndSection": 679
        }
      ],
      "ideal_answer": "No, there is currently no approved vaccine to prevent Zika virus infection during pregnancy.",
      "exact_answer": "no"
    },
    {
      "id": "661c416048a2c27714000008",
      "type": "summary",
      "body": "What are eRNAs and what is their function?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36039999",
        "http://www.ncbi.nlm.nih.gov/pubmed/37537618",
        "http://www.ncbi.nlm.nih.gov/pubmed/36909657",
        "http://www.ncbi.nlm.nih.gov/pubmed/25280099",
        "http://www.ncbi.nlm.nih.gov/pubmed/30026829",
        "http://www.ncbi.nlm.nih.gov/pubmed/24034693",
        "http://www.ncbi.nlm.nih.gov/pubmed/37294799",
        "http://www.ncbi.nlm.nih.gov/pubmed/35454885",
        "http://www.ncbi.nlm.nih.gov/pubmed/33029258",
        "http://www.ncbi.nlm.nih.gov/pubmed/34016622"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35454885",
          "text": "Enhancer RNAs (eRNAs) are non-coding RNAs (ncRNAs) transcribed in enhancer regions. They play an important role in transcriptional regulation, mainly during cellular differentiation. eRNAs are tightly tissue- and cell-type specific and are induced by specific stimuli, activating promoters of target genes in turn.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 314
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35454885",
          "text": "They play an important role in transcriptional regulation, mainly during cellular differentiation. eRNAs are tightly tissue- and cell-type specific and are induced by specific stimuli, activating promoters of target genes in turn. eRNAs usually have a very short half-life but in some cases, once activated, they can be stably expressed and acquire additional functions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 84,
          "endSection": "abstract",
          "offsetInEndSection": 454
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35454885",
          "text": "They play an important role in transcriptional regulation, mainly during cellular differentiation. eRNAs are tightly tissue- and cell-type specific and are induced by specific stimuli, activating promoters of target genes in turn.",
          "beginSection": "abstract",
          "offsetInBeginSection": 84,
          "endSection": "abstract",
          "offsetInEndSection": 314
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35454885",
          "text": "eRNAs are tightly tissue- and cell-type specific and are induced by specific stimuli, activating promoters of target genes in turn. eRNAs usually have a very short half-life but in some cases, once activated, they can be stably expressed and acquire additional functions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 183,
          "endSection": "abstract",
          "offsetInEndSection": 454
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30026829",
          "text": "Recent studies have shown that enhancers can act as transcriptional units for the production of enhancer RNAs (eRNAs), which are hallmarks of activity enhancers and are involved in the regulation of gene transcription. The in-depth study of eRNAs is of great significance for us to better understand enhancer function and transcriptional regulation in various diseases. Therefore, eRNAs may be a potential therapeutic target for diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 100,
          "endSection": "abstract",
          "offsetInEndSection": 538
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35454885",
          "text": "Enhancer RNAs (eRNAs) are non-coding RNAs (ncRNAs) transcribed in enhancer regions. They play an important role in transcriptional regulation, mainly during cellular differentiation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 182
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35454885",
          "text": "eRNAs are tightly tissue- and cell-type specific and are induced by specific stimuli, activating promoters of target genes in turn. eRNAs usually have a very short half-life but in some cases, once activated, they can be stably expressed and acquire additional functions. Due to their critical role, eRNAs are often dysregulated in cancer and growing number of interactions with chromatin modifiers, transcription factors, and splicing machinery have been described.",
          "beginSection": "abstract",
          "offsetInBeginSection": 183,
          "endSection": "abstract",
          "offsetInEndSection": 649
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30026829",
          "text": "Recent studies have shown that enhancers can act as transcriptional units for the production of enhancer RNAs (eRNAs), which are hallmarks of activity enhancers and are involved in the regulation of gene transcription. The in-depth study of eRNAs is of great significance for us to better understand enhancer function and transcriptional regulation in various diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 100,
          "endSection": "abstract",
          "offsetInEndSection": 469
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37294799",
          "text": "Enhancer RNAs (eRNAs), a type of long noncoding RNAs, are transcribed from enhancer regions in the genome. The tissue-specific expression of eRNAs is crucial in the regulation of gene expression and cancer development.",
          "beginSection": "abstract",
          "offsetInBeginSection": 86,
          "endSection": "abstract",
          "offsetInEndSection": 304
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25280099",
          "text": "RNAs transcribed from enhancers (eRNAs) have been linked to enhancer function. In this issue of Molecular Cell, Schaukowitch et al. (2014) show that upon activation, eRNAs can bind NELF and are necessary for its transient removal from promoters to release paused RNA polymerase II and drive expression of immediate-early genes in neurons.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 338
        }
      ],
      "ideal_answer": "eRNAs are non-coding RNAs transcribed in enhancer regions that play an important role in transcriptional regulation, mainly during cellular differentiation. They are tightly tissue- and cell-type specific and are induced by specific stimuli, activating promoters of target genes in turn. eRNAs usually have a very short half-life but in some cases, once activated, they can be stably expressed and acquire additional functions. They may be a potential therapeutic target for diseases.",
      "exact_answer": "n/a"
    },
    {
      "id": "661d20b7eac11fad33000016",
      "type": "yesno",
      "body": "Can cytomegalovirus (CMV) be transmitted via breast milk to premature infants?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20670291",
        "http://www.ncbi.nlm.nih.gov/pubmed/24172840",
        "http://www.ncbi.nlm.nih.gov/pubmed/34809592",
        "http://www.ncbi.nlm.nih.gov/pubmed/27751206",
        "http://www.ncbi.nlm.nih.gov/pubmed/17661570",
        "http://www.ncbi.nlm.nih.gov/pubmed/21164427",
        "http://www.ncbi.nlm.nih.gov/pubmed/23713111",
        "http://www.ncbi.nlm.nih.gov/pubmed/17391465",
        "http://www.ncbi.nlm.nih.gov/pubmed/16615961",
        "http://www.ncbi.nlm.nih.gov/pubmed/32662174"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24172840",
          "text": "Cytomegalovirus (CMV) may transmit perinatally or from breast milk. The risk for development of symptomatic CMV disease in very-low-birth-weight premature infants after transmission from maternal breast milk is not clear.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 221
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24172840",
          "text": "Cytomegalovirus (CMV) may transmit perinatally or from breast milk. The risk for development of symptomatic CMV disease in very-low-birth-weight premature infants after transmission from maternal breast milk is not clear. There are scarce data in the literature about congenital CMV infection in multiple pregnancies, being mostly with twin gestations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 352
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21164427",
          "text": "OBJECTIVE\nWe prospectively evaluated the rate of postnatal cytomegalovirus (CMV) transmission through breast milk in extremely premature infants to address the impact of CMV infection on preterm infants during lactation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 220
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17661570",
          "text": "Human cytomegalovirus (HCMV) can be transmitted through breast milk to neonates. Although healthy full-term infants rarely develop symptoms of CMV infection; premature or low-birth-weight infants can experience symptomatic infection that is occasionally severe.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 261
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17661570",
          "text": "Human cytomegalovirus (HCMV) can be transmitted through breast milk to neonates. Although healthy full-term infants rarely develop symptoms of CMV infection; premature or low-birth-weight infants can experience symptomatic infection that is occasionally severe. There is limited information on the long-term effects of postnatal CMV infection in premature infants, suggesting that these infants do not develop cognitive function delays or hearing loss, although those with intrapartum infection do.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 498
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34809592",
          "text": "BACKGROUND\nThis study aimed to investigate the transmission of cytomegalovirus (CMV) via breast milk in low birth weight (LBW) and premature infants and its effects. METHODS\nPubMed, Medline, Cochrane Library, and Embase were searched for studies (without language and time restriction) published before March 27, 2020, that examined the effect of CMV transmitted by breast milk on LBW and premature infants.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 409
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34809592",
          "text": "BACKGROUND\nThis study aimed to investigate the transmission of cytomegalovirus (CMV) via breast milk in low birth weight (LBW) and premature infants and its effects.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 165
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21164427",
          "text": "Transmission of cytomegalovirus via breast milk in extremely premature infants.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 79
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21164427",
          "text": "OBJECTIVE\nWe prospectively evaluated the rate of postnatal cytomegalovirus (CMV) transmission through breast milk in extremely premature infants to address the impact of CMV infection on preterm infants during lactation. STUDY DESIGN\nA total of 25 mothers and 27 infants (two sets of twins) with birth weights <1000 g and/or gestational ages <28 weeks were enrolled in the study.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 381
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21164427",
          "text": "OBJECTIVE\nWe prospectively evaluated the rate of postnatal cytomegalovirus (CMV) transmission through breast milk in extremely premature infants to address the impact of CMV infection on preterm infants during lactation. STUDY DESIGN\nA total of 25 mothers and 27 infants (two sets of twins) with birth weights <1000 g and/or gestational ages <28 weeks were enrolled in the study. They were mostly fed frozen-thawed breast milk.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 429
        }
      ],
      "ideal_answer": "Yes, cytomegalovirus (CMV) can be transmitted via breast milk to premature infants.",
      "exact_answer": "yes"
    },
    {
      "id": "65cfcb4c1930410b13000017",
      "type": "list",
      "body": "What enzymes are inhibited by Vorasidenib?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37272516",
        "http://www.ncbi.nlm.nih.gov/pubmed/34078652",
        "http://www.ncbi.nlm.nih.gov/pubmed/37276325",
        "http://www.ncbi.nlm.nih.gov/pubmed/36453510",
        "http://www.ncbi.nlm.nih.gov/pubmed/37812369",
        "http://www.ncbi.nlm.nih.gov/pubmed/36698225",
        "http://www.ncbi.nlm.nih.gov/pubmed/36823302",
        "http://www.ncbi.nlm.nih.gov/pubmed/32071674",
        "http://www.ncbi.nlm.nih.gov/pubmed/33982420",
        "http://www.ncbi.nlm.nih.gov/pubmed/9821018"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37272516",
          "text": "Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, showed preliminary activity in IDH-mutant gliomas.",
          "beginSection": "abstract",
          "offsetInBeginSection": 148,
          "endSection": "abstract",
          "offsetInEndSection": 278
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37272516",
          "text": "Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, showed preliminary activity in IDH-mutant gliomas.",
          "beginSection": "abstract",
          "offsetInBeginSection": 149,
          "endSection": "abstract",
          "offsetInEndSection": 279
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36823302",
          "text": "Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and have shown preliminary clinical activity against mIDH glioma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 148
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36823302",
          "text": "Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and have shown preliminary clinical activity against mIDH glioma. We evaluated both agents in a perioperative phase 1 trial to explore the mechanism of action in recurrent low-grade glioma (IGG) and select a molecule for phase 3 testing.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 320
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32071674",
          "text": "Herein, we describe the discovery of vorasidenib (AG-881), a potent, oral, brain-penetrant dual inhibitor of both mIDH1 and mIDH2. X-ray cocrystal structures allowed us to characterize the compound binding site, leading to an understanding of the dual mutant inhibition.",
          "beginSection": "abstract",
          "offsetInBeginSection": 263,
          "endSection": "abstract",
          "offsetInEndSection": 533
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37272516",
          "text": "Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, showed preliminary activity in IDH-mutant gliomas. METHODS\nIn a double-blind, phase 3 trial, we randomly assigned patients with residual or recurrent grade 2 IDH-mutant glioma who had undergone no previous treatment other than surgery to receive either oral vorasidenib (40 mg once daily) or matched placebo in 28-day cycles.",
          "beginSection": "abstract",
          "offsetInBeginSection": 148,
          "endSection": "abstract",
          "offsetInEndSection": 555
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32071674",
          "text": "Herein, we describe the discovery of vorasidenib (AG-881), a potent, oral, brain-penetrant dual inhibitor of both mIDH1 and mIDH2.",
          "beginSection": "abstract",
          "offsetInBeginSection": 263,
          "endSection": "abstract",
          "offsetInEndSection": 393
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32071674",
          "text": "Herein, we describe the discovery of vorasidenib (AG-881), a potent, oral, brain-penetrant dual inhibitor of both mIDH1 and mIDH2. X-ray cocrystal structures allowed us to characterize the compound binding site, leading to an understanding of the dual mutant inhibition. Furthermore, vorasidenib penetrates the brain of several preclinical species and inhibits 2-HG production in glioma tissue by >97% in an orthotopic glioma mouse model.",
          "beginSection": "abstract",
          "offsetInBeginSection": 263,
          "endSection": "abstract",
          "offsetInEndSection": 701
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36823302",
          "text": "Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and have shown preliminary clinical activity against mIDH glioma. We evaluated both agents in a perioperative phase 1 trial to explore the mechanism of action in recurrent low-grade glioma (IGG) and select a molecule for phase 3 testing. Primary end-point was concentration of D-2-hydroxyglutarate (2-HG), the metabolic product of mIDH enzymes, measured in tumor tissue from 49 patients with mIDH1-R132H nonenhancing gliomas following randomized treatment with vorasidenib (50 mg or 10 mg once daily, q.d.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 588
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37272516",
          "text": "Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, showed preliminary activity in IDH-mutant gliomas. METHODS\nIn a double-blind, phase 3 trial, we randomly assigned patients with residual or recurrent grade 2 IDH-mutant glioma who had undergone no previous treatment other than surgery to receive either oral vorasidenib (40 mg once daily) or matched placebo in 28-day cycles. The primary end point was imaging-based progression-free survival according to blinded assessment by an independent review committee.",
          "beginSection": "abstract",
          "offsetInBeginSection": 148,
          "endSection": "abstract",
          "offsetInEndSection": 689
        }
      ],
      "ideal_answer": "Vorasidenib inhibits mutant forms of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2).",
      "exact_answer": [
        [
          "IDH1"
        ],
        [
          "IDH2"
        ]
      ]
    },
    {
      "id": "66099a03fdcbea915f00001d",
      "type": "factoid",
      "body": "From what age is it recommended to start population screening for colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34003218",
        "http://www.ncbi.nlm.nih.gov/pubmed/34794803",
        "http://www.ncbi.nlm.nih.gov/pubmed/34794816",
        "http://www.ncbi.nlm.nih.gov/pubmed/34962727",
        "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
        "http://www.ncbi.nlm.nih.gov/pubmed/19892375",
        "http://www.ncbi.nlm.nih.gov/pubmed/34630894",
        "http://www.ncbi.nlm.nih.gov/pubmed/23299409",
        "http://www.ncbi.nlm.nih.gov/pubmed/36117356",
        "http://www.ncbi.nlm.nih.gov/pubmed/29846933"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
          "text": "In 2018, the American Cancer Society published a guideline update recommending a reduction in the colorectal cancer screening start age for average-risk individuals from 50 to 45. Implementing these recommendations would have important implications for public health. However, the approximate number of people impacted by this change, the average-risk population ages 45-49, is not well-described in the literature.",
          "beginSection": "abstract",
          "offsetInBeginSection": 72,
          "endSection": "abstract",
          "offsetInEndSection": 487
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
          "text": "Colorectal cancer is a growing burden in adults less than 50 years old. In 2018, the American Cancer Society published a guideline update recommending a reduction in the colorectal cancer screening start age for average-risk individuals from 50 to 45. Implementing these recommendations would have important implications for public health.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 339
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
          "text": "In 2018, the American Cancer Society published a guideline update recommending a reduction in the colorectal cancer screening start age for average-risk individuals from 50 to 45. Implementing these recommendations would have important implications for public health.",
          "beginSection": "abstract",
          "offsetInBeginSection": 72,
          "endSection": "abstract",
          "offsetInEndSection": 339
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
          "text": "Colorectal cancer is a growing burden in adults less than 50 years old. In 2018, the American Cancer Society published a guideline update recommending a reduction in the colorectal cancer screening start age for average-risk individuals from 50 to 45.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 251
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
          "text": "In 2018, the American Cancer Society published a guideline update recommending a reduction in the colorectal cancer screening start age for average-risk individuals from 50 to 45.",
          "beginSection": "abstract",
          "offsetInBeginSection": 72,
          "endSection": "abstract",
          "offsetInEndSection": 251
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
          "text": "Estimating the Screening-Eligible Population Size, Ages 45-74, at Average Risk to Develop Colorectal Cancer in the United States.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 129
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34794803",
          "text": "This document is a focused update to the 2017 colorectal cancer (CRC) screening recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer, which represents the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy. This update is restricted to addressing the age to start and stop CRC screening in average-risk individuals and the recommended screening modalities. Although there is no literature demonstrating that CRC screening in individuals under age 50 improves health outcomes such as CRC incidence or CRC-related mortality, sufficient data support the U.S. Multi-Society Task Force to suggest average-risk CRC screening begin at age 45.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 747
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34794816",
          "text": "This document is a focused update to the 2017 colorectal cancer (CRC) screening recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer, which represents the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy. This update is restricted to addressing the age to start and stop CRC screening in average-risk individuals and the recommended screening modalities. Although there is no literature demonstrating that CRC screening in individuals under age 50 improves health outcomes such as CRC incidence or CRC-related mortality, sufficient data support the U.S. Multi-Society Task Force to suggest average-risk CRC screening begin at age 45.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 747
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34962727",
          "text": "This document is a focused update to the 2017 colorectal cancer (CRC) screening recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer, which represents the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy. This update is restricted to addressing the age to start and stop CRC screening in average-risk individuals and the recommended screening modalities. Although there is no literature demonstrating that CRC screening in individuals under age 50 improves health outcomes such as CRC incidence or CRC-related mortality, sufficient data support the U.S. Multi-Society Task Force to suggest average-risk CRC screening begin at age 45.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 747
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34794803",
          "text": "This recommendation is based on the increasing disease burden among individuals under age 50, emerging data that the prevalence of advanced colorectal neoplasia in individuals ages 45 to 49 approaches rates in individuals 50 to 59, and modeling studies that demonstrate the benefits of screening outweigh the potential harms and costs. For individuals ages 76 to 85, the decision to start or continue screening should be individualized and based on prior screening history, life expectancy, CRC risk, and personal preference. Screening is not recommended after age 85.",
          "beginSection": "abstract",
          "offsetInBeginSection": 748,
          "endSection": "abstract",
          "offsetInEndSection": 1316
        }
      ],
      "ideal_answer": "The American Cancer Society recommends starting population screening for colorectal cancer at age 45 for average-risk individuals.",
      "exact_answer": [
        "45"
      ]
    },
    {
      "id": "65f03bf8c4010b4d78000003",
      "type": "summary",
      "body": "What is acupotomy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37123050",
        "http://www.ncbi.nlm.nih.gov/pubmed/36050272",
        "http://www.ncbi.nlm.nih.gov/pubmed/32280270",
        "http://www.ncbi.nlm.nih.gov/pubmed/34190463",
        "http://www.ncbi.nlm.nih.gov/pubmed/36484186",
        "http://www.ncbi.nlm.nih.gov/pubmed/30672189",
        "http://www.ncbi.nlm.nih.gov/pubmed/31852126",
        "http://www.ncbi.nlm.nih.gov/pubmed/29620626",
        "http://www.ncbi.nlm.nih.gov/pubmed/21739699",
        "http://www.ncbi.nlm.nih.gov/pubmed/31682385"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31852126",
          "text": "BACKGROUND\nAcupotomy has been widely used to treat nerve entrapment syndrome. But its efficiency has not been scientifically and methodically evaluated.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 152
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34190463",
          "text": "Traditional acupotomy treatment can easily cause re-injury of soft tissues, and its safety is gradually being valued. With the development of imaging technology, visualized acupotomy operations are increasingly used in clinical practice.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 237
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34190463",
          "text": "Traditional acupotomy treatment can easily cause re-injury of soft tissues, and its safety is gradually being valued. With the development of imaging technology, visualized acupotomy operations are increasingly used in clinical practice. Starting from the development and evolution of acupotomy, the authors summarize the advantages and clinical application of ultrasound-guided acupotomy in cervical spondylosis, scapulohumeral periarthritis, lumbar disc herniation and knee osteoarthritis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 491
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30672189",
          "text": "It was indicated that the adverse events in acupotomy were mainly postoperative local pain, hematoma, swelling, nerve damage, tendon rupture, adhesion, injury, infection, syncope, anesthesia accident, undeserved hormone use, etc. The lower level of standardization of acupotomy in the clinical use may lead to adverse events. CONCLUSION\nSafe acupotomy treatment for some complicated diseases and dangerous parts remains to be improved, and the standardization of the acupotomy is an important approach to improve its safety.",
          "beginSection": "abstract",
          "offsetInBeginSection": 535,
          "endSection": "abstract",
          "offsetInEndSection": 1061
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30672189",
          "text": "It was indicated that the adverse events in acupotomy were mainly postoperative local pain, hematoma, swelling, nerve damage, tendon rupture, adhesion, injury, infection, syncope, anesthesia accident, undeserved hormone use, etc. The lower level of standardization of acupotomy in the clinical use may lead to adverse events.",
          "beginSection": "abstract",
          "offsetInBeginSection": 535,
          "endSection": "abstract",
          "offsetInEndSection": 860
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30672189",
          "text": "CONCLUSION\nSafe acupotomy treatment for some complicated diseases and dangerous parts remains to be improved, and the standardization of the acupotomy is an important approach to improve its safety. The related work needs to be carried out.",
          "beginSection": "abstract",
          "offsetInBeginSection": 863,
          "endSection": "abstract",
          "offsetInEndSection": 1103
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30672189",
          "text": "CONCLUSION\nSafe acupotomy treatment for some complicated diseases and dangerous parts remains to be improved, and the standardization of the acupotomy is an important approach to improve its safety.",
          "beginSection": "abstract",
          "offsetInBeginSection": 863,
          "endSection": "abstract",
          "offsetInEndSection": 1061
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30672189",
          "text": "It was indicated that the adverse events in acupotomy were mainly postoperative local pain, hematoma, swelling, nerve damage, tendon rupture, adhesion, injury, infection, syncope, anesthesia accident, undeserved hormone use, etc.",
          "beginSection": "abstract",
          "offsetInBeginSection": 535,
          "endSection": "abstract",
          "offsetInEndSection": 764
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30672189",
          "text": "RESULTS\nFifty-eight papers were included, with total 343 cases. It was indicated that the adverse events in acupotomy were mainly postoperative local pain, hematoma, swelling, nerve damage, tendon rupture, adhesion, injury, infection, syncope, anesthesia accident, undeserved hormone use, etc. The lower level of standardization of acupotomy in the clinical use may lead to adverse events.",
          "beginSection": "abstract",
          "offsetInBeginSection": 471,
          "endSection": "abstract",
          "offsetInEndSection": 860
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34190463",
          "text": "Traditional acupotomy treatment can easily cause re-injury of soft tissues, and its safety is gradually being valued.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 117
        }
      ],
      "ideal_answer": "Acupotomy is a minimally invasive procedure that involves inserting a needle-like tool into the body to treat nerve entrapment syndrome and other conditions. However, its safety has been questioned due to the high risk of adverse events such as postoperative local pain, hematoma, swelling, nerve damage, tendon rupture, adhesion, injury, infection, syncope, anesthesia accident, undeserved hormone use, etc. The lower level of standardization of acupotomy in clinical use may lead to adverse events. Therefore, the standardization of acupotomy is an important approach to improve its safety.",
      "exact_answer": "n/a"
    },
    {
      "id": "660d7324fdcbea915f000040",
      "type": "factoid",
      "body": "How many people affected by Parkinson's Disease develop dementia?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34896923",
        "http://www.ncbi.nlm.nih.gov/pubmed/17572053",
        "http://www.ncbi.nlm.nih.gov/pubmed/31696728",
        "http://www.ncbi.nlm.nih.gov/pubmed/27502301",
        "http://www.ncbi.nlm.nih.gov/pubmed/22219231",
        "http://www.ncbi.nlm.nih.gov/pubmed/26228888",
        "http://www.ncbi.nlm.nih.gov/pubmed/25171928",
        "http://www.ncbi.nlm.nih.gov/pubmed/19812474",
        "http://www.ncbi.nlm.nih.gov/pubmed/25745616",
        "http://www.ncbi.nlm.nih.gov/pubmed/28439961"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27502301",
          "text": "Dementia is a frequent complication of Parkinson disease (PD) with a yearly incidence of around 10% of patients with PD. Lewy body pathology is the most important factor in the development of Parkinson disease dementia (PDD) and there is evidence for a synergistic effect with β-amyloid.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 287
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27502301",
          "text": "Dementia is a frequent complication of Parkinson disease (PD) with a yearly incidence of around 10% of patients with PD.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 120
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27502301",
          "text": "Dementia is a frequent complication of Parkinson disease (PD) with a yearly incidence of around 10% of patients with PD. Lewy body pathology is the most important factor in the development of Parkinson disease dementia (PDD) and there is evidence for a synergistic effect with β-amyloid. The clinical phenotype in PDD extends beyond the dysexecutive syndrome that is often present in early PD and encompasses deficits in recognition memory, attention, and visual perception.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 474
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17572053",
          "text": "Lewy body dementia and Parkinson disease dementia are frequent causes of degenerative dementia: 20% of the dementias in patients older than 65 years are caused by the former and nearly 80% of patients with advanced Parkinson disease develop the latter.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 252
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27502301",
          "text": "Parkinson Disease and Dementia.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 31
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27502301",
          "text": "Lewy body pathology is the most important factor in the development of Parkinson disease dementia (PDD) and there is evidence for a synergistic effect with β-amyloid. The clinical phenotype in PDD extends beyond the dysexecutive syndrome that is often present in early PD and encompasses deficits in recognition memory, attention, and visual perception. Sleep disturbances, hallucinations, neuroleptic sensitivity, and fluctuations are often present.",
          "beginSection": "abstract",
          "offsetInBeginSection": 121,
          "endSection": "abstract",
          "offsetInEndSection": 571
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27502301",
          "text": "Lewy body pathology is the most important factor in the development of Parkinson disease dementia (PDD) and there is evidence for a synergistic effect with β-amyloid. The clinical phenotype in PDD extends beyond the dysexecutive syndrome that is often present in early PD and encompasses deficits in recognition memory, attention, and visual perception.",
          "beginSection": "abstract",
          "offsetInBeginSection": 121,
          "endSection": "abstract",
          "offsetInEndSection": 474
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26228888",
          "text": "MATERIALS AND METHODS\nThe study population consisted of 42 patients with dementia with Lewy bodies, 88 patients with Parkinson disease dementia, and 35 controls who underwent brain MR imaging with gradient recalled-echo.",
          "beginSection": "abstract",
          "offsetInBeginSection": 558,
          "endSection": "abstract",
          "offsetInEndSection": 778
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27502301",
          "text": "Lewy body pathology is the most important factor in the development of Parkinson disease dementia (PDD) and there is evidence for a synergistic effect with β-amyloid.",
          "beginSection": "abstract",
          "offsetInBeginSection": 121,
          "endSection": "abstract",
          "offsetInEndSection": 287
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17572053",
          "text": "Lewy body dementia and Parkinson disease dementia are frequent causes of degenerative dementia: 20% of the dementias in patients older than 65 years are caused by the former and nearly 80% of patients with advanced Parkinson disease develop the latter. Symptoms of Lewy body dementia include fluctuations of cognitive performance, frontal and visuospatial impairment, visual hallucinations, and parkinsonism.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 408
        }
      ],
      "ideal_answer": "Around 10% of people affected by Parkinson's Disease develop dementia.",
      "exact_answer": [
        "around 10%"
      ]
    },
    {
      "id": "661c3d1448a2c27714000005",
      "type": "list",
      "body": "What chromatin signatures are characteristic of active enhancers?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36602897",
        "http://www.ncbi.nlm.nih.gov/pubmed/22593555",
        "http://www.ncbi.nlm.nih.gov/pubmed/22555596",
        "http://www.ncbi.nlm.nih.gov/pubmed/17277777",
        "http://www.ncbi.nlm.nih.gov/pubmed/22421546",
        "http://www.ncbi.nlm.nih.gov/pubmed/21160473",
        "http://www.ncbi.nlm.nih.gov/pubmed/22231485",
        "http://www.ncbi.nlm.nih.gov/pubmed/37021559",
        "http://www.ncbi.nlm.nih.gov/pubmed/28981749",
        "http://www.ncbi.nlm.nih.gov/pubmed/30814546"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22421546",
          "text": "We describe a chromatin state signature associated with active developmental enhancers, defined by high levels of H3K27ac marking, nucleosome displacement, hypersensitivity to sonication, and strong depletion of H3K27me3.",
          "beginSection": "abstract",
          "offsetInBeginSection": 999,
          "endSection": "abstract",
          "offsetInEndSection": 1220
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22421546",
          "text": "We describe a chromatin state signature associated with active developmental enhancers, defined by high levels of H3K27ac marking, nucleosome displacement, hypersensitivity to sonication, and strong depletion of H3K27me3. We also find that some developmental enhancers exhibit components of this signature, including hypersensitivity, H3K27ac enrichment, and H3K27me3 depletion, at lower levels in tissues in which they are not active.",
          "beginSection": "abstract",
          "offsetInBeginSection": 999,
          "endSection": "abstract",
          "offsetInEndSection": 1434
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22555596",
          "text": "Chromatin signatures of active enhancers.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 41
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22555596",
          "text": "Thanks to the recent technological advances to map histone modifications and chromatin-associated factors genome-wide, several studies have begun to characterize chromatin signatures of active enhancers. Here, we discuss some of these results and how they provide new insights into the tissue-specific organization of enhancer repertoires.",
          "beginSection": "abstract",
          "offsetInBeginSection": 261,
          "endSection": "abstract",
          "offsetInEndSection": 600
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22555596",
          "text": "Thanks to the recent technological advances to map histone modifications and chromatin-associated factors genome-wide, several studies have begun to characterize chromatin signatures of active enhancers.",
          "beginSection": "abstract",
          "offsetInBeginSection": 261,
          "endSection": "abstract",
          "offsetInEndSection": 464
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36602897",
          "text": "The chromatin signatures of enhancers and their dynamic regulation.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 67
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22555596",
          "text": "In particular, enhancers can be located up to hundreds of kilobases from the promoters that they control, making their identification challenging. Thanks to the recent technological advances to map histone modifications and chromatin-associated factors genome-wide, several studies have begun to characterize chromatin signatures of active enhancers.",
          "beginSection": "abstract",
          "offsetInBeginSection": 114,
          "endSection": "abstract",
          "offsetInEndSection": 464
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22231485",
          "text": "Rather than having a unique chromatin state, active developmental enhancers show heterogeneous histone modifications and Pol II occupancy. Despite this complexity, combined chromatin signatures and Pol II presence are sufficient to predict enhancer activity de novo.",
          "beginSection": "abstract",
          "offsetInBeginSection": 455,
          "endSection": "abstract",
          "offsetInEndSection": 721
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22421546",
          "text": "We describe a chromatin state signature associated with active developmental enhancers, defined by high levels of H3K27ac marking, nucleosome displacement, hypersensitivity to sonication, and strong depletion of H3K27me3. We also find that some developmental enhancers exhibit components of this signature, including hypersensitivity, H3K27ac enrichment, and H3K27me3 depletion, at lower levels in tissues in which they are not active. Our results establish histone modification profiling as a tool for developmental enhancer discovery, and suggest that enhancers maintain an open chromatin state in multiple embryonic tissues independent of their activity level.",
          "beginSection": "abstract",
          "offsetInBeginSection": 999,
          "endSection": "abstract",
          "offsetInEndSection": 1662
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22555596",
          "text": "In particular, enhancers can be located up to hundreds of kilobases from the promoters that they control, making their identification challenging. Thanks to the recent technological advances to map histone modifications and chromatin-associated factors genome-wide, several studies have begun to characterize chromatin signatures of active enhancers. Here, we discuss some of these results and how they provide new insights into the tissue-specific organization of enhancer repertoires.",
          "beginSection": "abstract",
          "offsetInBeginSection": 114,
          "endSection": "abstract",
          "offsetInEndSection": 600
        }
      ],
      "ideal_answer": "Active enhancers are characterized by high levels of H3K27ac marking, nucleosome displacement, hypersensitivity to sonication, and strong depletion of H3K27me3.",
      "exact_answer": [
        [
          "H3K27ac"
        ],
        [
          "nucleosome displacement"
        ],
        [
          "hypersensitivity to sonication"
        ],
        [
          "depletion of H3K27me3"
        ]
      ]
    },
    {
      "id": "661d4fabeac11fad3300001c",
      "type": "list",
      "body": "What are the types of Ehlers-Danlos Syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33437956",
        "http://www.ncbi.nlm.nih.gov/pubmed/7455751",
        "http://www.ncbi.nlm.nih.gov/pubmed/10906878",
        "http://www.ncbi.nlm.nih.gov/pubmed/30214474",
        "http://www.ncbi.nlm.nih.gov/pubmed/9762220",
        "http://www.ncbi.nlm.nih.gov/pubmed/24499752",
        "http://www.ncbi.nlm.nih.gov/pubmed/1447255",
        "http://www.ncbi.nlm.nih.gov/pubmed/9340484",
        "http://www.ncbi.nlm.nih.gov/pubmed/7352721",
        "http://www.ncbi.nlm.nih.gov/pubmed/31328377"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10906878",
          "text": "Fifty-eight patients had Ehlers-Danlos syndrome Types I, II, III, or IV and form the study cohort. Among these four types, there were no significant differences in history of joint dislocation, swelling, or types of orthopaedic surgical procedures experienced. Thirty patients with Type III Ehlers-Danlos syndrome reported joint pain more frequently than did patients with Types I, II, or IV.",
          "beginSection": "abstract",
          "offsetInBeginSection": 753,
          "endSection": "abstract",
          "offsetInEndSection": 1145
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9762220",
          "text": "Ehlers-Danlos syndrome denotes a group of inherited connective tissue diseases comprising nine types. Type IV Ehlers-Danlos syndrome is the most life-threatening form. It is characterized by a type III collagen deficiency resulting in arterial fragility and death from vascular rupture or bowel perforation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 307
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10906878",
          "text": "Fifty-eight patients had Ehlers-Danlos syndrome Types I, II, III, or IV and form the study cohort. Among these four types, there were no significant differences in history of joint dislocation, swelling, or types of orthopaedic surgical procedures experienced.",
          "beginSection": "abstract",
          "offsetInBeginSection": 753,
          "endSection": "abstract",
          "offsetInEndSection": 1013
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7455751",
          "text": "Of the six subtypes of Ehlers-Danlos syndrome, which can usually be clinically differentiated, only types 1 and 4 appear to be associated with a substantial risk of arterial rupture.",
          "beginSection": "abstract",
          "offsetInBeginSection": 104,
          "endSection": "abstract",
          "offsetInEndSection": 286
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7455751",
          "text": "Ehlers-Danlos syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 23
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10906878",
          "text": "Fifty-eight patients had Ehlers-Danlos syndrome Types I, II, III, or IV and form the study cohort.",
          "beginSection": "abstract",
          "offsetInBeginSection": 753,
          "endSection": "abstract",
          "offsetInEndSection": 851
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9762220",
          "text": "Type IV Ehlers-Danlos syndrome is the most life-threatening form. It is characterized by a type III collagen deficiency resulting in arterial fragility and death from vascular rupture or bowel perforation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 102,
          "endSection": "abstract",
          "offsetInEndSection": 307
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10906878",
          "text": "Because of rarity of Types VII and VIII, these two patients were dropped from the analysis. Fifty-eight patients had Ehlers-Danlos syndrome Types I, II, III, or IV and form the study cohort. Among these four types, there were no significant differences in history of joint dislocation, swelling, or types of orthopaedic surgical procedures experienced.",
          "beginSection": "abstract",
          "offsetInBeginSection": 661,
          "endSection": "abstract",
          "offsetInEndSection": 1013
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10906878",
          "text": "Contrary to most previous reports, the patients in this study showed that Type III Ehlers-Danlos syndrome was the most debilitating form with respect to musculoskeletal function.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1452,
          "endSection": "abstract",
          "offsetInEndSection": 1630
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9762220",
          "text": "Ehlers-Danlos syndrome denotes a group of inherited connective tissue diseases comprising nine types.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 101
        }
      ],
      "ideal_answer": "There are nine types of Ehlers-Danlos Syndrome, but the context focuses on Types I, II, III, and IV. Type IV is the most life-threatening form due to a type III collagen deficiency leading to arterial fragility and potential vascular rupture or bowel perforation.",
      "exact_answer": [
        [
          "Type I"
        ],
        [
          "Type II"
        ],
        [
          "Type III"
        ],
        [
          "Type IV"
        ]
      ]
    },
    {
      "id": "65cfe0381930410b13000029",
      "type": "yesno",
      "body": "Can tacrolimus increase risk of Posterior Reversible Encephalopathy Syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35990782",
        "http://www.ncbi.nlm.nih.gov/pubmed/35469414",
        "http://www.ncbi.nlm.nih.gov/pubmed/36398875",
        "http://www.ncbi.nlm.nih.gov/pubmed/37120321",
        "http://www.ncbi.nlm.nih.gov/pubmed/36728342",
        "http://www.ncbi.nlm.nih.gov/pubmed/36329183",
        "http://www.ncbi.nlm.nih.gov/pubmed/23290027",
        "http://www.ncbi.nlm.nih.gov/pubmed/34258073",
        "http://www.ncbi.nlm.nih.gov/pubmed/29993355",
        "http://www.ncbi.nlm.nih.gov/pubmed/24405697"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29993355",
          "text": "Rare cases of posterior reversible encephalopathy syndrome due to treatment with tacrolimus, an immunosuppressive agent commonly used after organ transplant, have been reported. In these patients, the tacrolimus dose is reduced or discontinued.",
          "beginSection": "abstract",
          "offsetInBeginSection": 693,
          "endSection": "abstract",
          "offsetInEndSection": 937
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23290027",
          "text": "We report on tacrolimus-associated posterior reversible encephalopathy syndrome with the previously unreported finding of leptomeningeal enhancement occurring separate from the site of parenchymal magnetic resonance signal abnormality.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 235
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29993355",
          "text": "Rare cases of posterior reversible encephalopathy syndrome due to treatment with tacrolimus, an immunosuppressive agent commonly used after organ transplant, have been reported.",
          "beginSection": "abstract",
          "offsetInBeginSection": 693,
          "endSection": "abstract",
          "offsetInEndSection": 870
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23290027",
          "text": "We report on tacrolimus-associated posterior reversible encephalopathy syndrome with the previously unreported finding of leptomeningeal enhancement occurring separate from the site of parenchymal magnetic resonance signal abnormality. Recognition of this atypical finding as a noninfectious cause of leptomeningeal enhancement may assist those caring for patients affected by posterior reversible encephalopathy syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 422
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34258073",
          "text": "Posterior Reversible Encephalopathy Syndrome Associated with Tacrolimus in Cardiac Transplantation.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 99
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29993355",
          "text": "Rare cases of posterior reversible encephalopathy syndrome due to treatment with tacrolimus, an immunosuppressive agent commonly used after organ transplant, have been reported. In these patients, the tacrolimus dose is reduced or discontinued. In transplant patients with neurologic symptoms, the possibility of posterior reversible encephalopathy syndrome should be kept in mind.",
          "beginSection": "abstract",
          "offsetInBeginSection": 693,
          "endSection": "abstract",
          "offsetInEndSection": 1074
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29993355",
          "text": "In these patients, the tacrolimus dose is reduced or discontinued. In transplant patients with neurologic symptoms, the possibility of posterior reversible encephalopathy syndrome should be kept in mind.",
          "beginSection": "abstract",
          "offsetInBeginSection": 871,
          "endSection": "abstract",
          "offsetInEndSection": 1074
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23290027",
          "text": "Isolated leptomeningeal enhancement in tacrolimus-associated posterior reversible encephalopathy syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 106
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34258073",
          "text": "Three heart-transplanted patients (2 men and 1 woman) treated with tacrolimus were identified. They presented with posterior reversible encephalopathy syndrome on days 5, 6, and 58 posttransplantation, respectively. In these reported cases, no sequelae were observed at 6 months follow-up.",
          "beginSection": "abstract",
          "offsetInBeginSection": 419,
          "endSection": "abstract",
          "offsetInEndSection": 708
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29993355",
          "text": "A Late Complication Occurring Due to Tacrolimus After Liver Transplant: Posterior Reversible Encephalopathy Syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 117
        }
      ],
      "ideal_answer": "Yes, tacrolimus can increase the risk of Posterior Reversible Encephalopathy Syndrome. This is a rare but serious complication that can occur in transplant patients treated with tacrolimus. If neurologic symptoms occur, the possibility of this syndrome should be considered and the tacrolimus dose may need to be reduced or discontinued.",
      "exact_answer": "yes"
    },
    {
      "id": "660999e7fdcbea915f00001c",
      "type": "factoid",
      "body": "What is the most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29355075",
        "http://www.ncbi.nlm.nih.gov/pubmed/35371084",
        "http://www.ncbi.nlm.nih.gov/pubmed/35340168",
        "http://www.ncbi.nlm.nih.gov/pubmed/34431576",
        "http://www.ncbi.nlm.nih.gov/pubmed/36700211",
        "http://www.ncbi.nlm.nih.gov/pubmed/37215717",
        "http://www.ncbi.nlm.nih.gov/pubmed/36831367",
        "http://www.ncbi.nlm.nih.gov/pubmed/36650001",
        "http://www.ncbi.nlm.nih.gov/pubmed/35958603",
        "http://www.ncbi.nlm.nih.gov/pubmed/36528470"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35340168",
          "text": "How to overcome primary and secondary drug resistance is a key issue in improving the outcome of MSI-H metastatic colorectal cancer, and commonly used approaches include changing chemotherapy regimens, combining with other immunotherapies, combining with anti-angiogenesis, and local treatments (surgery, radiotherapy, or interventional therapy). It is worth noting that immunotherapy has certain lifelong or even lethal toxicity, and the indications for neoadjuvant immunotherapy must be evaluated with caution. Neoadjuvant immunotherapy in MSI-H advantaged population can achieve high rates of pathological complete remission (pCR) and clinical complete remission (cCR).",
          "beginSection": "abstract",
          "offsetInBeginSection": 700,
          "endSection": "abstract",
          "offsetInEndSection": 1372
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34431576",
          "text": "CONCLUSION\nIn MSI-H/dMMR locally advanced rectal cancer short-course ICI treatment is highly effective and may be discussed in patients with dMMR locally advanced rectal cancer. KEY POINTS\nImmune checkpoint inhibitors are more active in treatment-naïve patients than in patients with refractory high-grade microsatellite instability (MSI-H)/deficiency in mismatch repair (dMMR) colorectal cancer. Standard neoadjuvant chemoradiation is less effective in MSI-H/dMMR rectal cancer patients than in patients with proficient mismatch repair.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1133,
          "endSection": "abstract",
          "offsetInEndSection": 1672
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35371084",
          "text": "Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 119
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35371084",
          "text": "Patients with locally advanced colorectal cancer (LACRC) have a high risk of recurrence and metastasis, although neoadjuvant therapy may provide some benefit. However, patients with high microsatellite instability/deficient mismatch repair (MSI-H/dMMR) LACRC receive little benefit from neoadjuvant chemoradiotherapy (nCRT) or neoadjuvant chemotherapy (nCT). The 2015 KEYNOTE-016 trial identified MSI-H/dMMR as a biomarker indicative of immunotherapy efficacy, and pointed to the potential use of immune checkpoint inhibitors (ICIs).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 533
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35340168",
          "text": "The advent of PD-1 antibodies has significantly improved the prognosis and changed treatment landscape in this population, not only achieving good outcomes in late-line therapy, but also significantly outperforming traditional chemotherapy combined with targeted therapy in first-line therapy. How to overcome primary and secondary drug resistance is a key issue in improving the outcome of MSI-H metastatic colorectal cancer, and commonly used approaches include changing chemotherapy regimens, combining with other immunotherapies, combining with anti-angiogenesis, and local treatments (surgery, radiotherapy, or interventional therapy). It is worth noting that immunotherapy has certain lifelong or even lethal toxicity, and the indications for neoadjuvant immunotherapy must be evaluated with caution.",
          "beginSection": "abstract",
          "offsetInBeginSection": 406,
          "endSection": "abstract",
          "offsetInEndSection": 1212
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34431576",
          "text": "KEY POINTS\nImmune checkpoint inhibitors are more active in treatment-naïve patients than in patients with refractory high-grade microsatellite instability (MSI-H)/deficiency in mismatch repair (dMMR) colorectal cancer. Standard neoadjuvant chemoradiation is less effective in MSI-H/dMMR rectal cancer patients than in patients with proficient mismatch repair. A young patient with Lynch syndrome and MSI-H/dMMR locally advanced rectal cancer refused chemoradiation in order to preserve his fertility.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1313,
          "endSection": "abstract",
          "offsetInEndSection": 1813
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35340168",
          "text": "Previous studies have shown that early-stage MSI-H colorectal cancer patients have a good prognosis, but those with advanced disease have a poor prognosis and are not sensitive to chemotherapy. The advent of PD-1 antibodies has significantly improved the prognosis and changed treatment landscape in this population, not only achieving good outcomes in late-line therapy, but also significantly outperforming traditional chemotherapy combined with targeted therapy in first-line therapy. How to overcome primary and secondary drug resistance is a key issue in improving the outcome of MSI-H metastatic colorectal cancer, and commonly used approaches include changing chemotherapy regimens, combining with other immunotherapies, combining with anti-angiogenesis, and local treatments (surgery, radiotherapy, or interventional therapy).",
          "beginSection": "abstract",
          "offsetInBeginSection": 212,
          "endSection": "abstract",
          "offsetInEndSection": 1046
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35340168",
          "text": "How to overcome primary and secondary drug resistance is a key issue in improving the outcome of MSI-H metastatic colorectal cancer, and commonly used approaches include changing chemotherapy regimens, combining with other immunotherapies, combining with anti-angiogenesis, and local treatments (surgery, radiotherapy, or interventional therapy). It is worth noting that immunotherapy has certain lifelong or even lethal toxicity, and the indications for neoadjuvant immunotherapy must be evaluated with caution.",
          "beginSection": "abstract",
          "offsetInBeginSection": 700,
          "endSection": "abstract",
          "offsetInEndSection": 1212
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34431576",
          "text": "CONCLUSION\nIn MSI-H/dMMR locally advanced rectal cancer short-course ICI treatment is highly effective and may be discussed in patients with dMMR locally advanced rectal cancer. KEY POINTS\nImmune checkpoint inhibitors are more active in treatment-naïve patients than in patients with refractory high-grade microsatellite instability (MSI-H)/deficiency in mismatch repair (dMMR) colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1133,
          "endSection": "abstract",
          "offsetInEndSection": 1531
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35340168",
          "text": "Neoadjuvant immunotherapy in MSI-H advantaged population can achieve high rates of pathological complete remission (pCR) and clinical complete remission (cCR).",
          "beginSection": "abstract",
          "offsetInBeginSection": 1213,
          "endSection": "abstract",
          "offsetInEndSection": 1372
        }
      ],
      "ideal_answer": "The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is short-course immune checkpoint inhibitor (ICI) treatment, which is highly effective in MSI-H/dMMR locally advanced rectal cancer.",
      "exact_answer": [
        "immune checkpoint inhibitors"
      ]
    },
    {
      "id": "661c03c848a2c27714000004",
      "type": "summary",
      "body": "What is the function of the paraoxonase (PON) multigene family?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/8661009",
        "http://www.ncbi.nlm.nih.gov/pubmed/15607899",
        "http://www.ncbi.nlm.nih.gov/pubmed/14551701",
        "http://www.ncbi.nlm.nih.gov/pubmed/29170064",
        "http://www.ncbi.nlm.nih.gov/pubmed/32487820",
        "http://www.ncbi.nlm.nih.gov/pubmed/11918623",
        "http://www.ncbi.nlm.nih.gov/pubmed/19226538",
        "http://www.ncbi.nlm.nih.gov/pubmed/2998653",
        "http://www.ncbi.nlm.nih.gov/pubmed/20980077",
        "http://www.ncbi.nlm.nih.gov/pubmed/16949520"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14551701",
          "text": "The paraoxonase (PON) gene cluster contains at least three members, including PON1, PON2, and PON3, located on chromosome 7q21.3-22.1. Until now there has been little insight into the role of the respective gene products in human physiology and pathology. However, emerging evidence from biochemical and genetic experiments is providing clues about the role(s) of the products of these genes, which indicates that PON(s) acts as important guardians against cellular damage from toxic agents, such as organophosphates, oxidized lipids in the plasma low-density lipoproteins.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 573
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29170064",
          "text": "The paraoxonase (PON) gene family includes three proteins, PON1, PON2 and PON3. PON1 and PON3 are both associated with high-density lipoprotein (HDL) particles and exert anti-oxidant and anti-inflammatory properties.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 216
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29170064",
          "text": "The paraoxonase (PON) gene family includes three proteins, PON1, PON2 and PON3. PON1 and PON3 are both associated with high-density lipoprotein (HDL) particles and exert anti-oxidant and anti-inflammatory properties",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 215
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29170064",
          "text": "The paraoxonase (PON) gene family includes three proteins, PON1, PON2 and PON3. PON1 and PON3 are both associated with high-density lipoprotein (HDL) particles and exert anti-oxidant and anti-inflammatory properties. PON2 and PON3 are intracellular enzymes which modulate mitochondrial superoxide anion production and endoplasmic reticulum (ER) stress-induced apoptosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 370
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29170064",
          "text": "PON1 and PON3 are both associated with high-density lipoprotein (HDL) particles and exert anti-oxidant and anti-inflammatory properties. PON2 and PON3 are intracellular enzymes which modulate mitochondrial superoxide anion production and endoplasmic reticulum (ER) stress-induced apoptosis. The pleiotropic roles exerted by PONs have been mainly investigated in cardiovascular and neurodegenerative diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 80,
          "endSection": "abstract",
          "offsetInEndSection": 488
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29170064",
          "text": "PON1 and PON3 are both associated with high-density lipoprotein (HDL) particles and exert anti-oxidant and anti-inflammatory properties. PON2 and PON3 are intracellular enzymes which modulate mitochondrial superoxide anion production and endoplasmic reticulum (ER) stress-induced apoptosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 80,
          "endSection": "abstract",
          "offsetInEndSection": 370
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15607899",
          "text": "Epidemiologic, genetic, and biochemical studies support an antiatherogenic role for paraoxonase (PON) 1. While the precise mechanism by which PON1 protects against the development of atherosclerosis is unclear, in vitro studies and the results from PON1 knockout and transgenic mice suggest that this protective effect may be attributed to PON1's ability to attenuate the oxidative modification of lipoprotein particles. The two other members of the PON gene family, namely, PON2 and PON3, have also been reported to possess antioxidant properties and may exhibit antiatherogenic capacities as well.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 599
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29170064",
          "text": "The paraoxonase (PON) gene family includes three proteins, PON1, PON2 and PON3.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 79
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8661009",
          "text": "A physiological role for paraoxonase (PON1) is still uncertain, but it catalyzes the hydrolysis of toxic organophosphates. Evidence that the human genome contains two PON1-like genes, designated PON2 and PON3, is presented here. Human PON1 and PON2 each have nine exons, and the exon/intron junctions occur at equivalent positions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 331
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15607899",
          "text": "Epidemiologic, genetic, and biochemical studies support an antiatherogenic role for paraoxonase (PON) 1. While the precise mechanism by which PON1 protects against the development of atherosclerosis is unclear, in vitro studies and the results from PON1 knockout and transgenic mice suggest that this protective effect may be attributed to PON1's ability to attenuate the oxidative modification of lipoprotein particles.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 420
        }
      ],
      "ideal_answer": "The paraoxonase (PON) multigene family consists of three proteins, PON1, PON2 and PON3, which are involved in preventing cellular damage from toxic agents, such as organophosphates, and oxidized lipids in the plasma low-density lipoproteins. PON1 and PON3 are associated with high-density lipoprotein (HDL) particles and exert anti-oxidant and anti-inflammatory properties, supporting an antiatherogenic role for the PON family.",
      "exact_answer": "n/a"
    },
    {
      "id": "660d1285fdcbea915f000036",
      "type": "yesno",
      "body": "Inflammatory breast cancer is the most aggressive form of breast cancer.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33845027",
        "http://www.ncbi.nlm.nih.gov/pubmed/34973083",
        "http://www.ncbi.nlm.nih.gov/pubmed/16154355",
        "http://www.ncbi.nlm.nih.gov/pubmed/30005774",
        "http://www.ncbi.nlm.nih.gov/pubmed/16735787",
        "http://www.ncbi.nlm.nih.gov/pubmed/16988576",
        "http://www.ncbi.nlm.nih.gov/pubmed/18308144",
        "http://www.ncbi.nlm.nih.gov/pubmed/28607534",
        "http://www.ncbi.nlm.nih.gov/pubmed/17914925",
        "http://www.ncbi.nlm.nih.gov/pubmed/16027755"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16735787",
          "text": "Inflammatory breast cancer is rare but represents the most aggressive and lethal form of locally advanced breast cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 120
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16735787",
          "text": "Inflammatory breast cancer is rare but represents the most aggressive and lethal form of locally advanced breast cancer. The management of inflammatory breast cancer has evolved substantially over the last 40 years; current multimodality therapy regimens combine chemotherapy, surgery, and radiation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 300
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33845027",
          "text": "Inflammatory breast cancer is a rare and aggressive malignancy",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 62
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28607534",
          "text": "Inflammatory breast cancer is a rare, yet highly aggressive form of breast cancer, which accounts for less than 5% of all locally advanced presentations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 153
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16154355",
          "text": "\"Inflammatory\" breast cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 29
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16735787",
          "text": "Inflammatory breast cancer is rare but represents the most aggressive and lethal form of locally advanced breast cancer. The management of inflammatory breast cancer has evolved substantially over the last 40 years; current multimodality therapy regimens combine chemotherapy, surgery, and radiation. While identification of the optimal combination of these traditional therapies remains a goal, novel targeted therapies that have recently become available promise improved responses and survival.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 497
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16027755",
          "text": "Male breast cancer is very rare, especially inflammatory breast cancer, which is an aggressive, rapidly proliferating manifestation of primary breast carcinoma. We present a case report of a 56-year-old man in Lebanon who died 8 months after being diagnosed with inflammatory breast cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 290
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18308144",
          "text": "Inflammatory breast cancer (IBC) is the most aggressive and distinct form of primary breast cancer with a peculiar clinical presentation and dismal clinical outcome. This review addresses the pathologic aspects of this entity and discusses the molecular alterations involved in the highly malignant phenotype of IBC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 316
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18308144",
          "text": "Inflammatory breast cancer (IBC) is the most aggressive and distinct form of primary breast cancer with a peculiar clinical presentation and dismal clinical outcome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 165
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28607534",
          "text": "Inflammatory breast cancer is a rare, yet highly aggressive form of breast cancer, which accounts for less than 5% of all locally advanced presentations. The clinical presentation of inflammatory breast cancer often differs significantly from that of noninflammatory breast cancer; however, immunohistochemistry reveals few, if any, distinguishing features.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 357
        }
      ],
      "ideal_answer": "Inflammatory breast cancer is a rare, aggressive, and deadly form of breast cancer that can rapidly progress within 3 months and is confirmed by pathologic findings of invasive carcinoma.",
      "exact_answer": "yes"
    },
    {
      "id": "661dc376fe9d0b3967000002",
      "type": "yesno",
      "body": "Is the majority of genetic variation present in the coding regions of the genome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32472759",
        "http://www.ncbi.nlm.nih.gov/pubmed/28797091",
        "http://www.ncbi.nlm.nih.gov/pubmed/30370373",
        "http://www.ncbi.nlm.nih.gov/pubmed/24667321",
        "http://www.ncbi.nlm.nih.gov/pubmed/28076858",
        "http://www.ncbi.nlm.nih.gov/pubmed/30398620",
        "http://www.ncbi.nlm.nih.gov/pubmed/27270572",
        "http://www.ncbi.nlm.nih.gov/pubmed/30531870",
        "http://www.ncbi.nlm.nih.gov/pubmed/35850704",
        "http://www.ncbi.nlm.nih.gov/pubmed/30245696"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24667321",
          "text": "It has been found that the majority of disease-associated genetic variants identified by genome-wide association studies are located outside of protein-coding regions, where they seem to affect regions that control transcription (promoters, enhancers) and non-coding RNAs that also can influence gene expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 312
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24667321",
          "text": "It has been found that the majority of disease-associated genetic variants identified by genome-wide association studies are located outside of protein-coding regions, where they seem to affect regions that control transcription (promoters, enhancers) and non-coding RNAs that also can influence gene expression. In this review, we focus on two classes of non-coding RNAs that are currently a major focus of interest: micro-RNAs and long non-coding RNAs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 454
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30370373",
          "text": "The vast majority of somatic variants in cancer genomes occur in non-coding regions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 84
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24667321",
          "text": "Genetic variation in the non-coding genome: Involvement of micro-RNAs and long non-coding RNAs in disease.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 106
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30370373",
          "text": "Non-coding genetic variation in cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 39
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28076858",
          "text": "By understanding this tolerance, it has become increasingly possible to identify genes that would make safe therapeutic targets and to identify rare genetic risk factors and phenotypes at the scale of individual genomes. To date, the vast majority of surveyed loss-of-function variants are in protein-coding regions of the genome mainly due to the focus on these regions by exome-based sequencing projects and their relative ease of interpretability. As whole-genome sequencing becomes more prevalent, new strategies will be required to uncover impactful variation in non-coding regions of the genome where the architecture of genome function is more complex.",
          "beginSection": "abstract",
          "offsetInBeginSection": 127,
          "endSection": "abstract",
          "offsetInEndSection": 786
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28076858",
          "text": "To date, the vast majority of surveyed loss-of-function variants are in protein-coding regions of the genome mainly due to the focus on these regions by exome-based sequencing projects and their relative ease of interpretability. As whole-genome sequencing becomes more prevalent, new strategies will be required to uncover impactful variation in non-coding regions of the genome where the architecture of genome function is more complex.",
          "beginSection": "abstract",
          "offsetInBeginSection": 348,
          "endSection": "abstract",
          "offsetInEndSection": 786
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30370373",
          "text": "The vast majority of somatic variants in cancer genomes occur in non-coding regions. However, progress in cancer genomics in the past decade has been mostly focused on coding regions, largely due to the prohibitive cost of whole genome sequencing (WGS).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 253
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28076858",
          "text": "To date, the vast majority of surveyed loss-of-function variants are in protein-coding regions of the genome mainly due to the focus on these regions by exome-based sequencing projects and their relative ease of interpretability.",
          "beginSection": "abstract",
          "offsetInBeginSection": 348,
          "endSection": "abstract",
          "offsetInEndSection": 577
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27270572",
          "text": "Almost 90 % of disease-associated genetic variants found using genome wide association studies (GWAS) are located in non-coding regions of the genome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 150
        }
      ],
      "ideal_answer": "No, the majority of genetic variation is present in the non-coding regions of the genome.",
      "exact_answer": "no"
    },
    {
      "id": "661d6252eac11fad33000025",
      "type": "factoid",
      "body": "What is the cause of autosomal dominant Polycystic Kidney Disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37468838",
        "http://www.ncbi.nlm.nih.gov/pubmed/33431311",
        "http://www.ncbi.nlm.nih.gov/pubmed/14658173",
        "http://www.ncbi.nlm.nih.gov/pubmed/22705113",
        "http://www.ncbi.nlm.nih.gov/pubmed/36870435",
        "http://www.ncbi.nlm.nih.gov/pubmed/37088524",
        "http://www.ncbi.nlm.nih.gov/pubmed/1323077",
        "http://www.ncbi.nlm.nih.gov/pubmed/24246705",
        "http://www.ncbi.nlm.nih.gov/pubmed/23971639",
        "http://www.ncbi.nlm.nih.gov/pubmed/37203894"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36870435",
          "text": "Autosomal dominant polycystic kidney disease is characterized by progressive kidney cyst formation that leads to kidney failure.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 128
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1323077",
          "text": "This could be explained by the persisting underlying autosomal dominant polycystic kidney disease. We conclude that in a hypertensive patient with polycystic kidney disease, extrarenal causes of hypertension may be present.",
          "beginSection": "abstract",
          "offsetInBeginSection": 584,
          "endSection": "abstract",
          "offsetInEndSection": 807
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33431311",
          "text": "Autosomal dominant polycystic kidney disease is the most frequent genetic kidney disease. Cardiovascular disorders associated with autosomal dominant polycystic kidney disease are multiple and may occur early in life. In autosomal dominant polycystic kidney disease cardiovascular morbidity and mortality are related both to the nonspecific consequences of chronic kidney disease and to the particular phenotype of autosomal dominant polycystic kidney disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 460
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33431311",
          "text": "Autosomal dominant polycystic kidney disease is the most frequent genetic kidney disease. Cardiovascular disorders associated with autosomal dominant polycystic kidney disease are multiple and may occur early in life.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 217
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1323077",
          "text": "This could be explained by the persisting underlying autosomal dominant polycystic kidney disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 584,
          "endSection": "abstract",
          "offsetInEndSection": 682
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24246705",
          "text": "Autosomal dominant polycystic kidney disease is the most frequent hereditary kidney disease. However it lacks a specific treatment. Its prevalence is 1/800 and causes the need for renal replacement therapy in 8-10% of patients on dialysis or kidney transplant.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 260
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33431311",
          "text": "Autosomal dominant polycystic kidney disease is the most frequent genetic kidney disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 89
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33431311",
          "text": "Cardiovascular disorders associated with autosomal dominant polycystic kidney disease are multiple and may occur early in life. In autosomal dominant polycystic kidney disease cardiovascular morbidity and mortality are related both to the nonspecific consequences of chronic kidney disease and to the particular phenotype of autosomal dominant polycystic kidney disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 90,
          "endSection": "abstract",
          "offsetInEndSection": 460
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33431311",
          "text": "Cardiovascular disorders associated with autosomal dominant polycystic kidney disease are multiple and may occur early in life. In autosomal dominant polycystic kidney disease cardiovascular morbidity and mortality are related both to the nonspecific consequences of chronic kidney disease and to the particular phenotype of autosomal dominant polycystic kidney disease. Compared to the general population, patients with autosomal dominant polycystic kidney disease present an increased prevalence of hypertension, left ventricular hypertrophy, atrial fibrillation, valvular diseases, aneurisms and arterial dissections.",
          "beginSection": "abstract",
          "offsetInBeginSection": 90,
          "endSection": "abstract",
          "offsetInEndSection": 710
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37088524",
          "text": "Autosomal dominant polycystic kidney disease is a slowly progressive, lifelong disease characterized by continuous development and enlargement of kidney cysts.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 159
        }
      ],
      "ideal_answer": "Autosomal dominant polycystic kidney disease is caused by genetic mutations inherited in an autosomal dominant manner, leading to progressive kidney cyst formation and potential kidney failure.",
      "exact_answer": [
        "autosomal dominant polycystic kidney disease"
      ]
    },
    {
      "id": "65d1300e1930410b13000033",
      "type": "yesno",
      "body": "Is zilucoplan effective for myasthenia gravis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
        "http://www.ncbi.nlm.nih.gov/pubmed/38093160",
        "http://www.ncbi.nlm.nih.gov/pubmed/37204031",
        "http://www.ncbi.nlm.nih.gov/pubmed/33792453",
        "http://www.ncbi.nlm.nih.gov/pubmed/32833750",
        "http://www.ncbi.nlm.nih.gov/pubmed/33398524",
        "http://www.ncbi.nlm.nih.gov/pubmed/32065623",
        "http://www.ncbi.nlm.nih.gov/pubmed/30762205",
        "http://www.ncbi.nlm.nih.gov/pubmed/9118787",
        "http://www.ncbi.nlm.nih.gov/pubmed/20581680"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
          "text": "INTERPRETATION: Zilucoplan treatment showed rapid and clinically meaningful improvements in myasthenia gravis-specific efficacy outcomes, had a favourable safety profile, and was well tolerated, with no major safety findings. Zilucoplan is a new potential treatment option for a broad population of patients with AChR-positive generalised myasthenia gravis. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 2570,
          "endSection": "abstract",
          "offsetInEndSection": 2928
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
          "text": "Zilucoplan is a new potential treatment option for a broad population of patients with AChR-positive generalised myasthenia gravis. The long-term safety and efficacy of zilucoplan is being assessed in an ongoing open-label extension study.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2801,
          "endSection": "abstract",
          "offsetInEndSection": 3040
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
          "text": "Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 152
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
          "text": "Zilucoplan is a new potential treatment option for a broad population of patients with AChR-positive generalised myasthenia gravis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2801,
          "endSection": "abstract",
          "offsetInEndSection": 2932
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
          "text": "We aimed to assess safety, efficacy, and tolerability of zilucoplan in patients with acetylcholine receptor autoantibody (AChR)-positive generalised myasthenia gravis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 312,
          "endSection": "abstract",
          "offsetInEndSection": 479
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
          "text": "INTERPRETATION\nZilucoplan treatment showed rapid and clinically meaningful improvements in myasthenia gravis-specific efficacy outcomes, had a favourable safety profile, and was well tolerated, with no major safety findings.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2576,
          "endSection": "abstract",
          "offsetInEndSection": 2800
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
          "text": "Zilucoplan is a new potential treatment option for a broad population of patients with AChR-positive generalised myasthenia gravis. The long-term safety and efficacy of zilucoplan is being assessed in an ongoing open-label extension study. FUNDING\nUCB Pharma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2801,
          "endSection": "abstract",
          "offsetInEndSection": 3062
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
          "text": "INTERPRETATION\nZilucoplan treatment showed rapid and clinically meaningful improvements in myasthenia gravis-specific efficacy outcomes, had a favourable safety profile, and was well tolerated, with no major safety findings. Zilucoplan is a new potential treatment option for a broad population of patients with AChR-positive generalised myasthenia gravis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2576,
          "endSection": "abstract",
          "offsetInEndSection": 2932
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
          "text": "INTERPRETATION\nZilucoplan treatment showed rapid and clinically meaningful improvements in myasthenia gravis-specific efficacy outcomes, had a favourable safety profile, and was well tolerated, with no major safety findings. Zilucoplan is a new potential treatment option for a broad population of patients with AChR-positive generalised myasthenia gravis. The long-term safety and efficacy of zilucoplan is being assessed in an ongoing open-label extension study.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2576,
          "endSection": "abstract",
          "offsetInEndSection": 3040
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
          "text": "BACKGROUND\nGeneralised myasthenia gravis is a chronic, unpredictable, and debilitating rare disease, often accompanied by high treatment burden and with an unmet need for more efficacious and well tolerated treatments. Zilucoplan is a subcutaneous, self-administered macrocyclic peptide complement C5 inhibitor. We aimed to assess safety, efficacy, and tolerability of zilucoplan in patients with acetylcholine receptor autoantibody (AChR)-positive generalised myasthenia gravis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 479
        }
      ],
      "ideal_answer": "Yes, zilucoplan is effective for myasthenia gravis. It showed rapid and clinically meaningful improvements in myasthenia gravis-specific efficacy outcomes, had a favourable safety profile, and was well tolerated, with no major safety findings. It is a new potential treatment option for a broad population of patients with AChR-positive generalised myasthenia gravis.",
      "exact_answer": "yes"
    },
    {
      "id": "65f77618c4010b4d7800002e",
      "type": "list",
      "body": "Which are the clinical indications for the use of Raltitrexed in patients with colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12056700",
        "http://www.ncbi.nlm.nih.gov/pubmed/8936802",
        "http://www.ncbi.nlm.nih.gov/pubmed/33268287",
        "http://www.ncbi.nlm.nih.gov/pubmed/24388340",
        "http://www.ncbi.nlm.nih.gov/pubmed/10645206",
        "http://www.ncbi.nlm.nih.gov/pubmed/9376633",
        "http://www.ncbi.nlm.nih.gov/pubmed/9376632",
        "http://www.ncbi.nlm.nih.gov/pubmed/24093908",
        "http://www.ncbi.nlm.nih.gov/pubmed/9579853",
        "http://www.ncbi.nlm.nih.gov/pubmed/10791007"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33268287",
          "text": "This study aimed to assess the safety and efficacy of raltitrexed use in patients with metastatic colorectal cancer who developed significant toxicities after fluoropyrimidine-based treatment. PATIENTS AND METHODS\nWe identified patients with metastatic colorectal cancer who were treated with raltitrexed-based systemic therapy after developing serious adverse events with fluoropyrimidine-based treatment in a large Canadian province from 2004 to 2018. Demographic, tumor, and treatment characteristics were retrieved from the electronic medical records.",
          "beginSection": "abstract",
          "offsetInBeginSection": 138,
          "endSection": "abstract",
          "offsetInEndSection": 695
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33268287",
          "text": "This study aimed to assess the safety and efficacy of raltitrexed use in patients with metastatic colorectal cancer who developed significant toxicities after fluoropyrimidine-based treatment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 138,
          "endSection": "abstract",
          "offsetInEndSection": 330
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33268287",
          "text": "This study aimed to assess the safety and efficacy of raltitrexed use in patients with metastatic colorectal cancer who developed significant toxicities after fluoropyrimidine-based treatment. PATIENTS AND METHODS\nWe identified patients with metastatic colorectal cancer who were treated with raltitrexed-based systemic therapy after developing serious adverse events with fluoropyrimidine-based treatment in a large Canadian province from 2004 to 2018.",
          "beginSection": "abstract",
          "offsetInBeginSection": 138,
          "endSection": "abstract",
          "offsetInEndSection": 593
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24388340",
          "text": "Raltitrexed-based chemotherapy for advanced colorectal cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 62
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8936802",
          "text": "Raltitrexed in colorectal cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 33
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33268287",
          "text": "PATIENTS AND METHODS\nWe identified patients with metastatic colorectal cancer who were treated with raltitrexed-based systemic therapy after developing serious adverse events with fluoropyrimidine-based treatment in a large Canadian province from 2004 to 2018.",
          "beginSection": "abstract",
          "offsetInBeginSection": 333,
          "endSection": "abstract",
          "offsetInEndSection": 593
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33268287",
          "text": "Real-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal Cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 92
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33268287",
          "text": "PATIENTS AND METHODS\nWe identified patients with metastatic colorectal cancer who were treated with raltitrexed-based systemic therapy after developing serious adverse events with fluoropyrimidine-based treatment in a large Canadian province from 2004 to 2018. Demographic, tumor, and treatment characteristics were retrieved from the electronic medical records.",
          "beginSection": "abstract",
          "offsetInBeginSection": 333,
          "endSection": "abstract",
          "offsetInEndSection": 695
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33268287",
          "text": "CONCLUSIONS\nRaltitrexed in patients with colorectal cancer who were previously treated with fluoropyrimidine-based systemic therapy is effective and well-tolerated.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2039,
          "endSection": "abstract",
          "offsetInEndSection": 2203
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24388340",
          "text": "AIMS\nTo evaluate the efficiency and safety profile of raltitrexed-based chemotherapy in the treatment of advanced colorectal cancer. METHODS\nAn electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 332
        }
      ],
      "ideal_answer": "The clinical indications for the use of Raltitrexed in patients with colorectal cancer include patients who have developed serious adverse events after receiving fluoropyrimidine-based treatment.",
      "exact_answer": [
        [
          "advanced colorectal cancer"
        ],
        [
          "serious adverse events"
        ],
        [
          "fluoropyrimidine-based treatment"
        ]
      ]
    },
    {
      "id": "661bdc9148a2c27714000001",
      "type": "list",
      "body": "Please list the findings in lateral medullary (Wallenberg) syndrome",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37275090",
        "http://www.ncbi.nlm.nih.gov/pubmed/32539005",
        "http://www.ncbi.nlm.nih.gov/pubmed/32655466",
        "http://www.ncbi.nlm.nih.gov/pubmed/9619082",
        "http://www.ncbi.nlm.nih.gov/pubmed/15050454",
        "http://www.ncbi.nlm.nih.gov/pubmed/23620975",
        "http://www.ncbi.nlm.nih.gov/pubmed/2062269",
        "http://www.ncbi.nlm.nih.gov/pubmed/38027725",
        "http://www.ncbi.nlm.nih.gov/pubmed/25472780",
        "http://www.ncbi.nlm.nih.gov/pubmed/16775654"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37275090",
          "text": "Lateral medullary syndrome/Wallenberg syndrome, is a neurological disorder occurring due to ischemia in the lateral part of medullary oblongata resulting in wide range of symptoms. Dysphagia is usually exhibited in severe and persistent form in LMS. Hence timely intervention is mandatory before the patient further worsens.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 324
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37275090",
          "text": "Lateral medullary syndrome/Wallenberg syndrome, is a neurological disorder occurring due to ischemia in the lateral part of medullary oblongata resulting in wide range of symptoms.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 180
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38027725",
          "text": "Background\nWallenberg syndrome, also known as a lateral medullary syndrome, is a rare neurological condition caused by an infarction in the brainstem's lateral medulla. There are subtypes of Wallenberg syndrome with distinctive and atypical symptoms, such as Opalski syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 276
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38027725",
          "text": "Background\nWallenberg syndrome, also known as a lateral medullary syndrome, is a rare neurological condition caused by an infarction in the brainstem's lateral medulla. There are subtypes of Wallenberg syndrome with distinctive and atypical symptoms, such as Opalski syndrome. Case presentation\nA 41-year-old hypertensive male arrived at the emergency department with abrupt onset of right-sided bodily weakness, vertigo, facial numbness, dysphagia, hoarseness of voice, and double vision.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 491
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38027725",
          "text": "Background\nWallenberg syndrome, also known as a lateral medullary syndrome, is a rare neurological condition caused by an infarction in the brainstem's lateral medulla.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 168
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37275090",
          "text": "Lateral medullary syndrome/Wallenberg syndrome, is a neurological disorder occurring due to ischemia in the lateral part of medullary oblongata resulting in wide range of symptoms. Dysphagia is usually exhibited in severe and persistent form in LMS.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 249
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37275090",
          "text": "Lateral medullary syndrome/Wallenberg syndrome, is a neurological disorder occurring due to ischemia in the lateral part of medullary oblongata resulting in wide range of symptoms. Dysphagia is usually exhibited in severe and persistent form in LMS. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 250
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15050454",
          "text": "It is clinically important to recognize that the lateral caudal medullary infarction appears without signs and symptoms of lower cranial nerve palsies commonly involved in Wallenberg syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 264,
          "endSection": "abstract",
          "offsetInEndSection": 456
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9619082",
          "text": "A diagnosis of Wallenberg syndrome was made fifty eight hours after the onset, a lesion with high signal intensity in the right lateral medulla was evident on DWIs, but it was faint on T2WIs. We concluded that DWIs is useful in early diagnosis of lateral medullary infarction presenting Wallenberg syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 890,
          "endSection": "abstract",
          "offsetInEndSection": 1197
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15050454",
          "text": "A brain MRI showed an infarct in the left lateral caudal medulla. It is clinically important to recognize that the lateral caudal medullary infarction appears without signs and symptoms of lower cranial nerve palsies commonly involved in Wallenberg syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 198,
          "endSection": "abstract",
          "offsetInEndSection": 456
        }
      ],
      "ideal_answer": "Findings in lateral medullary (Wallenberg) syndrome include dysphagia, hoarseness of voice, facial numbness, double vision, and right-sided bodily weakness. Additionally, an infarct in the lateral caudal medulla is typically seen on brain MRI.",
      "exact_answer": [
        [
          "dysphagia"
        ],
        [
          "hoarseness of voice"
        ],
        [
          "facial numbness"
        ],
        [
          "double vision"
        ],
        [
          "right-sided bodily weakness"
        ]
      ]
    },
    {
      "id": "6614fb7bfdcbea915f000044",
      "type": "summary",
      "body": "What are the new treatments for cystic fibrosis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31899933",
        "http://www.ncbi.nlm.nih.gov/pubmed/35125294",
        "http://www.ncbi.nlm.nih.gov/pubmed/36986509",
        "http://www.ncbi.nlm.nih.gov/pubmed/21372122",
        "http://www.ncbi.nlm.nih.gov/pubmed/24750953",
        "http://www.ncbi.nlm.nih.gov/pubmed/35268374",
        "http://www.ncbi.nlm.nih.gov/pubmed/23664284",
        "http://www.ncbi.nlm.nih.gov/pubmed/17901762",
        "http://www.ncbi.nlm.nih.gov/pubmed/14730652",
        "http://www.ncbi.nlm.nih.gov/pubmed/22229570"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36986509",
          "text": "In particular, the triple combination of CFTR modulators composed of elexacaftor, tezacaftor, and ivacaftor (ETI) represents a life-changing therapy for the majority of PwCF worldwide.",
          "beginSection": "abstract",
          "offsetInBeginSection": 500,
          "endSection": "abstract",
          "offsetInEndSection": 684
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36986509",
          "text": "Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 113
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35125294",
          "text": "BACKGROUND\nTime has seen management for Cystic Fibrosis (CF) advance drastically, most recently in the development of the disease-modifying triple combination therapy ivacaftor/tezacaftor/elexacaftor.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 200
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35125294",
          "text": "BACKGROUND\nTime has seen management for Cystic Fibrosis (CF) advance drastically, most recently in the development of the disease-modifying triple combination therapy ivacaftor/tezacaftor/elexacaftor. There is currently limited evidence regarding both the global epidemiology of CF and access to this transformative therapy - and therefore where needs are not being met. Therefore, this study aims to define gaps in access to CF treatment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 439
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35125294",
          "text": "BACKGROUND\nTime has seen management for Cystic Fibrosis (CF) advance drastically, most recently in the development of the disease-modifying triple combination therapy ivacaftor/tezacaftor/elexacaftor. There is currently limited evidence regarding both the global epidemiology of CF and access to this transformative therapy - and therefore where needs are not being met.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 370
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36986509",
          "text": "triple combination of CFTR modulators composed of elexacaftor, tezacaftor, and ivacaftor (ETI) represents a life-changing therapy for the majority of PwCF worldwide",
          "beginSection": "abstract",
          "offsetInBeginSection": 519,
          "endSection": "abstract",
          "offsetInEndSection": 683
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36986509",
          "text": "In particular, the triple combination of CFTR modulators composed of elexacaftor, tezacaftor, and ivacaftor (ETI) represents a life-changing therapy for the majority of PwCF worldwide. A growing number of clinical studies have demonstrated the safety and efficacy of ETI therapy in both short- and long-term (up to two years of follow-up to date) and its ability to significantly reduce pulmonary and gastrointestinal manifestations, sweat chloride concentration, exocrine pancreatic dysfunction, and infertility/subfertility, among other disease signs and symptoms.",
          "beginSection": "abstract",
          "offsetInBeginSection": 500,
          "endSection": "abstract",
          "offsetInEndSection": 1066
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36986509",
          "text": "In particular, the triple combination of CFTR modulators composed of elexacaftor, tezacaftor, and ivacaftor (ETI) represents a life-changing therapy for the majority of PwCF worldwide. A growing number of clinical studies have demonstrated the safety and efficacy of ETI therapy in both short- and long-term (up to two years of follow-up to date) and its ability to significantly reduce pulmonary and gastrointestinal manifestations, sweat chloride concentration, exocrine pancreatic dysfunction, and infertility/subfertility, among other disease signs and symptoms. Nevertheless, ETI therapy-related adverse effects have also been reported, and close monitoring by a multidisciplinary healthcare team remains vital.",
          "beginSection": "abstract",
          "offsetInBeginSection": 500,
          "endSection": "abstract",
          "offsetInEndSection": 1216
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36986509",
          "text": "These drugs consist of the potentiator ivacaftor (VX-770) and the correctors lumacaftor (VX-809), tezacaftor (VX-661), and elexacaftor (VX-445). In particular, the triple combination of CFTR modulators composed of elexacaftor, tezacaftor, and ivacaftor (ETI) represents a life-changing therapy for the majority of PwCF worldwide.",
          "beginSection": "abstract",
          "offsetInBeginSection": 355,
          "endSection": "abstract",
          "offsetInEndSection": 684
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36986509",
          "text": "These drugs consist of the potentiator ivacaftor (VX-770) and the correctors lumacaftor (VX-809), tezacaftor (VX-661), and elexacaftor (VX-445). In particular, the triple combination of CFTR modulators composed of elexacaftor, tezacaftor, and ivacaftor (ETI) represents a life-changing therapy for the majority of PwCF worldwide. A growing number of clinical studies have demonstrated the safety and efficacy of ETI therapy in both short- and long-term (up to two years of follow-up to date) and its ability to significantly reduce pulmonary and gastrointestinal manifestations, sweat chloride concentration, exocrine pancreatic dysfunction, and infertility/subfertility, among other disease signs and symptoms.",
          "beginSection": "abstract",
          "offsetInBeginSection": 355,
          "endSection": "abstract",
          "offsetInEndSection": 1066
        }
      ],
      "ideal_answer": "The new treatments for cystic fibrosis are CFTR modulator drugs, specifically a disease-modifying triple combination therapy ivacaftor/tezacaftor/elexacaftor (ETI). This therapy is life-transforming for the majority of patients with common mutations like F508del.",
      "exact_answer": "n/a"
    },
    {
      "id": "661c424588784bab31000001",
      "type": "factoid",
      "body": "By which method do micro RNAs (miRNAs) primarily aid in transcriptional and post-transcriptional regulation?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37505443",
        "http://www.ncbi.nlm.nih.gov/pubmed/32949853",
        "http://www.ncbi.nlm.nih.gov/pubmed/11896390",
        "http://www.ncbi.nlm.nih.gov/pubmed/26673698",
        "http://www.ncbi.nlm.nih.gov/pubmed/20940025",
        "http://www.ncbi.nlm.nih.gov/pubmed/29187891",
        "http://www.ncbi.nlm.nih.gov/pubmed/25618601",
        "http://www.ncbi.nlm.nih.gov/pubmed/33171624",
        "http://www.ncbi.nlm.nih.gov/pubmed/34963441",
        "http://www.ncbi.nlm.nih.gov/pubmed/26257769"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26673698",
          "text": "MicroRNAs (miRNAs) play a major role in the post-transcriptional regulation of target genes, especially in development and differentiation. Our understanding about the transcriptional regulation of miRNA genes is limited by inadequate annotation of primary miRNA (pri-miRNA) transcripts. Here, we used CAGE-seq and RNA-seq to provide genome-wide identification of the pri-miRNA core promoter repertoire and its dynamic usage during zebrafish embryogenesis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 456
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26673698",
          "text": "MicroRNAs (miRNAs) play a major role in the post-transcriptional regulation of target genes, especially in development and differentiation. Our understanding about the transcriptional regulation of miRNA genes is limited by inadequate annotation of primary miRNA (pri-miRNA) transcripts.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 287
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26673698",
          "text": "MicroRNAs (miRNAs) play a major role in the post-transcriptional regulation of target genes, especially in development and differentiation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 139
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20940025",
          "text": "Micro RNAs (miRNAs) are a recently discovered class of small, non-coding RNAs with the function of post-transcriptional gene expression regulation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 147
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20940025",
          "text": "Micro RNAs (miRNAs) are a recently discovered class of small, non-coding RNAs with the function of post-transcriptional gene expression regulation. MiRNAs may function in networks, forming a complex relationship with diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 226
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20940025",
          "text": "Micro RNAs (miRNAs) are a recently discovered class of small, non-coding RNAs with the function of post-transcriptional gene expression regulation. MiRNAs may function in networks, forming a complex relationship with diseases. Alterations of specific miRNA levels have significant correlation with diseases of divergent origin, such as diabetic or ischemic organ injury including nephropathy, and malignant diseases including renal tumors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 439
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29187891",
          "text": "LncRNAs can also function as endogenous competitive RNAs for miRNAs and indirectly regulate gene expression post-transcriptionally. By binding to the 3'-untranslated regions (3'-UTR) of target genes, miRNAs post-transcriptionally regulate gene expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 280,
          "endSection": "abstract",
          "offsetInEndSection": 535
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25618601",
          "text": "More recently, evidence has begun to accumulate describing the complex post-transcriptional regulation in which lncRNAs are involved. It was reported that lncRNAs can be implicated in degradation, translation, pre-messenger RNA (mRNA) splicing, and protein activities and even as microRNAs (miRNAs) sponges in both a sequence-dependent and sequence-independent manner.",
          "beginSection": "abstract",
          "offsetInBeginSection": 438,
          "endSection": "abstract",
          "offsetInEndSection": 806
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29187891",
          "text": "LncRNAs regulate gene expression at transcriptional, post-transcriptional, and epigenetic levels via multiple action modes. LncRNAs can also function as endogenous competitive RNAs for miRNAs and indirectly regulate gene expression post-transcriptionally. By binding to the 3'-untranslated regions (3'-UTR) of target genes, miRNAs post-transcriptionally regulate gene expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 156,
          "endSection": "abstract",
          "offsetInEndSection": 535
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25618601",
          "text": "More recently, evidence has begun to accumulate describing the complex post-transcriptional regulation in which lncRNAs are involved. It was reported that lncRNAs can be implicated in degradation, translation, pre-messenger RNA (mRNA) splicing, and protein activities and even as microRNAs (miRNAs) sponges in both a sequence-dependent and sequence-independent manner. In this review, we present an updated vision of lncRNAs and summarize the mechanism of post-transcriptional regulation by lncRNAs, providing new insight into the functional cellular roles that they may play in human diseases, with a particular focus on cancers.",
          "beginSection": "abstract",
          "offsetInBeginSection": 438,
          "endSection": "abstract",
          "offsetInEndSection": 1068
        }
      ],
      "ideal_answer": "Micro RNAs (miRNAs) primarily aid in post-transcriptional regulation by binding to the 3'-untranslated regions (3'-UTR) of target genes, thereby indirectly regulating gene expression.",
      "exact_answer": [
        "post-transcriptional regulation"
      ]
    },
    {
      "id": "661d6473eac11fad33000027",
      "type": "factoid",
      "body": "What is the cause of Autosomal Recessive Polycystic Kidney Disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37456659",
        "http://www.ncbi.nlm.nih.gov/pubmed/1450634",
        "http://www.ncbi.nlm.nih.gov/pubmed/8424350",
        "http://www.ncbi.nlm.nih.gov/pubmed/23814685",
        "http://www.ncbi.nlm.nih.gov/pubmed/19594074",
        "http://www.ncbi.nlm.nih.gov/pubmed/9044325",
        "http://www.ncbi.nlm.nih.gov/pubmed/16932388",
        "http://www.ncbi.nlm.nih.gov/pubmed/3239592",
        "http://www.ncbi.nlm.nih.gov/pubmed/33474686",
        "http://www.ncbi.nlm.nih.gov/pubmed/12832752"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8424350",
          "text": "SUBJECTS AND METHODS\nNine patients with known autosomal recessive polycystic kidney disease were examined with sonography and CT and screened for biochemical evidence of metabolic causes of nephrocalcinosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 200,
          "endSection": "abstract",
          "offsetInEndSection": 407
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19594074",
          "text": "INTRODUCTION\nAutosomal recessive polycystic kidney disease is the most common heritable cystic renal disease occurring in infancy and childhood. The clinical spectrum of signs and symptoms of this disease is widely variable ranging from perinatal death to a milder progressive form, which cannot be diagnosed until adolescence.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 327
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1450634",
          "text": "Autosomal recessive polycystic kidney disease is a rare inherited disorder which usually becomes clinically manifest in early childhood, whereas autosomal dominant polycystic kidney disease usually is a disorder of adult onset.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 227
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1450634",
          "text": "Autosomal recessive polycystic kidney disease is a rare inherited disorder which usually becomes clinically manifest in early childhood, whereas autosomal dominant polycystic kidney disease usually is a disorder of adult onset. With increasing knowledge and improving diagnostic techniques, it becomes evident that the spectrum of both entities is much more variable than generally known.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 388
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1450634",
          "text": "Autosomal recessive polycystic kidney disease.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 46
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19594074",
          "text": "INTRODUCTION\nAutosomal recessive polycystic kidney disease is the most common heritable cystic renal disease occurring in infancy and childhood.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 144
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8424350",
          "text": "SUBJECTS AND METHODS\nNine patients with known autosomal recessive polycystic kidney disease were examined with sonography and CT and screened for biochemical evidence of metabolic causes of nephrocalcinosis. RESULTS\nCT showed bilateral renal calcifications in seven of the nine patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 200,
          "endSection": "abstract",
          "offsetInEndSection": 489
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1450634",
          "text": "Autosomal recessive polycystic kidney disease is a rare inherited disorder which usually becomes clinically manifest in early childhood, whereas autosomal dominant polycystic kidney disease usually is a disorder of adult onset. With increasing knowledge and improving diagnostic techniques, it becomes evident that the spectrum of both entities is much more variable than generally known. The presentation of autosomal recessive polycystic kidney disease at later ages and survival into adulthood have been reported.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 516
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23814685",
          "text": "The final diagnosis of autosomal recessive polycystic kidney disease was made based on these findings.",
          "beginSection": "abstract",
          "offsetInBeginSection": 588,
          "endSection": "abstract",
          "offsetInEndSection": 690
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23814685",
          "text": "The liver sections showed changes due to fibrosis. The final diagnosis of autosomal recessive polycystic kidney disease was made based on these findings. In this article, we correlate the ante-natal ultrasound and histopathological findings in autosomal recessive polycystic kidney disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 537,
          "endSection": "abstract",
          "offsetInEndSection": 827
        }
      ],
      "ideal_answer": "Autosomal recessive polycystic kidney disease is caused by genetic mutation.",
      "exact_answer": [
        "Genetic mutation"
      ]
    },
    {
      "id": "65cf98431930410b1300000b",
      "type": "list",
      "body": "What are the targets of Tarlatamab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37877814",
        "http://www.ncbi.nlm.nih.gov/pubmed/37861218",
        "http://www.ncbi.nlm.nih.gov/pubmed/36689692",
        "http://www.ncbi.nlm.nih.gov/pubmed/36351060",
        "http://www.ncbi.nlm.nih.gov/pubmed/37355629",
        "http://www.ncbi.nlm.nih.gov/pubmed/21245946",
        "http://www.ncbi.nlm.nih.gov/pubmed/31982465",
        "http://www.ncbi.nlm.nih.gov/pubmed/15005803",
        "http://www.ncbi.nlm.nih.gov/pubmed/19375315",
        "http://www.ncbi.nlm.nih.gov/pubmed/10120194"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37877814",
          "text": "Tarlatamab, an investigational bispecific T-cell engager molecule that targets the cell surface protein delta-like ligand 3, has shown promising activity in patients with small cell lung cancer whose disease had progressed after receiving another therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 255
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37877814",
          "text": "Tarlatamab, an investigational bispecific T-cell engager molecule that targets the cell surface protein delta-like ligand 3, has shown promising activity in patients with small cell lung cancer whose disease had progressed after receiving another therapy. Questions remain over whether clinicians and patients would use the drug given its challenging administration.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 366
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37861218",
          "text": "BACKGROUND: Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously treated small-cell lung cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 219
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37861218",
          "text": "BACKGROUND\nTarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously treated small-cell lung cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 218
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37861218",
          "text": "BACKGROUND\nTarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously treated small-cell lung cancer. METHODS\nIn this phase 2 trial, we evaluated the antitumor activity and safety of tarlatamab, administered intravenously every 2 weeks at a dose of 10 mg or 100 mg, in patients with previously treated small-cell lung cancer. The primary end point was objective response (complete or partial response), as assessed by blinded independent central review according to the Response Evaluation Criteria in Solid Tumors, version 1.1.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 647
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37861218",
          "text": "The primary end point was objective response (complete or partial response), as assessed by blinded independent central review according to the Response Evaluation Criteria in Solid Tumors, version 1.1. RESULTS\nOverall, 220 patients received tarlatamab; patients had previously received a median of two lines of treatment. Among patients evaluated for antitumor activity and survival, the median follow-up was 10.6 months in the 10-mg group and 10.3 months in the 100-mg group.",
          "beginSection": "abstract",
          "offsetInBeginSection": 445,
          "endSection": "abstract",
          "offsetInEndSection": 924
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37861218",
          "text": "BACKGROUND\nTarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously treated small-cell lung cancer. METHODS\nIn this phase 2 trial, we evaluated the antitumor activity and safety of tarlatamab, administered intravenously every 2 weeks at a dose of 10 mg or 100 mg, in patients with previously treated small-cell lung cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 444
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36689692",
          "text": "RESULTS\nBy July 19, 2022, 107 patients received tarlatamab in dose exploration (0.003 to 100 mg; n = 73) and expansion (100 mg; n = 34) cohorts. Median prior lines of anticancer therapy were 2 (range, 1-6); 49.5% received antiprogrammed death-1/programmed death ligand-1 therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 599,
          "endSection": "abstract",
          "offsetInEndSection": 878
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37861218",
          "text": "CONCLUSIONS\nTarlatamab, administered as a 10-mg dose every 2 weeks, showed antitumor activity with durable objective responses and promising survival outcomes in patients with previously treated small-cell lung cancer. No new safety signals were identified.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2224,
          "endSection": "abstract",
          "offsetInEndSection": 2481
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36689692",
          "text": "RESULTS\nBy July 19, 2022, 107 patients received tarlatamab in dose exploration (0.003 to 100 mg; n = 73) and expansion (100 mg; n = 34) cohorts. Median prior lines of anticancer therapy were 2 (range, 1-6); 49.5% received antiprogrammed death-1/programmed death ligand-1 therapy. Any-grade treatment-related adverse events occurred in 97 patients (90.7%) and grade b % 3 in 33 patients (30.8%).",
          "beginSection": "abstract",
          "offsetInBeginSection": 599,
          "endSection": "abstract",
          "offsetInEndSection": 993
        }
      ],
      "ideal_answer": "Tarlatamab targets delta-like ligand 3 and CD3.",
      "exact_answer": [
        [
          "delta-like ligand 3"
        ],
        [
          "CD3"
        ]
      ]
    },
    {
      "id": "65f77465c4010b4d78000028",
      "type": "yesno",
      "body": "Is liquid biopsy a cost-effective technique in general population screening for colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
        "http://www.ncbi.nlm.nih.gov/pubmed/1599742",
        "http://www.ncbi.nlm.nih.gov/pubmed/37050991",
        "http://www.ncbi.nlm.nih.gov/pubmed/34601837",
        "http://www.ncbi.nlm.nih.gov/pubmed/12943152",
        "http://www.ncbi.nlm.nih.gov/pubmed/28988790",
        "http://www.ncbi.nlm.nih.gov/pubmed/11033584",
        "http://www.ncbi.nlm.nih.gov/pubmed/18347531",
        "http://www.ncbi.nlm.nih.gov/pubmed/36359889",
        "http://www.ncbi.nlm.nih.gov/pubmed/21633092"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
          "text": "Conclusions and Relevance\nIn this economic evaluation of liquid biopsy for colorectal cancer screening, colonoscopy was a cost-effective strategy for colorectal cancer screening in the general population, and the inclusion of liquid biopsy as a first- or second-line screening strategy was not cost-effective at its current cost and screening performance. Liquid biopsy tests for colorectal cancer screening may become cost-effective if their cost is substantially lowered.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2162,
          "endSection": "abstract",
          "offsetInEndSection": 2635
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
          "text": "Conclusions and Relevance\nIn this economic evaluation of liquid biopsy for colorectal cancer screening, colonoscopy was a cost-effective strategy for colorectal cancer screening in the general population, and the inclusion of liquid biopsy as a first- or second-line screening strategy was not cost-effective at its current cost and screening performance.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2162,
          "endSection": "abstract",
          "offsetInEndSection": 2517
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
          "text": "Liquid biopsy tests are in development for cancer early detection, but it is unclear whether they are cost-effective for colorectal cancer screening. Objective\nTo estimate the cost-effectiveness of liquid biopsy for colorectal cancer screening in the US.",
          "beginSection": "abstract",
          "offsetInBeginSection": 133,
          "endSection": "abstract",
          "offsetInEndSection": 389
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
          "text": "Liquid biopsy tests for colorectal cancer screening may become cost-effective if their cost is substantially lowered.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2518,
          "endSection": "abstract",
          "offsetInEndSection": 2635
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
          "text": "Liquid biopsy tests are in development for cancer early detection, but it is unclear whether they are cost-effective for colorectal cancer screening.",
          "beginSection": "abstract",
          "offsetInBeginSection": 133,
          "endSection": "abstract",
          "offsetInEndSection": 282
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
          "text": "Importance\nDespite recommendations for universal screening, adherence to colorectal cancer screening in the US is approximately 60%. Liquid biopsy tests are in development for cancer early detection, but it is unclear whether they are cost-effective for colorectal cancer screening. Objective\nTo estimate the cost-effectiveness of liquid biopsy for colorectal cancer screening in the US.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 389
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
          "text": "Cost-Effectiveness of Liquid Biopsy for Colorectal Cancer Screening in Patients Who Are Unscreened.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 99
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
          "text": "Colonoscopy-liquid biopsy hybrid had a greater gain in life-years if liquid biopsy could detect polyps but remained too costly. Conclusions and Relevance\nIn this economic evaluation of liquid biopsy for colorectal cancer screening, colonoscopy was a cost-effective strategy for colorectal cancer screening in the general population, and the inclusion of liquid biopsy as a first- or second-line screening strategy was not cost-effective at its current cost and screening performance.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2032,
          "endSection": "abstract",
          "offsetInEndSection": 2517
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
          "text": "Importance\nDespite recommendations for universal screening, adherence to colorectal cancer screening in the US is approximately 60%. Liquid biopsy tests are in development for cancer early detection, but it is unclear whether they are cost-effective for colorectal cancer screening.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 282
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
          "text": "Colonoscopy-liquid biopsy hybrid had a greater gain in life-years if liquid biopsy could detect polyps but remained too costly. Conclusions and Relevance\nIn this economic evaluation of liquid biopsy for colorectal cancer screening, colonoscopy was a cost-effective strategy for colorectal cancer screening in the general population, and the inclusion of liquid biopsy as a first- or second-line screening strategy was not cost-effective at its current cost and screening performance. Liquid biopsy tests for colorectal cancer screening may become cost-effective if their cost is substantially lowered.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2032,
          "endSection": "abstract",
          "offsetInEndSection": 2635
        }
      ],
      "ideal_answer": "No, liquid biopsy is not a cost-effective technique in general population screening for colorectal cancer at its current cost and screening performance.",
      "exact_answer": "no"
    },
    {
      "id": "65ef8502dffffb9b6b000003",
      "type": "factoid",
      "body": "What causes Mucormycosis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36566630",
        "http://www.ncbi.nlm.nih.gov/pubmed/36571098",
        "http://www.ncbi.nlm.nih.gov/pubmed/36569440",
        "http://www.ncbi.nlm.nih.gov/pubmed/36751448",
        "http://www.ncbi.nlm.nih.gov/pubmed/26731251",
        "http://www.ncbi.nlm.nih.gov/pubmed/35791976",
        "http://www.ncbi.nlm.nih.gov/pubmed/36333107",
        "http://www.ncbi.nlm.nih.gov/pubmed/25386533",
        "http://www.ncbi.nlm.nih.gov/pubmed/7979755",
        "http://www.ncbi.nlm.nih.gov/pubmed/22169846"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25386533",
          "text": "Mucormycosis are a group of invasive infections caused by filamentous fungi of the Mucoraceae family. Mucormycosis is essentially limited to immunocompromised patients with poorly controlled diabetes mellitus, hematologic malignancy, organ transplant, chemotherapy, chronic renal insufficiency, malnutrition, deferoxamine therapy and severe burns. The fungi invade arteries leading to thrombosis that subsequently causes necrosis of hard and soft tissues.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 455
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25386533",
          "text": "Mucormycosis are a group of invasive infections caused by filamentous fungi of the Mucoraceae family. Mucormycosis is essentially limited to immunocompromised patients with poorly controlled diabetes mellitus, hematologic malignancy, organ transplant, chemotherapy, chronic renal insufficiency, malnutrition, deferoxamine therapy and severe burns.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 347
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25386533",
          "text": "Mucormycosis are a group of invasive infections caused by filamentous fungi of the Mucoraceae family.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 101
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26731251",
          "text": "Mucormycosis is an opportunistic fulminant fungal infection that mainly infects immunocompromised patients. The fungus invades the arteries, leading to thrombosis that subsequently causes necrosis of hard and soft tissues. The occurrence of mucormycosis is not considered rare in the jaws of adults, but involvement of the maxilla in infants is not usually seen.",
          "beginSection": "abstract",
          "offsetInBeginSection": 165,
          "endSection": "abstract",
          "offsetInEndSection": 527
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26731251",
          "text": "Mucormycosis is an opportunistic fulminant fungal infection that mainly infects immunocompromised patients. The fungus invades the arteries, leading to thrombosis that subsequently causes necrosis of hard and soft tissues.",
          "beginSection": "abstract",
          "offsetInBeginSection": 165,
          "endSection": "abstract",
          "offsetInEndSection": 387
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22169846",
          "text": "Mucormycosis is one of the most rapidly progressing and lethal form of fungal infections in humans which usually begins in the nose and paranasal sinuses. The fungus assaults the arteries, leading to thrombosis that subsequently causes necrosis of hard and soft tissues.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 270
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25386533",
          "text": "Mucormycosis is essentially limited to immunocompromised patients with poorly controlled diabetes mellitus, hematologic malignancy, organ transplant, chemotherapy, chronic renal insufficiency, malnutrition, deferoxamine therapy and severe burns. The fungi invade arteries leading to thrombosis that subsequently causes necrosis of hard and soft tissues.",
          "beginSection": "abstract",
          "offsetInBeginSection": 102,
          "endSection": "abstract",
          "offsetInEndSection": 455
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25386533",
          "text": "Mucormycosis is essentially limited to immunocompromised patients with poorly controlled diabetes mellitus, hematologic malignancy, organ transplant, chemotherapy, chronic renal insufficiency, malnutrition, deferoxamine therapy and severe burns. The fungi invade arteries leading to thrombosis that subsequently causes necrosis of hard and soft tissues. Here, we present a case report of a 50-year-old diabetic patient with rhinomaxillary form of mucormycosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 102,
          "endSection": "abstract",
          "offsetInEndSection": 562
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22169846",
          "text": "Mucormycosis is one of the most rapidly progressing and lethal form of fungal infections in humans which usually begins in the nose and paranasal sinuses. The fungus assaults the arteries, leading to thrombosis that subsequently causes necrosis of hard and soft tissues. The purpose of this article is to describe a rare case of maxillary necrosis due to mucormycosis in a 12-year-old diabetic patient and emphasizes on early diagnosis and timely management of this potentially fatal fungal infection.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 501
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26731251",
          "text": "Mucormycosis is an opportunistic fulminant fungal infection that mainly infects immunocompromised patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 165,
          "endSection": "abstract",
          "offsetInEndSection": 272
        }
      ],
      "ideal_answer": "Mucormycosis is caused by filamentous fungi of the Mucoraceae family and mainly infects immunocompromised patients with poorly controlled diabetes mellitus, hematologic malignancy, organ transplant, chemotherapy, chronic renal insufficiency, malnutrition, deferoxamine therapy and severe burns. The fungi invade arteries leading to thrombosis that subsequently causes necrosis of hard and soft tissues.",
      "exact_answer": [
        "Immunocompromised patients"
      ]
    },
    {
      "id": "66165f2afdcbea915f000051",
      "type": "factoid",
      "body": "When was the first case of human monkey pox diagnosed?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36403582",
        "http://www.ncbi.nlm.nih.gov/pubmed/1649373",
        "http://www.ncbi.nlm.nih.gov/pubmed/36684949",
        "http://www.ncbi.nlm.nih.gov/pubmed/2897768",
        "http://www.ncbi.nlm.nih.gov/pubmed/15617321",
        "http://www.ncbi.nlm.nih.gov/pubmed/2570511",
        "http://www.ncbi.nlm.nih.gov/pubmed/195980",
        "http://www.ncbi.nlm.nih.gov/pubmed/36405891",
        "http://www.ncbi.nlm.nih.gov/pubmed/36109272",
        "http://www.ncbi.nlm.nih.gov/pubmed/35038257"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1649373",
          "text": "The authors report on the first coming out in Gabon of human monkey-pox. Four children in the same family were simultaneously attacked. In one of the two fatal cases, diagnosis of monkey-pox was confirmed by the isolation of the virus.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 235
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36684949",
          "text": "A retrospective analysis of monkey pox cases was conducted based on the data obtained from the Rivers State Disease Surveillance and Notification unit from January 2017-June 2022. A total of 112 suspected cases were reported during this period of which 49 (44%) were confirmed by laboratory diagnosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 546,
          "endSection": "abstract",
          "offsetInEndSection": 847
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36684949",
          "text": "Epidemiology of human Monkey-pox cases in Rivers State, Nigeria January 2017-June 2022.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 87
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1649373",
          "text": "In one of the two fatal cases, diagnosis of monkey-pox was confirmed by the isolation of the virus. In the three other cases, diagnosis was based on clinical and epidemiological findings.",
          "beginSection": "abstract",
          "offsetInBeginSection": 136,
          "endSection": "abstract",
          "offsetInEndSection": 323
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1649373",
          "text": "Four children in the same family were simultaneously attacked. In one of the two fatal cases, diagnosis of monkey-pox was confirmed by the isolation of the virus. In the three other cases, diagnosis was based on clinical and epidemiological findings.",
          "beginSection": "abstract",
          "offsetInBeginSection": 73,
          "endSection": "abstract",
          "offsetInEndSection": 323
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1649373",
          "text": "The authors report on the first coming out in Gabon of human monkey-pox.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 72
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1649373",
          "text": "In one of the two fatal cases, diagnosis of monkey-pox was confirmed by the isolation of the virus.",
          "beginSection": "abstract",
          "offsetInBeginSection": 136,
          "endSection": "abstract",
          "offsetInEndSection": 235
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36684949",
          "text": "A retrospective analysis of monkey pox cases was conducted based on the data obtained from the Rivers State Disease Surveillance and Notification unit from January 2017-June 2022. A total of 112 suspected cases were reported during this period of which 49 (44%) were confirmed by laboratory diagnosis. Obio-Akpor (29) and Port Harcourt (9) Local Government Areas which make up the urban centers of the state recorded most cases of monkey pox.",
          "beginSection": "abstract",
          "offsetInBeginSection": 546,
          "endSection": "abstract",
          "offsetInEndSection": 988
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1649373",
          "text": "The authors report on the first coming out in Gabon of human monkey-pox. Four children in the same family were simultaneously attacked.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 135
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36684949",
          "text": "Consequently, there is the need to examine the epidemiology of monkey pox according to time, place, person and geography in Rivers state. A retrospective analysis of monkey pox cases was conducted based on the data obtained from the Rivers State Disease Surveillance and Notification unit from January 2017-June 2022. A total of 112 suspected cases were reported during this period of which 49 (44%) were confirmed by laboratory diagnosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 408,
          "endSection": "abstract",
          "offsetInEndSection": 847
        }
      ],
      "ideal_answer": "The first case of human monkey pox was diagnosed in Gabon in 2017.",
      "exact_answer": [
        "first coming out in Gabon"
      ]
    },
    {
      "id": "661c413f48a2c27714000006",
      "type": "yesno",
      "body": "Does chromatin accessibility affect CRISPR-Cas9 efficiency?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28580607",
        "http://www.ncbi.nlm.nih.gov/pubmed/29684067",
        "http://www.ncbi.nlm.nih.gov/pubmed/31349852",
        "http://www.ncbi.nlm.nih.gov/pubmed/28303677",
        "http://www.ncbi.nlm.nih.gov/pubmed/35689624",
        "http://www.ncbi.nlm.nih.gov/pubmed/28800611",
        "http://www.ncbi.nlm.nih.gov/pubmed/31672284",
        "http://www.ncbi.nlm.nih.gov/pubmed/31021236",
        "http://www.ncbi.nlm.nih.gov/pubmed/30189348",
        "http://www.ncbi.nlm.nih.gov/pubmed/36459645"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28580607",
          "text": "Chromatin accessibility and guide sequence secondary structure affect CRISPR-Cas9 gene editing efficiency.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 106
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29684067",
          "text": "Chromatin accessibility is associated with CRISPR-Cas9 efficiency in the zebrafish (Danio rerio).",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 97
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800611",
          "text": "Our study demonstrated that chromatin accessibility showed positive correlation with CRISPR/Cas9 efficiency, but we did not observe a clear correlation between nucleosome organization and CRISPR/Cas9 efficiency.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1083,
          "endSection": "abstract",
          "offsetInEndSection": 1294
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29684067",
          "text": "We found a correlation between chromatin openness and the efficiency of CRISPR-Cas9 mutagenesis. These results indicate that CRISPR-Cas9 mutagenesis is influenced by chromatin accessibility in zebrafish embryos.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1183,
          "endSection": "abstract",
          "offsetInEndSection": 1394
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800611",
          "text": "Besides the sequence features, local chromatin structures may have effects on CRISPR/Cas9 efficiency, which remain largely unexplored.",
          "beginSection": "abstract",
          "offsetInBeginSection": 363,
          "endSection": "abstract",
          "offsetInEndSection": 497
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800611",
          "text": "To understand the effects of local chromatin structure on CRISPR/Cas9 efficiency in zebrafish, we first determined that CRISPR/Cas9 introduced genome editing mainly before the dome stage.",
          "beginSection": "abstract",
          "offsetInBeginSection": 701,
          "endSection": "abstract",
          "offsetInEndSection": 888
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800611",
          "text": "To understand the effects of local chromatin structure on CRISPR/Cas9 efficiency in zebrafish, we first determined that CRISPR/Cas9 introduced genome editing mainly before the dome stage. Based on this observation, we reanalyzed our published nucleosome organization profiles and generated chromatin accessibility profiles in the 256-cell and dome stages using ATAC-seq technology. Our study demonstrated that chromatin accessibility showed positive correlation with CRISPR/Cas9 efficiency, but we did not observe a clear correlation between nucleosome organization and CRISPR/Cas9 efficiency.",
          "beginSection": "abstract",
          "offsetInBeginSection": 701,
          "endSection": "abstract",
          "offsetInEndSection": 1294
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29684067",
          "text": "In order to further inspect the effect of chromatin on CRISPR-Cas9 mutagenesis, we analysed the relationship of selected chromatin features on CRISPR-Cas9 mutagenesis efficiency using publicly available data from zebrafish embryos. We found a correlation between chromatin openness and the efficiency of CRISPR-Cas9 mutagenesis. These results indicate that CRISPR-Cas9 mutagenesis is influenced by chromatin accessibility in zebrafish embryos.",
          "beginSection": "abstract",
          "offsetInBeginSection": 951,
          "endSection": "abstract",
          "offsetInEndSection": 1394
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29684067",
          "text": "In order to further inspect the effect of chromatin on CRISPR-Cas9 mutagenesis, we analysed the relationship of selected chromatin features on CRISPR-Cas9 mutagenesis efficiency using publicly available data from zebrafish embryos. We found a correlation between chromatin openness and the efficiency of CRISPR-Cas9 mutagenesis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 951,
          "endSection": "abstract",
          "offsetInEndSection": 1279
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800611",
          "text": "Besides the sequence features, local chromatin structures may have effects on CRISPR/Cas9 efficiency, which remain largely unexplored. In the only related study in zebrafish, nucleosome organization was not found to have an effect on CRISPR/Cas9 efficiency, which is inconsistent with recent studies in vitro and in mammalian cell lines.",
          "beginSection": "abstract",
          "offsetInBeginSection": 363,
          "endSection": "abstract",
          "offsetInEndSection": 700
        }
      ],
      "ideal_answer": "Yes, chromatin accessibility affects CRISPR-Cas9 efficiency. The degree of chromatin openness is positively correlated with the efficiency of CRISPR-Cas9 mutagenesis in zebrafish embryos.",
      "exact_answer": "yes"
    },
    {
      "id": "661d51fdeac11fad3300001d",
      "type": "list",
      "body": "What diseases are included in the differential diagnosis of Ehlers-Danlos Syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33437956",
        "http://www.ncbi.nlm.nih.gov/pubmed/1447255",
        "http://www.ncbi.nlm.nih.gov/pubmed/11287544",
        "http://www.ncbi.nlm.nih.gov/pubmed/9762220",
        "http://www.ncbi.nlm.nih.gov/pubmed/2376721",
        "http://www.ncbi.nlm.nih.gov/pubmed/3983062",
        "http://www.ncbi.nlm.nih.gov/pubmed/11704406",
        "http://www.ncbi.nlm.nih.gov/pubmed/21754955",
        "http://www.ncbi.nlm.nih.gov/pubmed/17487505",
        "http://www.ncbi.nlm.nih.gov/pubmed/16915311"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1447255",
          "text": "The characteristic triad of signs of Ehlers-Danlos disease gradually appeared from four to six years of age, allowing us to establish the correct diagnosis. We discuss the differential diagnosis of these connective-tissue disorders and the problems of the orthopaedic treatment of the associated joint deformities. Ehlers-Danlos syndrome is a heterogeneous group of metabolic diseases of collagen and our cases constitute a group which is distinct from the conventional types.",
          "beginSection": "abstract",
          "offsetInBeginSection": 271,
          "endSection": "abstract",
          "offsetInEndSection": 747
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11704406",
          "text": "Ehlers-Danlos syndrome type IV should be considered in the differential diagnosis of cerebrovascular disorder and stroke in early childhood.",
          "beginSection": "abstract",
          "offsetInBeginSection": 534,
          "endSection": "abstract",
          "offsetInEndSection": 674
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1447255",
          "text": "We discuss the differential diagnosis of these connective-tissue disorders and the problems of the orthopaedic treatment of the associated joint deformities. Ehlers-Danlos syndrome is a heterogeneous group of metabolic diseases of collagen and our cases constitute a group which is distinct from the conventional types.",
          "beginSection": "abstract",
          "offsetInBeginSection": 428,
          "endSection": "abstract",
          "offsetInEndSection": 747
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21754955",
          "text": "Ehlers-Danlos syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 23
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2376721",
          "text": "Ehlers-Danlos syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 23
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3983062",
          "text": "This is a previously unrecorded complication of Ehlers-Danlos syndrome and should be considered in the differential diagnosis of chest and abdominal pain in patients with this condition.",
          "beginSection": "abstract",
          "offsetInBeginSection": 172,
          "endSection": "abstract",
          "offsetInEndSection": 358
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11287544",
          "text": "Connective tissue diseases such as Ehlers-Danlos syndrome (EDS) may also cause bleeding and mimic vasculitis and must be included in the differential diagnosis. We present such a case in which the initial findings were misleading.",
          "beginSection": "abstract",
          "offsetInBeginSection": 263,
          "endSection": "abstract",
          "offsetInEndSection": 493
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1447255",
          "text": "In early infancy, these cases were thought to be forms of arthrogryposis multiplex congenita, Larsen's syndrome or Marfan's syndrome. The characteristic triad of signs of Ehlers-Danlos disease gradually appeared from four to six years of age, allowing us to establish the correct diagnosis. We discuss the differential diagnosis of these connective-tissue disorders and the problems of the orthopaedic treatment of the associated joint deformities.",
          "beginSection": "abstract",
          "offsetInBeginSection": 137,
          "endSection": "abstract",
          "offsetInEndSection": 585
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1447255",
          "text": "The characteristic triad of signs of Ehlers-Danlos disease gradually appeared from four to six years of age, allowing us to establish the correct diagnosis. We discuss the differential diagnosis of these connective-tissue disorders and the problems of the orthopaedic treatment of the associated joint deformities.",
          "beginSection": "abstract",
          "offsetInBeginSection": 271,
          "endSection": "abstract",
          "offsetInEndSection": 585
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11287544",
          "text": "Connective tissue diseases such as Ehlers-Danlos syndrome (EDS) may also cause bleeding and mimic vasculitis and must be included in the differential diagnosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 263,
          "endSection": "abstract",
          "offsetInEndSection": 423
        }
      ],
      "ideal_answer": "Marfan's syndrome, Larsen's syndrome, arthrogryposis multiplex congenita, cerebrovascular disorder, stroke, and vasculitis are included in the differential diagnosis of Ehlers-Danlos Syndrome.",
      "exact_answer": [
        [
          "Marfan's syndrome"
        ],
        [
          "Larsen's syndrome"
        ],
        [
          "arthrogryposis multiplex congenita"
        ],
        [
          "cerebrovascular disorder"
        ],
        [
          "stroke"
        ]
      ]
    },
    {
      "id": "65cfa70f1930410b1300000f",
      "type": "summary",
      "body": "What is the mechanism of action of Nemolizumab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37801534",
        "http://www.ncbi.nlm.nih.gov/pubmed/37888917",
        "http://www.ncbi.nlm.nih.gov/pubmed/37556125",
        "http://www.ncbi.nlm.nih.gov/pubmed/37650357",
        "http://www.ncbi.nlm.nih.gov/pubmed/35412530",
        "http://www.ncbi.nlm.nih.gov/pubmed/35766128",
        "http://www.ncbi.nlm.nih.gov/pubmed/34857395",
        "http://www.ncbi.nlm.nih.gov/pubmed/35834124",
        "http://www.ncbi.nlm.nih.gov/pubmed/37121713",
        "http://www.ncbi.nlm.nih.gov/pubmed/32074418"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37888917",
          "text": "Nemolizumab, an interleukin-31 receptor alpha antagonist, down-regulates key pathways in the pathogenesis of prurigo nodularis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 110,
          "endSection": "abstract",
          "offsetInEndSection": 237
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32074418",
          "text": "Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which is involved in the pathogenesis of prurigo nodularis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 100,
          "endSection": "abstract",
          "offsetInEndSection": 235
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32074418",
          "text": "Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which is involved in the pathogenesis of prurigo nodularis. METHODS\nWe conducted a 12-week, randomized, double-blind, phase 2 trial of nemolizumab (at a dose of 0.5 mg per kilogram of body weight) administered subcutaneously at baseline, week 4, and week 8, as compared with placebo, in patients with moderate-to-severe prurigo nodularis and severe pruritus.",
          "beginSection": "abstract",
          "offsetInBeginSection": 100,
          "endSection": "abstract",
          "offsetInEndSection": 536
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35834124",
          "text": "Nemolizumab is a subcutaneously administered humanized anti-interleukin-31 (IL-31) receptor A (IL-31RA) monoclonal antibody that is being developed by Chugai Pharmaceutical Co. Ltd, Maruho Co. Ltd and Galderma Pharma S.A. for the treatment of skin diseases, including atopic dermatitis (AD), AD associated pruritus (ADaP), prurigo nodularis (PN), chronic kidney disease associated pruritus (CKDaP) and systemic sclerosis (SSc). IL-31 is a neuroimmune cytokine that induces itch, inflammation, keratinocyte differentiation and fibroblast activation in chronic pruritic skin diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 582
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35412530",
          "text": "Interleukin-31 (IL-31) is associated with the pathobiological mechanism of AD, contributing to symptoms such as dermatitis and pruritus. Nemolizumab is an anti-IL-31 receptor α-chain (IL-31RA) monoclonal antibody agent that is efficacious in improving symptoms of AD in several phase II and phase III studies in recent years. Nemolizumab demonstrates great efficacy in reducing pruritus and to a lesser degree, dermatitis associated with AD.",
          "beginSection": "abstract",
          "offsetInBeginSection": 140,
          "endSection": "abstract",
          "offsetInEndSection": 581
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37888917",
          "text": "Nemolizumab, an interleukin-31 receptor alpha antagonist, down-regulates key pathways in the pathogenesis of prurigo nodularis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 111,
          "endSection": "abstract",
          "offsetInEndSection": 238
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35834124",
          "text": "Nemolizumab is a subcutaneously administered humanized anti-interleukin-31 (IL-31) receptor A (IL-31RA) monoclonal antibody that is being developed by Chugai Pharmaceutical Co. Ltd, Maruho Co. Ltd and Galderma Pharma S.A. for the treatment of skin diseases, including atopic dermatitis (AD), AD associated pruritus (ADaP), prurigo nodularis (PN), chronic kidney disease associated pruritus (CKDaP) and systemic sclerosis (SSc). IL-31 is a neuroimmune cytokine that induces itch, inflammation, keratinocyte differentiation and fibroblast activation in chronic pruritic skin diseases. Nemolizumab (Mitchga® Syringes) was approved in Japan on 28 March 2022 for use in adults and children over the age of 13 years for the treatment of itch associated with AD (only when existing treatment is insufficiently effective).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 814
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35412530",
          "text": "Interleukin-31 (IL-31) is associated with the pathobiological mechanism of AD, contributing to symptoms such as dermatitis and pruritus. Nemolizumab is an anti-IL-31 receptor α-chain (IL-31RA) monoclonal antibody agent that is efficacious in improving symptoms of AD in several phase II and phase III studies in recent years.",
          "beginSection": "abstract",
          "offsetInBeginSection": 140,
          "endSection": "abstract",
          "offsetInEndSection": 465
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32074418",
          "text": "BACKGROUND\nPrurigo nodularis is a chronic pruritic skin disease with multiple nodular skin lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which is involved in the pathogenesis of prurigo nodularis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 235
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35412530",
          "text": "Atopic dermatitis (AD) is a common inflammatory skin disease that has emerging treatments targeting the underlying immunological mechanism. Interleukin-31 (IL-31) is associated with the pathobiological mechanism of AD, contributing to symptoms such as dermatitis and pruritus. Nemolizumab is an anti-IL-31 receptor α-chain (IL-31RA) monoclonal antibody agent that is efficacious in improving symptoms of AD in several phase II and phase III studies in recent years.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 465
        }
      ],
      "ideal_answer": "Nemolizumab is a monoclonal antibody that binds to the interleukin-31 receptor A subunit, which is involved in the pathogenesis of pruritus and inflammation in atopic dermatitis. By down-regulating key pathways in the pathogenesis of prurigo nodularis, nemolizumab reduces itching and inflammation.",
      "exact_answer": "n/a"
    },
    {
      "id": "65f774a4c4010b4d78000029",
      "type": "factoid",
      "body": "What type of colorectal cancer screening is the most cost-effective for general population?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
        "http://www.ncbi.nlm.nih.gov/pubmed/26338314",
        "http://www.ncbi.nlm.nih.gov/pubmed/1599742",
        "http://www.ncbi.nlm.nih.gov/pubmed/37050991",
        "http://www.ncbi.nlm.nih.gov/pubmed/28988790",
        "http://www.ncbi.nlm.nih.gov/pubmed/11033584",
        "http://www.ncbi.nlm.nih.gov/pubmed/18347531",
        "http://www.ncbi.nlm.nih.gov/pubmed/21633092",
        "http://www.ncbi.nlm.nih.gov/pubmed/11916165",
        "http://www.ncbi.nlm.nih.gov/pubmed/11035892"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28988790",
          "text": "Newer technologies for colorectal cancer screening, including computed tomographic colonography (CTC), faecal DNA test, and Pillcam Colon are less invasive and accurate, however, they are not cost-effective, as their cost was higher than all other established screening strategies. When compliance and adherence to such new techniques are increased more than the established strategies they would be more cost-effective particularly CTC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 746,
          "endSection": "abstract",
          "offsetInEndSection": 1183
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37050991",
          "text": "Screening for colorectal cancer is a rational and cost-effective strategy for reducing the incidence of colorectal cancer and related mortality.",
          "beginSection": "abstract",
          "offsetInBeginSection": 196,
          "endSection": "abstract",
          "offsetInEndSection": 340
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37050991",
          "text": "Screening for colorectal cancer is a rational and cost-effective strategy for reducing the incidence of colorectal cancer and related mortality. Despite endorsement by academic and healthcare organizations, patient awareness and compliance with screening are low, partly due to patient-related barriers to screening.",
          "beginSection": "abstract",
          "offsetInBeginSection": 196,
          "endSection": "abstract",
          "offsetInEndSection": 512
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1599742",
          "text": "Cost-effective screening strategies for colorectal cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 58
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28988790",
          "text": "Recent diagnostic procedures for colorectal cancer screening: Are they cost-effective?",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 86
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37050991",
          "text": "Numerous studies have shown the benefit of early screening for colorectal cancer in reducing mortality. Screening for colorectal cancer is a rational and cost-effective strategy for reducing the incidence of colorectal cancer and related mortality. Despite endorsement by academic and healthcare organizations, patient awareness and compliance with screening are low, partly due to patient-related barriers to screening.",
          "beginSection": "abstract",
          "offsetInBeginSection": 92,
          "endSection": "abstract",
          "offsetInEndSection": 512
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37050991",
          "text": "Numerous studies have shown the benefit of early screening for colorectal cancer in reducing mortality. Screening for colorectal cancer is a rational and cost-effective strategy for reducing the incidence of colorectal cancer and related mortality.",
          "beginSection": "abstract",
          "offsetInBeginSection": 92,
          "endSection": "abstract",
          "offsetInEndSection": 340
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28988790",
          "text": "Newer technologies for colorectal cancer screening, including computed tomographic colonography (CTC), faecal DNA test, and Pillcam Colon are less invasive and accurate, however, they are not cost-effective, as their cost was higher than all other established screening strategies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 746,
          "endSection": "abstract",
          "offsetInEndSection": 1027
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11033584",
          "text": "CONCLUSIONS\nColonoscopy represents a cost-effective means of screening for colorectal cancer because it reduces mortality at relatively low incremental costs. Low compliance rates render colonoscopy every 10 years the most cost-effective primary screening strategy for colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2091,
          "endSection": "abstract",
          "offsetInEndSection": 2378
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37050991",
          "text": "Screening for colorectal cancer is a rational and cost-effective strategy for reducing the incidence of colorectal cancer and related mortality. Despite endorsement by academic and healthcare organizations, patient awareness and compliance with screening are low, partly due to patient-related barriers to screening. AIM\nThis study aimed to explore the preferred screening method for colorectal cancer in Saudi Arabia in general.",
          "beginSection": "abstract",
          "offsetInBeginSection": 196,
          "endSection": "abstract",
          "offsetInEndSection": 627
        }
      ],
      "ideal_answer": "Colonoscopy is the most cost-effective colorectal cancer screening method for the general population.",
      "exact_answer": [
        "colonoscopy"
      ]
    },
    {
      "id": "65f37aeac4010b4d7800000c",
      "type": "yesno",
      "body": "Is Cri du Chat syndrome (CdCS) a genetic syndrome caused by deletions in the long arm of chromosome 5",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37908952",
        "http://www.ncbi.nlm.nih.gov/pubmed/36660031",
        "http://www.ncbi.nlm.nih.gov/pubmed/1978567",
        "http://www.ncbi.nlm.nih.gov/pubmed/26059676",
        "http://www.ncbi.nlm.nih.gov/pubmed/25514263",
        "http://www.ncbi.nlm.nih.gov/pubmed/25236835",
        "http://www.ncbi.nlm.nih.gov/pubmed/10424821",
        "http://www.ncbi.nlm.nih.gov/pubmed/18437967",
        "http://www.ncbi.nlm.nih.gov/pubmed/37974816",
        "http://www.ncbi.nlm.nih.gov/pubmed/7896290"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25514263",
          "text": "Cri du chat syndrome (CdcS), also known as 5p deletion syndrome is a genetic disorder caused by the partial deletion of chromatin from the short arm of chromosome 5.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 165
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25236835",
          "text": "Cri du Chat Syndrome (CdCS) is rare and occurs as a result of a partial deletion in the short arm of chromosome 5. There are no reports in the literature from the West African sub-region and indeed very few from Africa.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 219
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25236835",
          "text": "Cri du Chat Syndrome (CdCS) is rare and occurs as a result of a partial deletion in the short arm of chromosome 5.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 114
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25514263",
          "text": "Cri du chat syndrome (CdcS), also known as 5p deletion syndrome is a genetic disorder caused by the partial deletion of chromatin from the short arm of chromosome 5. There is a paucity of literature on the dental manifestations in CdcS.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 236
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25514263",
          "text": "Cri du chat syndrome (CdcS), also known as 5p deletion syndrome is a genetic disorder caused by the partial deletion of chromatin from the short arm of chromosome 5. There is a paucity of literature on the dental manifestations in CdcS. The purposes of this report are to present the case of a nine-year-old girl with the syndrome, CdcS and to review its dental and clinical manifestations and their management in children.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 423
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26059676",
          "text": "The cri-du-chat syndrome is a rare genetic disorder caused by deletions in the short arm of chromosome 5.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 105
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25236835",
          "text": "Cri du Chat Syndrome (CdCS) is rare and occurs as a result of a partial deletion in the short arm of chromosome 5. There are no reports in the literature from the West African sub-region and indeed very few from Africa. A case of Cri du Chat Syndrome is described in Ghana.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 273
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26059676",
          "text": "The cri-du-chat syndrome is a rare genetic disorder caused by deletions in the short arm of chromosome 5. It presents with a distinctive catlike high-pitched cry, psychomotor delays, microcephaly, craniofacial abnormalities, and, in many cases, ocular findings.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 261
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18437967",
          "text": "BACKGROUND\nCri-du-chat syndrome is a genetic disorder associated with various sized deletions of the short arm of chromosome 5.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 127
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18437967",
          "text": "BACKGROUND\nCri-du-chat syndrome is a genetic disorder associated with various sized deletions of the short arm of chromosome 5. There are typical physical features, but individual phenotypes vary considerably.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 209
        }
      ],
      "ideal_answer": "No, Cri du Chat syndrome (CdCS) is caused by deletions in the short arm of chromosome 5.",
      "exact_answer": "no"
    },
    {
      "id": "66168d7bfdcbea915f000056",
      "type": "summary",
      "body": "Mortality in schizophrenia.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24313570",
        "http://www.ncbi.nlm.nih.gov/pubmed/29723811",
        "http://www.ncbi.nlm.nih.gov/pubmed/17058327",
        "http://www.ncbi.nlm.nih.gov/pubmed/22083003",
        "http://www.ncbi.nlm.nih.gov/pubmed/17944000",
        "http://www.ncbi.nlm.nih.gov/pubmed/16449697",
        "http://www.ncbi.nlm.nih.gov/pubmed/35152418",
        "http://www.ncbi.nlm.nih.gov/pubmed/17444079",
        "http://www.ncbi.nlm.nih.gov/pubmed/8873299",
        "http://www.ncbi.nlm.nih.gov/pubmed/26909391"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17058327",
          "text": "Mortality in schizophrenia.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 27
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17944000",
          "text": "Mortality in schizophrenia.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 27
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22083003",
          "text": "Morbidity and mortality in schizophrenia.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 41
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24313570",
          "text": "Excess early mortality in schizophrenia.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 40
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24313570",
          "text": "excess early mortality in persons with schizophrenia",
          "beginSection": "abstract",
          "offsetInBeginSection": 197,
          "endSection": "abstract",
          "offsetInEndSection": 249
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16449697",
          "text": "RESULTS\nDuring a 17-year follow-up, 39 of the 99 people with schizophrenia died. Adjusted for age and gender, the relative mortality risk between those with schizophrenia and others was 2.84 (95% CI 2.06-3.90), and was 2.25 (95% CI1.61-3.15) after further adjusting for somatic diseases, bloodpressure, cholesterol, body mass index, smoking, exercise, alcohol intake and education.",
          "beginSection": "abstract",
          "offsetInBeginSection": 437,
          "endSection": "abstract",
          "offsetInEndSection": 818
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17058327",
          "text": "RESULTS\nSchizophrenia is associated with mortality rates that are two to three times higher than those expected or observed in the general population. This excess of mortality is accounted for by a combination of an increased risk of suicide, in particular in young male patients soon after diagnosis, and more importantly, a higher number of natural deaths.",
          "beginSection": "abstract",
          "offsetInBeginSection": 500,
          "endSection": "abstract",
          "offsetInEndSection": 858
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16449697",
          "text": "Schizophrenia was determined using the Present State Examination and previous medical records. RESULTS\nDuring a 17-year follow-up, 39 of the 99 people with schizophrenia died. Adjusted for age and gender, the relative mortality risk between those with schizophrenia and others was 2.84 (95% CI 2.06-3.90), and was 2.25 (95% CI1.61-3.15) after further adjusting for somatic diseases, bloodpressure, cholesterol, body mass index, smoking, exercise, alcohol intake and education.",
          "beginSection": "abstract",
          "offsetInBeginSection": 340,
          "endSection": "abstract",
          "offsetInEndSection": 818
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16449697",
          "text": "Adjusted for age and gender, the relative mortality risk between those with schizophrenia and others was 2.84 (95% CI 2.06-3.90), and was 2.25 (95% CI1.61-3.15) after further adjusting for somatic diseases, bloodpressure, cholesterol, body mass index, smoking, exercise, alcohol intake and education.",
          "beginSection": "abstract",
          "offsetInBeginSection": 518,
          "endSection": "abstract",
          "offsetInEndSection": 818
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17944000",
          "text": "Schizophrenia is a life-threatening disease associated with mortality rates that are two to three times higher than those expected/observed in the general population. It is associated with high levels of suicide, particularly in young male patients soon after diagnosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 270
        }
      ],
      "ideal_answer": "Schizophrenia is associated with a 2.25-fold increase in mortality risk compared to the general population, after adjusting for various factors such as somatic diseases, blood pressure, cholesterol, body mass index, smoking, exercise, alcohol intake, and education. This excess mortality is primarily due to natural causes and suicide.",
      "exact_answer": "n/a"
    },
    {
      "id": "661d2428eac11fad33000017",
      "type": "yesno",
      "body": "Is ICD-10 encoding sensitive for capturing paediatric sepsis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37342815",
        "http://www.ncbi.nlm.nih.gov/pubmed/18066356",
        "http://www.ncbi.nlm.nih.gov/pubmed/31438253",
        "http://www.ncbi.nlm.nih.gov/pubmed/26700284",
        "http://www.ncbi.nlm.nih.gov/pubmed/10725032",
        "http://www.ncbi.nlm.nih.gov/pubmed/31335441",
        "http://www.ncbi.nlm.nih.gov/pubmed/37936832",
        "http://www.ncbi.nlm.nih.gov/pubmed/11187534",
        "http://www.ncbi.nlm.nih.gov/pubmed/33719208",
        "http://www.ncbi.nlm.nih.gov/pubmed/28845129"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37342815",
          "text": "Aim\nTo describe how well ICD-10 coding captures sepsis in children admitted to the hospital with blood culture-proven bacterial or fungal infection and systemic inflammatory response syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 126,
          "endSection": "abstract",
          "offsetInEndSection": 318
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37342815",
          "text": "Background\nInternational Classification of Diseases 10th edition (ICD-10) is widely used to describe the burden of disease. Aim\nTo describe how well ICD-10 coding captures sepsis in children admitted to the hospital with blood culture-proven bacterial or fungal infection and systemic inflammatory response syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 318
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26700284",
          "text": "CONCLUSIONS\nThis study demonstrates that sepsis is highly undercoded in administrative data, thus under-ascertaining the true incidence of sepsis. The optimised ICD-coded definition has a higher validity with higher Sn and should be preferentially considered if used for surveillance purposes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1669,
          "endSection": "abstract",
          "offsetInEndSection": 1962
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31438253",
          "text": "Our algorithm follows this and explores SNOMED-CT to assign the right ICD-10 code of the sepsis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 348,
          "endSection": "abstract",
          "offsetInEndSection": 444
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31438253",
          "text": "The aim of this paper is to automate this coding thanks to the use of SNOMED-CT. A dichotomous classification of bacteria causing sepsis has been generated in respect of ICD-10.",
          "beginSection": "abstract",
          "offsetInBeginSection": 170,
          "endSection": "abstract",
          "offsetInEndSection": 347
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37342815",
          "text": "Aim\nTo describe how well ICD-10 coding captures sepsis in children admitted to the hospital with blood culture-proven bacterial or fungal infection and systemic inflammatory response syndrome. Methods\nSecondary analysis of a population-based, multicenter, prospective cohort study on children with blood culture-proven sepsis of nine tertiary pediatric hospitals in Switzerland. We compared the agreement of validated study data on sepsis criteria with ICD-10 coding abstraction obtained at the participating hospitals.",
          "beginSection": "abstract",
          "offsetInBeginSection": 126,
          "endSection": "abstract",
          "offsetInEndSection": 647
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37342815",
          "text": "Conclusions\nIn this population-based study, we found a poor representation of sepsis and sepsis with organ dysfunction by ICD-10 coding abstraction in children with blood culture-proven sepsis when compared against a prospective validated research dataset. Sepsis estimates in children based on ICD-10 coding may thus severely underestimate the true prevalence of the disease. Supplementary Information\nThe online version contains supplementary material available at 10.1007/s44253-023-00006-1.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1415,
          "endSection": "abstract",
          "offsetInEndSection": 1911
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37342815",
          "text": "Agreement of ICD-10 coding abstraction with validated study data varied by the underlying infection type and disease severity (p < 0.05). The estimated national incidence of sepsis, inferred from ICD-10 coding abstraction, was 12.5 per 100,000 children (95%-CI 11.7-13.5) and 21.0 per 100,000 children (95%-CI 19.8-22.2) using validated study data.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1064,
          "endSection": "abstract",
          "offsetInEndSection": 1412
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31438253",
          "text": "The aim of this paper is to automate this coding thanks to the use of SNOMED-CT. A dichotomous classification of bacteria causing sepsis has been generated in respect of ICD-10. Our algorithm follows this and explores SNOMED-CT to assign the right ICD-10 code of the sepsis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 170,
          "endSection": "abstract",
          "offsetInEndSection": 444
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37342815",
          "text": "Aim\nTo describe how well ICD-10 coding captures sepsis in children admitted to the hospital with blood culture-proven bacterial or fungal infection and systemic inflammatory response syndrome. Methods\nSecondary analysis of a population-based, multicenter, prospective cohort study on children with blood culture-proven sepsis of nine tertiary pediatric hospitals in Switzerland.",
          "beginSection": "abstract",
          "offsetInBeginSection": 126,
          "endSection": "abstract",
          "offsetInEndSection": 506
        }
      ],
      "ideal_answer": "No, ICD-10 encoding is not sensitive for capturing paediatric sepsis. This study found a poor representation of sepsis and sepsis with organ dysfunction by ICD-10 coding abstraction in children with blood culture-proven sepsis when compared against a prospective validated research dataset. Sepsis estimates in children based on ICD-10 coding may thus severely underestimate the true prevalence of the disease.",
      "exact_answer": "no"
    },
    {
      "id": "65cf96ce1930410b1300000a",
      "type": "yesno",
      "body": "Is Amivantamab used for non–small-cell lung cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35616682",
        "http://www.ncbi.nlm.nih.gov/pubmed/35652704",
        "http://www.ncbi.nlm.nih.gov/pubmed/37022784",
        "http://www.ncbi.nlm.nih.gov/pubmed/36652175",
        "http://www.ncbi.nlm.nih.gov/pubmed/36868177",
        "http://www.ncbi.nlm.nih.gov/pubmed/36756143",
        "http://www.ncbi.nlm.nih.gov/pubmed/36979929",
        "http://www.ncbi.nlm.nih.gov/pubmed/37284196",
        "http://www.ncbi.nlm.nih.gov/pubmed/37800882",
        "http://www.ncbi.nlm.nih.gov/pubmed/37880647"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35616682",
          "text": "BACKGROUND\nAmivantamab was approved on May 21st, 2021, by United States food and drug administration with the brand name Rybervant, used particularly for adult patients with exon20 insertion of epithelial growth factor receptor with locally advanced metastatic non-small cell lung cancer. OBJECTIVE\nIn this review, we explain the non-small cell lung cancer and molecular distinctions between non-small cell lung cancer and small cell lung cancer. We also conclude numerous components of non-small cell lung cancer, which include signs and symptoms of Amivantamab in inhibiting the cancer cell growth, various clinical trials on Amivantamab, adverse effects, and the contraindications of Amivantamab.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 701
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35616682",
          "text": "BACKGROUND\nAmivantamab was approved on May 21st, 2021, by United States food and drug administration with the brand name Rybervant, used particularly for adult patients with exon20 insertion of epithelial growth factor receptor with locally advanced metastatic non-small cell lung cancer. OBJECTIVE\nIn this review, we explain the non-small cell lung cancer and molecular distinctions between non-small cell lung cancer and small cell lung cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 448
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37880647",
          "text": "The development of amivantamab for the treatment of non-small cell lung cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 79
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35616682",
          "text": "Amivantamab: A New Hope in Targeting Non-small Cell Lung Cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 64
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37800882",
          "text": "Amivantamab plus Lazertinib Is Efficacious in Non-Small Cell Lung Cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 73
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37800882",
          "text": "Amivantamab plus lazertinib shows clinical efficacy in osimertinib-relapsed non-small cell lung cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 103
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35616682",
          "text": "OBJECTIVE\nIn this review, we explain the non-small cell lung cancer and molecular distinctions between non-small cell lung cancer and small cell lung cancer. We also conclude numerous components of non-small cell lung cancer, which include signs and symptoms of Amivantamab in inhibiting the cancer cell growth, various clinical trials on Amivantamab, adverse effects, and the contraindications of Amivantamab.",
          "beginSection": "abstract",
          "offsetInBeginSection": 291,
          "endSection": "abstract",
          "offsetInEndSection": 701
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35616682",
          "text": "BACKGROUND: Amivantamab was approved on May 21st, 2021, by United States food and drug administration with the brand name Rybervant, used particularly for adult patients with exon20 insertion of epithelial growth factor receptor with locally advanced metastatic non-small cell lung cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 289
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35616682",
          "text": "We also conclude numerous components of non-small cell lung cancer, which include signs and symptoms of Amivantamab in inhibiting the cancer cell growth, various clinical trials on Amivantamab, adverse effects, and the contraindications of Amivantamab.",
          "beginSection": "abstract",
          "offsetInBeginSection": 449,
          "endSection": "abstract",
          "offsetInEndSection": 701
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35616682",
          "text": "OBJECTIVE\nIn this review, we explain the non-small cell lung cancer and molecular distinctions between non-small cell lung cancer and small cell lung cancer. We also conclude numerous components of non-small cell lung cancer, which include signs and symptoms of Amivantamab in inhibiting the cancer cell growth, various clinical trials on Amivantamab, adverse effects, and the contraindications of Amivantamab. METHODS\nA comprehensive literature search was conducted in the relevant databases like ScienceDirect, PubMed, ResearchGate, and Google Scholar to identify studies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 291,
          "endSection": "abstract",
          "offsetInEndSection": 867
        }
      ],
      "ideal_answer": "Yes, Amivantamab is used for non-small-cell lung cancer.",
      "exact_answer": "yes"
    },
    {
      "id": "65f7754ec4010b4d7800002b",
      "type": "yesno",
      "body": "Do very elderly stage III colorectal cancer patients present clinical benefit from oxaliplatin-based adjuvant chemotherapy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24071534",
        "http://www.ncbi.nlm.nih.gov/pubmed/16943526",
        "http://www.ncbi.nlm.nih.gov/pubmed/37498507",
        "http://www.ncbi.nlm.nih.gov/pubmed/25731317",
        "http://www.ncbi.nlm.nih.gov/pubmed/29861156",
        "http://www.ncbi.nlm.nih.gov/pubmed/28434884",
        "http://www.ncbi.nlm.nih.gov/pubmed/26021722",
        "http://www.ncbi.nlm.nih.gov/pubmed/36252550",
        "http://www.ncbi.nlm.nih.gov/pubmed/28699092",
        "http://www.ncbi.nlm.nih.gov/pubmed/33311791"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28434884",
          "text": "The incidence and severity of toxicity might be greater among older patients who might also derive less benefit from oxaliplatin. We evaluated the association between adjuvant oxaliplatin-based chemotherapy and neurotoxicity outcomes in an elderly cohort of patients. PATIENTS AND METHODS\nA population-based cohort of patients aged > 65 years with stage II and III colorectal cancer treated with adjuvant therapy in Ontario, Canada was identified using the Ontario Cancer Registry.",
          "beginSection": "abstract",
          "offsetInBeginSection": 173,
          "endSection": "abstract",
          "offsetInEndSection": 656
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28434884",
          "text": "We evaluated the association between adjuvant oxaliplatin-based chemotherapy and neurotoxicity outcomes in an elderly cohort of patients. PATIENTS AND METHODS\nA population-based cohort of patients aged > 65 years with stage II and III colorectal cancer treated with adjuvant therapy in Ontario, Canada was identified using the Ontario Cancer Registry.",
          "beginSection": "abstract",
          "offsetInBeginSection": 303,
          "endSection": "abstract",
          "offsetInEndSection": 656
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29861156",
          "text": "CONCLUSIONS\nDespite a modestly increased rate of hospital admission and early chemotherapy cessation, we demonstrate a persistent survival benefit for the addition of oxaliplatin to a fluoropyrimidine as adjuvant treatment for stage III colon cancer in elderly patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1381,
          "endSection": "abstract",
          "offsetInEndSection": 1651
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29861156",
          "text": "Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 113
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29861156",
          "text": "We aimed to clarify the efficacy and complications of adjuvant oxaliplatin and fluoropyrimidine chemotherapy for patients 70 years and older with stage III colon cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 170,
          "endSection": "abstract",
          "offsetInEndSection": 339
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29861156",
          "text": "We aimed to clarify the efficacy and complications of adjuvant oxaliplatin and fluoropyrimidine chemotherapy for patients 70 years and older with stage III colon cancer. PATIENTS AND METHODS\nAll patients with stage III colon adenocarcinoma were identified from an Australian cancer registry (2006-2013).",
          "beginSection": "abstract",
          "offsetInBeginSection": 170,
          "endSection": "abstract",
          "offsetInEndSection": 475
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25731317",
          "text": "The Oxa-based adjuvant chemotherapy was tolerated equally well in Stage II and III colorectal cancer patients with or without perforation. Further studies are needed to compare the effect of oxaliplatin with other adjuvant chemotherapies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1383,
          "endSection": "abstract",
          "offsetInEndSection": 1621
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29861156",
          "text": "BACKGROUND\nColon cancer is common in the elderly, but owing to under representation in clinical trials, the benefit of standard therapies is uncertain in this age group. We aimed to clarify the efficacy and complications of adjuvant oxaliplatin and fluoropyrimidine chemotherapy for patients 70 years and older with stage III colon cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 339
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28434884",
          "text": "BACKGROUND\nThe addition of oxaliplatin to adjuvant treatment regimens for colorectal cancer has been shown to improve overall survival at the expense of increased toxicity. The incidence and severity of toxicity might be greater among older patients who might also derive less benefit from oxaliplatin. We evaluated the association between adjuvant oxaliplatin-based chemotherapy and neurotoxicity outcomes in an elderly cohort of patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 440
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25731317",
          "text": "This retrospective study evaluated the efficiency of oxaliplatin-based (Oxa-based) adjuvant chemotherapy for colorectal cancer with perforation. The study included 38 patients who underwent surgery for perforation associated with StageII and III colorectal cancer between April 1998 and March 2013.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 298
        }
      ],
      "ideal_answer": "Yes, very elderly stage III colorectal cancer patients present clinical benefit from oxaliplatin-based adjuvant chemotherapy. Despite a modestly increased rate of hospital admission and early chemotherapy cessation, a persistent survival benefit was demonstrated for the addition of oxaliplatin to a fluoropyrimidine as adjuvant treatment for stage III colon cancer in elderly patients.",
      "exact_answer": "yes"
    },
    {
      "id": "660982eefdcbea915f000012",
      "type": "factoid",
      "body": "Where would Odocoileus virginianus be found?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37429851",
        "http://www.ncbi.nlm.nih.gov/pubmed/36710856",
        "http://www.ncbi.nlm.nih.gov/pubmed/37494882",
        "http://www.ncbi.nlm.nih.gov/pubmed/526903",
        "http://www.ncbi.nlm.nih.gov/pubmed/6284330",
        "http://www.ncbi.nlm.nih.gov/pubmed/12678047",
        "http://www.ncbi.nlm.nih.gov/pubmed/33308731",
        "http://www.ncbi.nlm.nih.gov/pubmed/29792761",
        "http://www.ncbi.nlm.nih.gov/pubmed/12528459",
        "http://www.ncbi.nlm.nih.gov/pubmed/12528439"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33308731",
          "text": "Here, blood samples from three white-tailed deer (Odocoileus virginianus) from a region in northeastern Mexico were analyzed by blood smear, PCR, and DNA sequencing.",
          "beginSection": "abstract",
          "offsetInBeginSection": 326,
          "endSection": "abstract",
          "offsetInEndSection": 491
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29792761",
          "text": "Theileriosis in Multiple Neonatal White-tailed Deer ( Odocoileus virginianus) in Delaware, USA.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 95
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33308731",
          "text": "Clinical diseases due to Theileria cervi have been reported in white-tailed deer (Odocoileus virginianus) and mule deer (Odocoileus hemionus) in the USA, however, information about this parasite has not been documented in Mexico. Here, blood samples from three white-tailed deer (Odocoileus virginianus) from a region in northeastern Mexico were analyzed by blood smear, PCR, and DNA sequencing.",
          "beginSection": "abstract",
          "offsetInBeginSection": 96,
          "endSection": "abstract",
          "offsetInEndSection": 491
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29792761",
          "text": "Postmortem examination of 21 neonatal white-tailed deer ( Odocoileus virginianus) from Delaware, US identified six fawns with Theileria spp. organisms or suspected infection.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 174
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29792761",
          "text": "Postmortem examination of 21 neonatal white-tailed deer ( Odocoileus virginianus) from Delaware, US identified six fawns with Theileria spp.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 140
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12528459",
          "text": "On 14 March 2001, an 8 mo old, male white-tailed deer (Odocoileus virginianus) was found in lateral recumbency exhibiting neurologic signs including inability to rise, opisthotonus, paddling, and respiratory distress. There was evidence of minor cranial trauma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 261
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33308731",
          "text": "First molecular evidence of Theileria cervi infection in white-tailed deer (Odocoileus virginianus) in Mexico.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 110
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33308731",
          "text": "Clinical diseases due to Theileria cervi have been reported in white-tailed deer (Odocoileus virginianus) and mule deer (Odocoileus hemionus) in the USA, however, information about this parasite has not been documented in Mexico. Here, blood samples from three white-tailed deer (Odocoileus virginianus) from a region in northeastern Mexico were analyzed by blood smear, PCR, and DNA sequencing. The results confirmed the presence of T. cervi for the first time in white-tailed deer in Mexico.",
          "beginSection": "abstract",
          "offsetInBeginSection": 96,
          "endSection": "abstract",
          "offsetInEndSection": 589
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12528459",
          "text": "On 14 March 2001, an 8 mo old, male white-tailed deer (Odocoileus virginianus) was found in lateral recumbency exhibiting neurologic signs including inability to rise, opisthotonus, paddling, and respiratory distress.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 217
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6284330",
          "text": "Hepatocellular adenocarcinoma in a white-tailed deer (Odocoileus virginianus).",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 78
        }
      ],
      "ideal_answer": "White-tailed deer (Odocoileus virginianus) are found in northeastern Mexico.",
      "exact_answer": [
        "northeastern Mexico"
      ]
    },
    {
      "id": "65f868eac4010b4d78000056",
      "type": "summary",
      "body": "What is the rationale behind treating melanoma with immunotherapy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32671117",
        "http://www.ncbi.nlm.nih.gov/pubmed/35247927",
        "http://www.ncbi.nlm.nih.gov/pubmed/33256089",
        "http://www.ncbi.nlm.nih.gov/pubmed/15001157",
        "http://www.ncbi.nlm.nih.gov/pubmed/33002195",
        "http://www.ncbi.nlm.nih.gov/pubmed/21192262",
        "http://www.ncbi.nlm.nih.gov/pubmed/8977556",
        "http://www.ncbi.nlm.nih.gov/pubmed/30552520",
        "http://www.ncbi.nlm.nih.gov/pubmed/36674809",
        "http://www.ncbi.nlm.nih.gov/pubmed/33847208"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8977556",
          "text": "Immunotherapy and biologic therapy of malignant melanoma are based on a sound scientific rationale and show promising preliminary results. As the nature of immune response to melanoma becomes further characterized, it is likely that more specific immune manipulations may be approached clinically. The fact that complete and partial remissions are induced in some patients with metastatic malignant melanoma by INF-alpha, IL-2, LAK cells, TIL cells, tumor vaccines, and the like clearly indicates a potential role for immunotherapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 532
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8977556",
          "text": "Immunotherapy and biologic therapy of malignant melanoma are based on a sound scientific rationale and show promising preliminary results. As the nature of immune response to melanoma becomes further characterized, it is likely that more specific immune manipulations may be approached clinically.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 297
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32671117",
          "text": "Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compromised patients, the evidence of brisk lymphocytic infiltrates in both primary tumors and metastases, the documented recognition of melanoma antigens by tumor-infiltrating T lymphocytes and, most important, evidence that melanoma responds to immunotherapy. The use of immunotherapy in the treatment of metastatic melanoma is a relatively late discovery for this malignancy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 472
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32671117",
          "text": "Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compromised patients, the evidence of brisk lymphocytic infiltrates in both primary tumors and metastases, the documented recognition of melanoma antigens by tumor-infiltrating T lymphocytes and, most important, evidence that melanoma responds to immunotherapy. The use of immunotherapy in the treatment of metastatic melanoma is a relatively late discovery for this malignancy. Recent studies have shown a significantly higher success rate with combination of immunotherapy and chemotherapy, radiotherapy, or targeted molecular therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 631
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32671117",
          "text": "The use of immunotherapy in the treatment of metastatic melanoma is a relatively late discovery for this malignancy. Recent studies have shown a significantly higher success rate with combination of immunotherapy and chemotherapy, radiotherapy, or targeted molecular therapy. Immunotherapy is associated to a panel of dysimmune toxicities called immune-related adverse events that can affect one or more organs and may limit its use.",
          "beginSection": "abstract",
          "offsetInBeginSection": 356,
          "endSection": "abstract",
          "offsetInEndSection": 789
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32671117",
          "text": "Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compromised patients, the evidence of brisk lymphocytic infiltrates in both primary tumors and metastases, the documented recognition of melanoma antigens by tumor-infiltrating T lymphocytes and, most important, evidence that melanoma responds to immunotherapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 355
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32671117",
          "text": "Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compromised patients, the evidence of brisk lymphocytic infiltrates in both primary tumors and metastases, the documented recognition of melanoma antigens by tumor-infiltrating T lymphocytes and, most important, evidence that melanoma responds to immunotherapy",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 354
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15001157",
          "text": "The rationale for immunotherapy of human melanoma is based on the knowledge acquired in the molecular characterization of T cell defined antigens which are recognized in vitro by patients' lymphocytes. Based on this information, active immunotherapy (vaccination) and adoptive immunotherapy trials were conducted in metastatic melanoma patients. This review highlights the most important clinical studies and discuss their limits, in terms of both immune and clinical response considering the formulation of the vaccine (cellular, peptide/protein; DNA, etc.)",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 558
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8977556",
          "text": "As the nature of immune response to melanoma becomes further characterized, it is likely that more specific immune manipulations may be approached clinically. The fact that complete and partial remissions are induced in some patients with metastatic malignant melanoma by INF-alpha, IL-2, LAK cells, TIL cells, tumor vaccines, and the like clearly indicates a potential role for immunotherapy. As the overall response rates to these maneuvers are only in the range of 20%, more basic research is needed to understand more fully the immune mechanisms of tumor rejection.",
          "beginSection": "abstract",
          "offsetInBeginSection": 139,
          "endSection": "abstract",
          "offsetInEndSection": 708
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15001157",
          "text": "The rationale for immunotherapy of human melanoma is based on the knowledge acquired in the molecular characterization of T cell defined antigens which are recognized in vitro by patients' lymphocytes. Based on this information, active immunotherapy (vaccination) and adoptive immunotherapy trials were conducted in metastatic melanoma patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 345
        }
      ],
      "ideal_answer": "Melanoma is treated with immunotherapy because it is an immunologic malignancy, meaning it responds to immunotherapy. This is evident in the higher prevalence of melanoma in immune-compromised patients, the recognition of melanoma antigens by tumor-infiltrating T lymphocytes, and the documented response of melanoma to immunotherapy. Additionally, acral melanoma, a type of melanoma, has a suppressed immune environment with multiple, therapeutically tractable immune checkpoints, making it a candidate for immunotherapy.",
      "exact_answer": "n/a"
    },
    {
      "id": "661d56c0eac11fad3300001f",
      "type": "yesno",
      "body": "Is there a specific cure for Ehlers-Danlos Syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34560710",
        "http://www.ncbi.nlm.nih.gov/pubmed/7455751",
        "http://www.ncbi.nlm.nih.gov/pubmed/31328377",
        "http://www.ncbi.nlm.nih.gov/pubmed/10906878",
        "http://www.ncbi.nlm.nih.gov/pubmed/15552563",
        "http://www.ncbi.nlm.nih.gov/pubmed/18324963",
        "http://www.ncbi.nlm.nih.gov/pubmed/28176709",
        "http://www.ncbi.nlm.nih.gov/pubmed/36600979",
        "http://www.ncbi.nlm.nih.gov/pubmed/30214474",
        "http://www.ncbi.nlm.nih.gov/pubmed/30512708"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36600979",
          "text": "This report increases awareness for providers who care for patients with Ehlers-Danlos Syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1959,
          "endSection": "abstract",
          "offsetInEndSection": 2055
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7455751",
          "text": "Ehlers-Danlos syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 23
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15552563",
          "text": "There are no other reported cases of Ehlers-Danlos syndrome associated with non-adjacent spondylolisthesis. A review of the pathophysiology of the disease reveals possible mechanisms for this spinal abnormality.",
          "beginSection": "abstract",
          "offsetInBeginSection": 297,
          "endSection": "abstract",
          "offsetInEndSection": 508
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15552563",
          "text": "Review of this case reveals progressive lytic non-adjacent spondylolisthesis in a child with Ehlers-Danlos syndrome. There are no other reported cases of Ehlers-Danlos syndrome associated with non-adjacent spondylolisthesis. A review of the pathophysiology of the disease reveals possible mechanisms for this spinal abnormality.",
          "beginSection": "abstract",
          "offsetInBeginSection": 180,
          "endSection": "abstract",
          "offsetInEndSection": 508
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15552563",
          "text": "There are no other reported cases of Ehlers-Danlos syndrome associated with non-adjacent spondylolisthesis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 297,
          "endSection": "abstract",
          "offsetInEndSection": 404
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15552563",
          "text": "Clinical case analysis of a case of Ehlers-Danlos with non-adjacent spondylolisthesis. Review of this case reveals progressive lytic non-adjacent spondylolisthesis in a child with Ehlers-Danlos syndrome. There are no other reported cases of Ehlers-Danlos syndrome associated with non-adjacent spondylolisthesis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 93,
          "endSection": "abstract",
          "offsetInEndSection": 404
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36600979",
          "text": "Ehlers-Danlos Syndrome presents with clinical sequela across multiple body systems that require multidisciplinary care.",
          "beginSection": "abstract",
          "offsetInBeginSection": 176,
          "endSection": "abstract",
          "offsetInEndSection": 295
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10906878",
          "text": "This study was undertaken to assess functional orthopaedic problems of patients with Ehlers-Danlos syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 179,
          "endSection": "abstract",
          "offsetInEndSection": 287
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15552563",
          "text": "Review of this case reveals progressive lytic non-adjacent spondylolisthesis in a child with Ehlers-Danlos syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 180,
          "endSection": "abstract",
          "offsetInEndSection": 296
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15552563",
          "text": "Review of this case reveals progressive lytic non-adjacent spondylolisthesis in a child with Ehlers-Danlos syndrome. There are no other reported cases of Ehlers-Danlos syndrome associated with non-adjacent spondylolisthesis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 180,
          "endSection": "abstract",
          "offsetInEndSection": 404
        }
      ],
      "ideal_answer": "No, there is no specific cure for Ehlers-Danlos Syndrome.",
      "exact_answer": "no"
    },
    {
      "id": "65cfa8f81930410b13000010",
      "type": "factoid",
      "body": "What mutation is associated with the VEXAS syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37062784",
        "http://www.ncbi.nlm.nih.gov/pubmed/36537591",
        "http://www.ncbi.nlm.nih.gov/pubmed/37062498",
        "http://www.ncbi.nlm.nih.gov/pubmed/37418279",
        "http://www.ncbi.nlm.nih.gov/pubmed/36948992",
        "http://www.ncbi.nlm.nih.gov/pubmed/37673972",
        "http://www.ncbi.nlm.nih.gov/pubmed/35201420",
        "http://www.ncbi.nlm.nih.gov/pubmed/35885496",
        "http://www.ncbi.nlm.nih.gov/pubmed/36168114",
        "http://www.ncbi.nlm.nih.gov/pubmed/34864445"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35201420",
          "text": "VEXAS syndrome results from a somatic mutation affecting UBA1, a gene that codes for the E1 ubiquitin activating protein.",
          "beginSection": "abstract",
          "offsetInBeginSection": 165,
          "endSection": "abstract",
          "offsetInEndSection": 286
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35201420",
          "text": "VEXAS syndrome results from a somatic mutation affecting UBA1, a gene that codes for the E1 ubiquitin activating protein. Loss of UBA1 leads to a broad range of inflammatory conditions and a clinical course often refractive to therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 165,
          "endSection": "abstract",
          "offsetInEndSection": 400
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35201420",
          "text": "Vacuoles, E1 enzyme, x-linked, autoinflammatory, and somatic mutation (VEXAS) syndrome is a recently described disease associated with high morbidity and mortality. VEXAS syndrome results from a somatic mutation affecting UBA1, a gene that codes for the E1 ubiquitin activating protein.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 286
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35201420",
          "text": "Vacuoles, E1 enzyme, x-linked, autoinflammatory, and somatic mutation (VEXAS) syndrome is a recently described disease associated with high morbidity and mortality. VEXAS syndrome results from a somatic mutation affecting UBA1, a gene that codes for the E1 ubiquitin activating protein. Loss of UBA1 leads to a broad range of inflammatory conditions and a clinical course often refractive to therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 400
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35201420",
          "text": "Following blood analysis, both patients were diagnosed with VEXAS syndrome resulting from a mutation in the UBA1 gene.",
          "beginSection": "abstract",
          "offsetInBeginSection": 726,
          "endSection": "abstract",
          "offsetInEndSection": 844
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35201420",
          "text": "Vacuoles, E1 enzyme, x-linked, autoinflammatory, and somatic mutation (VEXAS) syndrome is a recently described disease associated with high morbidity and mortality.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 164
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864445",
          "text": "Vacuoles, E1, X-linked, autoimmunity, somatic (VEXAS) syndrome is characterized by a pathogenic mutation in UBA1, which leads to protean complications including autoimmunity and myelodysplasia.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 193
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35201420",
          "text": "VEXAS syndrome results from a somatic mutation affecting UBA1, a gene that codes for the E1 ubiquitin activating protein. Loss of UBA1 leads to a broad range of inflammatory conditions and a clinical course often refractive to therapy. We present the cases of two patients who demonstrated a rapid decline in overall health, decreased energy, arthralgias, anemia, fever, increased inflammatory markers, and characteristic bone marrow.",
          "beginSection": "abstract",
          "offsetInBeginSection": 165,
          "endSection": "abstract",
          "offsetInEndSection": 599
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37673972",
          "text": "The underlying diagnosis of VEXAS syndrome was confirmed by genetic testing, which revealed the UBA1 mutation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 642,
          "endSection": "abstract",
          "offsetInEndSection": 752
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35201420",
          "text": "Following blood analysis, both patients were diagnosed with VEXAS syndrome resulting from a mutation in the UBA1 gene. Our report highlights the pivotal role dermatologists have in early diagnosis of patients with VEXAS syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 726,
          "endSection": "abstract",
          "offsetInEndSection": 955
        }
      ],
      "ideal_answer": "The UBA1 mutation is associated with the VEXAS syndrome.",
      "exact_answer": [
        "UBA1"
      ]
    },
    {
      "id": "65f774dec4010b4d7800002a",
      "type": "yesno",
      "body": "Should routine PET-CT scan be indicated in the initial evaluation of locally advanced rectal cancer patients?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30899056",
        "http://www.ncbi.nlm.nih.gov/pubmed/33962569",
        "http://www.ncbi.nlm.nih.gov/pubmed/23420438",
        "http://www.ncbi.nlm.nih.gov/pubmed/23196674",
        "http://www.ncbi.nlm.nih.gov/pubmed/30556862",
        "http://www.ncbi.nlm.nih.gov/pubmed/36117452",
        "http://www.ncbi.nlm.nih.gov/pubmed/22875644",
        "http://www.ncbi.nlm.nih.gov/pubmed/31229791",
        "http://www.ncbi.nlm.nih.gov/pubmed/20430907",
        "http://www.ncbi.nlm.nih.gov/pubmed/21422901"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23420438",
          "text": "CONCLUSIONS\nThe TLG of the primary tumor in the initial FDG-PET/CT can be considered as a prognostic factor for patients with locally advanced rectal cancer treated with neoadjuvant CCRT.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1217,
          "endSection": "abstract",
          "offsetInEndSection": 1404
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36117452",
          "text": "Positron emission tomography(PET) is used in detection of recurrence or metastasis, but its value in routine preoperative rectal cancer staging remains unclear. Studies report that preoperative PET altered the stage in 39% and changed the management in 17-27% of patients. Our study aims to look at the utility of PET in routine preoperative staging of rectal cancer within 2 two colorectal units, and to determine if PET did result in a change in management.",
          "beginSection": "abstract",
          "offsetInBeginSection": 175,
          "endSection": "abstract",
          "offsetInEndSection": 634
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36117452",
          "text": "Positron emission tomography(PET) is used in detection of recurrence or metastasis, but its value in routine preoperative rectal cancer staging remains unclear. Studies report that preoperative PET altered the stage in 39% and changed the management in 17-27% of patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 175,
          "endSection": "abstract",
          "offsetInEndSection": 447
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23196674",
          "text": "MATERIALS AND METHODS\nThe study included 14 patients with locally advanced rectal cancer. Before chemoradiotherapy, PET/CT with F-FAZA was performed with static 15 min images 2 h after injection of F-FAZA. Attenuation correction was obtained with a low-dose CT, and a contrast-enhanced CT was performed immediately after the PET scan.",
          "beginSection": "abstract",
          "offsetInBeginSection": 224,
          "endSection": "abstract",
          "offsetInEndSection": 558
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36117452",
          "text": "30.3% of the patients had Stage 3 rectal cancer. 71.7% received neoadjuvant therapy. PET scan provided additional information in 55.5% of patients when compared with CT and MRI alone; 18.2% of the PET findings resulted in an altered management for the patient.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1038,
          "endSection": "abstract",
          "offsetInEndSection": 1298
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23196674",
          "text": "OBJECTIVE\nThe aim of this study was to investigate the feasibility of F-fluoroazomycinarabinofuranoside (F-FAZA) positron emission tomography (PET)/computed tomography (CT) in patients with locally advanced rectal cancer. MATERIALS AND METHODS\nThe study included 14 patients with locally advanced rectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 313
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30556862",
          "text": "All patients underwent conventional diagnostic/staging procedures to characterize the rectal lesion. The first whole-body 18F-FDG PET/CT was performed 1 week before the beginning of nCRT (baseline scan). The second 18F-FDG PET/CT was scheduled at 5-6 weeks from nCRT completion (post-nCRT scan).",
          "beginSection": "abstract",
          "offsetInBeginSection": 461,
          "endSection": "abstract",
          "offsetInEndSection": 756
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30556862",
          "text": "All patients underwent conventional diagnostic/staging procedures to characterize the rectal lesion. The first whole-body 18F-FDG PET/CT was performed 1 week before the beginning of nCRT (baseline scan).",
          "beginSection": "abstract",
          "offsetInBeginSection": 461,
          "endSection": "abstract",
          "offsetInEndSection": 664
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23196674",
          "text": "OBJECTIVE\nThe aim of this study was to investigate the feasibility of F-fluoroazomycinarabinofuranoside (F-FAZA) positron emission tomography (PET)/computed tomography (CT) in patients with locally advanced rectal cancer. MATERIALS AND METHODS\nThe study included 14 patients with locally advanced rectal cancer. Before chemoradiotherapy, PET/CT with F-FAZA was performed with static 15 min images 2 h after injection of F-FAZA.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 429
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36117452",
          "text": "Positron emission tomography(PET) is used in detection of recurrence or metastasis, but its value in routine preoperative rectal cancer staging remains unclear.",
          "beginSection": "abstract",
          "offsetInBeginSection": 175,
          "endSection": "abstract",
          "offsetInEndSection": 335
        }
      ],
      "ideal_answer": "No, routine PET-CT scan is not indicated in the initial evaluation of locally advanced rectal cancer patients. The study found that PET scan provided additional information in 55.5% of patients when compared with CT and MRI alone, but only 18.2% of the PET findings resulted in an altered management for the patient. The value of PET in routine preoperative rectal cancer staging remains unclear.",
      "exact_answer": "no"
    },
    {
      "id": "65f03163dffffb9b6b000005",
      "type": "list",
      "body": "Please list the selective endothelin A receptor antagonists",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32197449",
        "http://www.ncbi.nlm.nih.gov/pubmed/32726116",
        "http://www.ncbi.nlm.nih.gov/pubmed/32985601",
        "http://www.ncbi.nlm.nih.gov/pubmed/31593221",
        "http://www.ncbi.nlm.nih.gov/pubmed/32942043",
        "http://www.ncbi.nlm.nih.gov/pubmed/32249614",
        "http://www.ncbi.nlm.nih.gov/pubmed/11811376",
        "http://www.ncbi.nlm.nih.gov/pubmed/16219361",
        "http://www.ncbi.nlm.nih.gov/pubmed/8798180",
        "http://www.ncbi.nlm.nih.gov/pubmed/11425549"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8798180",
          "text": "Highly potent, orally active nonpeptide endothelin receptor antagonists have been identified, and are being used as pharmacological tools to elucidate the role of endothelin in pathological disorders. Subtype selective endothelin receptor antagonists will also be useful in understanding the physiological and pathological roles of the different subtypes of the endothelin receptors. The selectivity profile for the ideal endothelin receptor antagonist is presently unknown, and it may actually be that the optimal profile for a compound may depend on the clinical indication.",
          "beginSection": "abstract",
          "offsetInBeginSection": 117,
          "endSection": "abstract",
          "offsetInEndSection": 693
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8798180",
          "text": "The development of endothelin receptor antagonists has progressed rapidly since the initial discovery of endothelin. Highly potent, orally active nonpeptide endothelin receptor antagonists have been identified, and are being used as pharmacological tools to elucidate the role of endothelin in pathological disorders. Subtype selective endothelin receptor antagonists will also be useful in understanding the physiological and pathological roles of the different subtypes of the endothelin receptors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 500
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8798180",
          "text": "Highly potent, orally active nonpeptide endothelin receptor antagonists have been identified, and are being used as pharmacological tools to elucidate the role of endothelin in pathological disorders. Subtype selective endothelin receptor antagonists will also be useful in understanding the physiological and pathological roles of the different subtypes of the endothelin receptors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 117,
          "endSection": "abstract",
          "offsetInEndSection": 500
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11811376",
          "text": "Are selective endothelin A receptor antagonists better than mixed antagonists?",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 78
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16219361",
          "text": "Endothelin receptor antagonists.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 32
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8798180",
          "text": "Subtype selective endothelin receptor antagonists will also be useful in understanding the physiological and pathological roles of the different subtypes of the endothelin receptors. The selectivity profile for the ideal endothelin receptor antagonist is presently unknown, and it may actually be that the optimal profile for a compound may depend on the clinical indication.",
          "beginSection": "abstract",
          "offsetInBeginSection": 318,
          "endSection": "abstract",
          "offsetInEndSection": 693
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8798180",
          "text": "Subtype selective endothelin receptor antagonists will also be useful in understanding the physiological and pathological roles of the different subtypes of the endothelin receptors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 318,
          "endSection": "abstract",
          "offsetInEndSection": 500
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8798180",
          "text": "Subtype selective endothelin receptor antagonists will also be useful in understanding the physiological and pathological roles of the different subtypes of the endothelin receptors. The selectivity profile for the ideal endothelin receptor antagonist is presently unknown, and it may actually be that the optimal profile for a compound may depend on the clinical indication. In the near future, data from clinical trials with endothelin receptor antagonists will become available and will help to establish the role of endothelin in the etiology of human disease, as well as to provide valuable information concerning the optimum endothelin receptor subtype selectivity for antagonists needed for therapeutic agents.",
          "beginSection": "abstract",
          "offsetInBeginSection": 318,
          "endSection": "abstract",
          "offsetInEndSection": 1035
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8798180",
          "text": "The development of endothelin receptor antagonists has progressed rapidly since the initial discovery of endothelin. Highly potent, orally active nonpeptide endothelin receptor antagonists have been identified, and are being used as pharmacological tools to elucidate the role of endothelin in pathological disorders.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 317
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11811376",
          "text": "Antagonists that are highly selective for the endothelin A receptor (ETA) receptor subtype have a number of hypothetical advantages over non-selective antagonists.",
          "beginSection": "abstract",
          "offsetInBeginSection": 372,
          "endSection": "abstract",
          "offsetInEndSection": 535
        }
      ],
      "ideal_answer": "Bosentan, Ambrisentan, Sitaxentan. These are selective endothelin A receptor antagonists that have been identified and are being used as pharmacological tools to elucidate the role of endothelin in pathological disorders.",
      "exact_answer": [
        [
          "Bosentan"
        ],
        [
          "Ambrisentan"
        ],
        [
          "Sitaxentan"
        ]
      ]
    },
    {
      "id": "65f846bfc4010b4d78000045",
      "type": "summary",
      "body": "What is the transmission mechanism of the Hendra virus in humans?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33363250",
        "http://www.ncbi.nlm.nih.gov/pubmed/26978066",
        "http://www.ncbi.nlm.nih.gov/pubmed/12615503",
        "http://www.ncbi.nlm.nih.gov/pubmed/23592639",
        "http://www.ncbi.nlm.nih.gov/pubmed/25281398",
        "http://www.ncbi.nlm.nih.gov/pubmed/23534359",
        "http://www.ncbi.nlm.nih.gov/pubmed/11189712",
        "http://www.ncbi.nlm.nih.gov/pubmed/26403793",
        "http://www.ncbi.nlm.nih.gov/pubmed/24312221",
        "http://www.ncbi.nlm.nih.gov/pubmed/21781619"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12615503",
          "text": "Hendra virus is thought to have moved from flying-foxes to horses, and then from horses to people. There is a reasonably strong hypothesis for horse-to-human transmission: transmission of virus via nasal discharge, saliva and/or urine.",
          "beginSection": "abstract",
          "offsetInBeginSection": 372,
          "endSection": "abstract",
          "offsetInEndSection": 607
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12615503",
          "text": "Hendra virus is thought to have moved from flying-foxes to horses, and then from horses to people. There is a reasonably strong hypothesis for horse-to-human transmission: transmission of virus via nasal discharge, saliva and/or urine. In contrast, there is no strong hypothesis for flying-fox-to-human transmission.",
          "beginSection": "abstract",
          "offsetInBeginSection": 372,
          "endSection": "abstract",
          "offsetInEndSection": 688
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26978066",
          "text": "Hendra virus ecology and transmission.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 38
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23534359",
          "text": "Hendra virus, a member of the family Paramyxoviridae, was first recognized following a devastating outbreak in Queensland, Australia, in 1994. The naturally acquired symptomatic infection, characterized by a rapidly progressive illness involving the respiratory system and/or CNS, has so far only been recognized in horses and humans. However, there is potential for other species to be infected, with significant consequences for animal and human health.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 455
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25281398",
          "text": "Hendra virus.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 13
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12615503",
          "text": "The Australian paralysis tick may be the missing link in the transmission of Hendra virus from bats to horses to humans.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 120
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23534359",
          "text": "Hendra virus, a member of the family Paramyxoviridae, was first recognized following a devastating outbreak in Queensland, Australia, in 1994. The naturally acquired symptomatic infection, characterized by a rapidly progressive illness involving the respiratory system and/or CNS, has so far only been recognized in horses and humans.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 334
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23592639",
          "text": "Hendra virus (HeV) and Nipah virus (NiV) are emerging zoonotic viruses that cause severe and often lethal respiratory illness and encephalitis in humans. Henipaviruses can infect a wide range of species and human-to-human transmission has been observed for NiV. While the exact route of transmission in humans is not known, experimental infection in different animal species suggests that infection can be efficiently initiated after respiratory challenge.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 456
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11189712",
          "text": "The causative virus, now named Hendra virus (HeV), is the reference virus for a proposed new genus within the virus family Paramyxoviridae. The virus is a lethal zoonotic agent able to cause natural disease in humans and horses and experimentally induced disease in cats, guinea-pigs and mice.",
          "beginSection": "abstract",
          "offsetInBeginSection": 181,
          "endSection": "abstract",
          "offsetInEndSection": 474
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11189712",
          "text": "The causative virus, now named Hendra virus (HeV), is the reference virus for a proposed new genus within the virus family Paramyxoviridae. The virus is a lethal zoonotic agent able to cause natural disease in humans and horses and experimentally induced disease in cats, guinea-pigs and mice. The virus also naturally infects species of the family Megachiroptera, mainly subclinically, and such animals are the natural host of HeV.",
          "beginSection": "abstract",
          "offsetInBeginSection": 181,
          "endSection": "abstract",
          "offsetInEndSection": 613
        }
      ],
      "ideal_answer": "The Hendra virus is transmitted from horses to humans through nasal discharge, saliva, and/or urine. There is no strong hypothesis for flying-fox-to-human transmission.",
      "exact_answer": "n/a"
    },
    {
      "id": "661d5c97eac11fad33000021",
      "type": "factoid",
      "body": "What is the cause of Prader-Willi Syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37491450",
        "http://www.ncbi.nlm.nih.gov/pubmed/27570435",
        "http://www.ncbi.nlm.nih.gov/pubmed/16597186",
        "http://www.ncbi.nlm.nih.gov/pubmed/7826116",
        "http://www.ncbi.nlm.nih.gov/pubmed/2278477",
        "http://www.ncbi.nlm.nih.gov/pubmed/9391886",
        "http://www.ncbi.nlm.nih.gov/pubmed/1445035",
        "http://www.ncbi.nlm.nih.gov/pubmed/12699864",
        "http://www.ncbi.nlm.nih.gov/pubmed/8071507",
        "http://www.ncbi.nlm.nih.gov/pubmed/12064787"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12699864",
          "text": "Prader-Willi syndrome is a neurologic disorder caused by a mutation on chromosome 15. It is characterized by short stature, obesity, mild-to-moderate mental retardation, and multiple behavior problems including mood, self-abusive behavior, and compulsive-eating disorder. These behaviors have detrimental effects on the mental and physical health of patients with Prader-Willi syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 386
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12699864",
          "text": "Prader-Willi syndrome is a neurologic disorder caused by a mutation on chromosome 15. It is characterized by short stature, obesity, mild-to-moderate mental retardation, and multiple behavior problems including mood, self-abusive behavior, and compulsive-eating disorder.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 271
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12699864",
          "text": "Prader-Willi syndrome is a neurologic disorder caused by a mutation on chromosome 15.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 85
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9391886",
          "text": "Prader-Willi syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 22
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7826116",
          "text": "Diagnosis in Prader-Willi syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 35
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9391886",
          "text": "Prader-Willi syndrome is caused by abnormalities of the imprinted region of proximal 15q and results from absence of the normally active paternal genes in this region.",
          "beginSection": "abstract",
          "offsetInBeginSection": 406,
          "endSection": "abstract",
          "offsetInEndSection": 573
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9391886",
          "text": "Prader-Willi syndrome is a complex disorder affecting multiple systems with many manifestations relating to hypothalamic insufficiency. Major findings include infantile hypotonia, developmental delay and mental retardation, behaviour disorder, characteristic facial appearance, obesity, hypogonadism, and short stature. Obesity and the behavioural problems are the major causes of morbidity and mortality.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 405
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9391886",
          "text": "Prader-Willi syndrome is caused by abnormalities of the imprinted region of proximal 15q and results from absence of the normally active paternal genes in this region. Such absence results from paternal interstitial deletion, maternal uniparental disomy, or a mutation or other abnormality in the imprinting process. Diagnostic identification of all causes has become available in recent years, permitting early detection and institution of appropriate management.",
          "beginSection": "abstract",
          "offsetInBeginSection": 406,
          "endSection": "abstract",
          "offsetInEndSection": 870
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9391886",
          "text": "Prader-Willi syndrome is caused by abnormalities of the imprinted region of proximal 15q and results from absence of the normally active paternal genes in this region. Such absence results from paternal interstitial deletion, maternal uniparental disomy, or a mutation or other abnormality in the imprinting process.",
          "beginSection": "abstract",
          "offsetInBeginSection": 406,
          "endSection": "abstract",
          "offsetInEndSection": 722
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2278477",
          "text": "Prader-Labhart-Willi syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 30
        }
      ],
      "ideal_answer": "Prader-Willi Syndrome is caused by a mutation on chromosome 15, which results in the absence of the normally active paternal genes in this region. This absence can be due to paternal interstitial deletion, maternal uniparental disomy, or a mutation or other abnormality in the imprinting process.",
      "exact_answer": [
        "mutation on chromosome 15"
      ]
    },
    {
      "id": "65cfe1d21930410b1300002a",
      "type": "yesno",
      "body": "Can capivasertib be used for breast cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37256976",
        "http://www.ncbi.nlm.nih.gov/pubmed/36508589",
        "http://www.ncbi.nlm.nih.gov/pubmed/37046675",
        "http://www.ncbi.nlm.nih.gov/pubmed/35398754",
        "http://www.ncbi.nlm.nih.gov/pubmed/31836609",
        "http://www.ncbi.nlm.nih.gov/pubmed/31841354",
        "http://www.ncbi.nlm.nih.gov/pubmed/37543694",
        "http://www.ncbi.nlm.nih.gov/pubmed/34518313",
        "http://www.ncbi.nlm.nih.gov/pubmed/30860570",
        "http://www.ncbi.nlm.nih.gov/pubmed/32035020"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35398754",
          "text": "Preclinical studies demonstrated efficacy of capivasertib in breast cancer cell lines as a single agent or in combination with anti-HER2 agents and endocrine treatment, especially in tumors with PIK3CA or MTOR alterations. Phase I/II studies demonstrated greater efficacy when capivasertib was co-administered with paclitaxel, fulvestrant in hormone receptor (HR)-positive, HER2-negative breast cancer or olaparib.",
          "beginSection": "abstract",
          "offsetInBeginSection": 537,
          "endSection": "abstract",
          "offsetInEndSection": 951
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35398754",
          "text": "Preclinical studies demonstrated efficacy of capivasertib in breast cancer cell lines as a single agent or in combination with anti-HER2 agents and endocrine treatment, especially in tumors with PIK3CA or MTOR alterations. Phase I/II studies demonstrated greater efficacy when capivasertib was co-administered with paclitaxel, fulvestrant in hormone receptor (HR)-positive, HER2-negative breast cancer or olaparib. The recommended phase II dose of capivasertib as monotherapy was 480 mg bid on a 4-days-on, 3-days-off dosing schedule.",
          "beginSection": "abstract",
          "offsetInBeginSection": 537,
          "endSection": "abstract",
          "offsetInEndSection": 1071
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35398754",
          "text": "Preclinical studies demonstrated efficacy of capivasertib in breast cancer cell lines as a single agent or in combination with anti-HER2 agents and endocrine treatment, especially in tumors with PIK3CA or MTOR alterations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 537,
          "endSection": "abstract",
          "offsetInEndSection": 759
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35398754",
          "text": "\"The emerging role of capivasertib in breast cancer\".",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 53
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37256976",
          "text": "Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 65
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35398754",
          "text": "Phase I/II studies demonstrated greater efficacy when capivasertib was co-administered with paclitaxel, fulvestrant in hormone receptor (HR)-positive, HER2-negative breast cancer or olaparib.",
          "beginSection": "abstract",
          "offsetInBeginSection": 760,
          "endSection": "abstract",
          "offsetInEndSection": 951
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35398754",
          "text": "Phase I/II studies demonstrated greater efficacy when capivasertib was co-administered with paclitaxel, fulvestrant in hormone receptor (HR)-positive, HER2-negative breast cancer or olaparib. The recommended phase II dose of capivasertib as monotherapy was 480 mg bid on a 4-days-on, 3-days-off dosing schedule.",
          "beginSection": "abstract",
          "offsetInBeginSection": 760,
          "endSection": "abstract",
          "offsetInEndSection": 1071
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35398754",
          "text": "Ongoing Phase III trials of capivasertib in combination with fulvestrant (CAPItello-291), CDK4/6 inhibitor palbociclib (CAPItello-292) and paclitaxel (CAPItello- 290) will better clarify the therapeutic role of capivasertib in breast cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1239,
          "endSection": "abstract",
          "offsetInEndSection": 1480
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36508589",
          "text": "Capivasertib Doubles PFS in Some Breast Cancers.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 48
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37256976",
          "text": "CONCLUSIONS: Capivasertib-fulvestrant therapy resulted in significantly longer progression-free survival than treatment with fulvestrant alone among patients with hormone receptor-positive advanced breast cancer whose disease had progressed during or after previous aromatase inhibitor therapy with or without a CDK4/6 inhibitor. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 2088,
          "endSection": "abstract",
          "offsetInEndSection": 2418
        }
      ],
      "ideal_answer": "Yes, capivasertib can be used for breast cancer. It has been shown to be effective in preclinical studies and phase I/II clinical trials, especially in tumors with PIK3CA or MTOR alterations. Ongoing phase III trials will further clarify its therapeutic role in breast cancer.",
      "exact_answer": "yes"
    },
    {
      "id": "65f777d7c4010b4d78000032",
      "type": "factoid",
      "body": "What is the optimal timing of surgical resection after a neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26897480",
        "http://www.ncbi.nlm.nih.gov/pubmed/32966845",
        "http://www.ncbi.nlm.nih.gov/pubmed/34586340",
        "http://www.ncbi.nlm.nih.gov/pubmed/38012438",
        "http://www.ncbi.nlm.nih.gov/pubmed/29178095",
        "http://www.ncbi.nlm.nih.gov/pubmed/27489505",
        "http://www.ncbi.nlm.nih.gov/pubmed/30341253",
        "http://www.ncbi.nlm.nih.gov/pubmed/19372072",
        "http://www.ncbi.nlm.nih.gov/pubmed/20548274",
        "http://www.ncbi.nlm.nih.gov/pubmed/29594111"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26897480",
          "text": "Optimal Timing to Surgery after Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 97
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29178095",
          "text": "OBJECTIVE\nTo evaluate the short-term outcomes and perioperative safety of proximally extended resection for locally advanced rectal cancer after neoadjuvant chemoradiotherapy. METHODS\nFrom colorectal cancer database in The Sixth Affiliated Hospital of Sun Yat-sen University, a cohort of patients who underwent neoadjuvant chemoradiotherapy(1.8-2.0 Gy per day, 25-28 fractions, concurrent fluorouracil-based chemotherapy) followed by curative sphincter-preserving surgery for locally advanced rectal cancer between May 2016 and June 2017 were retrospectively identified.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 572
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29178095",
          "text": "OBJECTIVE\nTo evaluate the short-term outcomes and perioperative safety of proximally extended resection for locally advanced rectal cancer after neoadjuvant chemoradiotherapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 175
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29178095",
          "text": "[Efficacy analysis of proximally extended resection for locally advanced rectal cancer after neoadjuvant chemoradiotherapy].",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 124
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30341253",
          "text": "Chemoradiotherapy combined with surgical resection is the standard treatment for locally advanced rectal cancer, but not all the patients respond to neoadjuvant treatment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 171
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29178095",
          "text": "OBJECTIVE\nTo evaluate the short-term outcomes and perioperative safety of proximally extended resection for locally advanced rectal cancer after neoadjuvant chemoradiotherapy. METHODS\nFrom colorectal cancer database in The Sixth Affiliated Hospital of Sun Yat-sen University, a cohort of patients who underwent neoadjuvant chemoradiotherapy(1.8-2.0 Gy per day, 25-28 fractions, concurrent fluorouracil-based chemotherapy) followed by curative sphincter-preserving surgery for locally advanced rectal cancer between May 2016 and June 2017 were retrospectively identified. Exclusion criteria were synchronous colon cancer, intraoperatively confirmed distal metastasis, multiple visceral resection, and emergency operation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 722
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30341253",
          "text": "Chemoradiotherapy combined with surgical resection is the standard treatment for locally advanced rectal cancer, but not all the patients respond to neoadjuvant treatment. Transforming acidic coiled-coil protein-3 (TACC3) is frequently aberrantly expressed in rectal cancer tissue.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 281
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27489505",
          "text": "Neoadjuvant chemoradiotherapy has become the standard treatment for locally advanced rectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 99
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27489505",
          "text": "Neoadjuvant chemoradiotherapy has become the standard treatment for locally advanced rectal cancer. Neoadjuvant chemoradiotherapy not only can reduce tumor size and recurrence, but also increase the tumor resection rate and anus retention rate with very slight side effect.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 273
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29178095",
          "text": "CONCLUSION\nProximally extended resection is a radical and safe surgical alternative for locally advanced rectal cancer after neoadjuvant chemoradiotherapy, which can potentially reduce the risk of anastomosis complication.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2270,
          "endSection": "abstract",
          "offsetInEndSection": 2492
        }
      ],
      "ideal_answer": "The optimal timing of surgical resection after a neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is 12 weeks.",
      "exact_answer": [
        "12 weeks"
      ]
    },
    {
      "id": "660812b4fdcbea915f000006",
      "type": "yesno",
      "body": "Is Kagami-Ogata associated with a deletion in chromosome 14",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35864517",
        "http://www.ncbi.nlm.nih.gov/pubmed/33179779",
        "http://www.ncbi.nlm.nih.gov/pubmed/34746047",
        "http://www.ncbi.nlm.nih.gov/pubmed/34055463",
        "http://www.ncbi.nlm.nih.gov/pubmed/37222159",
        "http://www.ncbi.nlm.nih.gov/pubmed/30232357",
        "http://www.ncbi.nlm.nih.gov/pubmed/31853915",
        "http://www.ncbi.nlm.nih.gov/pubmed/35361407",
        "http://www.ncbi.nlm.nih.gov/pubmed/29375845",
        "http://www.ncbi.nlm.nih.gov/pubmed/32878913"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37222159",
          "text": "The maternally inherited 14q32 deletion was responsible for Kagami-Ogata syndrome in our patient.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1157,
          "endSection": "abstract",
          "offsetInEndSection": 1254
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37222159",
          "text": "The mother's chromosomal microarray also confirmed the identical 14q32.2 deletion, although she presented a normal phenotype. The maternally inherited 14q32 deletion was responsible for Kagami-Ogata syndrome in our patient. It was not sufficient, however, to produce Temple syndrome or any other pathogenic phenotype in the patient's mother.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1031,
          "endSection": "abstract",
          "offsetInEndSection": 1372
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37222159",
          "text": "The mother's chromosomal microarray also confirmed the identical 14q32.2 deletion, although she presented a normal phenotype. The maternally inherited 14q32 deletion was responsible for Kagami-Ogata syndrome in our patient.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1031,
          "endSection": "abstract",
          "offsetInEndSection": 1254
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30232357",
          "text": "Maternally inherited 133kb deletion of 14q32 causing Kagami-Ogata syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 75
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37222159",
          "text": "Deletions of the 14q32 region without involving DMRs, and encompassing only the RTL1as and MEG8 genes, are poorly described in the literature. The mother's chromosomal microarray also confirmed the identical 14q32.2 deletion, although she presented a normal phenotype. The maternally inherited 14q32 deletion was responsible for Kagami-Ogata syndrome in our patient.",
          "beginSection": "abstract",
          "offsetInBeginSection": 888,
          "endSection": "abstract",
          "offsetInEndSection": 1254
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37222159",
          "text": "The maternally inherited 14q32 deletion was responsible for Kagami-Ogata syndrome in our patient. It was not sufficient, however, to produce Temple syndrome or any other pathogenic phenotype in the patient's mother.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1157,
          "endSection": "abstract",
          "offsetInEndSection": 1372
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37222159",
          "text": "Here, we report a female with mild features of the Kagami-Ogata syndrome phenotype with polyhydramnios, neonatal hypotonia, feeding difficulties, abnormal foot morphology, patent foramen ovale, distal arthrogryposis, normal facial profile, and a bell-shaped thorax without coat hanger ribs. The single nucleotide polymorphism array revealed the interstitial deletion of chromosome 14q32.2-q32.31 (117 kb in size), involving the RTL1as and MEG8 genes, and other small nucleolar RNAs and microRNAs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 155,
          "endSection": "abstract",
          "offsetInEndSection": 651
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37222159",
          "text": "Here, we report a female with mild features of the Kagami-Ogata syndrome phenotype with polyhydramnios, neonatal hypotonia, feeding difficulties, abnormal foot morphology, patent foramen ovale, distal arthrogryposis, normal facial profile, and a bell-shaped thorax without coat hanger ribs. The single nucleotide polymorphism array revealed the interstitial deletion of chromosome 14q32.2-q32.31 (117 kb in size), involving the RTL1as and MEG8 genes, and other small nucleolar RNAs and microRNAs. The differentially methylated regions (DMRs) appeared unaltered.",
          "beginSection": "abstract",
          "offsetInBeginSection": 155,
          "endSection": "abstract",
          "offsetInEndSection": 716
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37222159",
          "text": "Kagami-Ogata syndrome and Temple syndrome are imprinting disorders caused by the abnormal expression of genes in an imprinted cluster on chromosome 14q32. Here, we report a female with mild features of the Kagami-Ogata syndrome phenotype with polyhydramnios, neonatal hypotonia, feeding difficulties, abnormal foot morphology, patent foramen ovale, distal arthrogryposis, normal facial profile, and a bell-shaped thorax without coat hanger ribs. The single nucleotide polymorphism array revealed the interstitial deletion of chromosome 14q32.2-q32.31 (117 kb in size), involving the RTL1as and MEG8 genes, and other small nucleolar RNAs and microRNAs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 651
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33179779",
          "text": "Kagami-Ogata syndrome (KOS14) is a rare congenital disorder associated with defective genomic imprinting of the chromosome 14q32 domain. Typical features include polyhydramnios, small and bell-shaped thorax, coat-hanger ribs, dysmorphic facial features, abdominal wall defects, placentomegaly, severe postnatal respiratory distress and intellectual disability.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 360
        }
      ],
      "ideal_answer": "Yes, Kagami-Ogata syndrome is associated with a deletion in chromosome 14.",
      "exact_answer": "yes"
    },
    {
      "id": "6614f672fdcbea915f000042",
      "type": "factoid",
      "body": "Are children affected by multiple sclerosis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32940341",
        "http://www.ncbi.nlm.nih.gov/pubmed/34940954",
        "http://www.ncbi.nlm.nih.gov/pubmed/24665290",
        "http://www.ncbi.nlm.nih.gov/pubmed/15851734",
        "http://www.ncbi.nlm.nih.gov/pubmed/24507529",
        "http://www.ncbi.nlm.nih.gov/pubmed/24640729",
        "http://www.ncbi.nlm.nih.gov/pubmed/15938672",
        "http://www.ncbi.nlm.nih.gov/pubmed/7619186",
        "http://www.ncbi.nlm.nih.gov/pubmed/24270187",
        "http://www.ncbi.nlm.nih.gov/pubmed/32294785"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24507529",
          "text": "Multiple sclerosis in children.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 31
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665290",
          "text": "Multiple sclerosis in children.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 31
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15938672",
          "text": "The onset of multiple sclerosis is being increasingly recognized in children and adolescents.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 93
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24640729",
          "text": "Axonal damage in children with multiple sclerosis are less apparent.",
          "beginSection": "abstract",
          "offsetInBeginSection": 756,
          "endSection": "abstract",
          "offsetInEndSection": 824
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15938672",
          "text": "Treatment of children and adolescents with multiple sclerosis.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 62
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15851734",
          "text": "Cognitive functioning in children and adolescents with multiple sclerosis.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 74
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24640729",
          "text": "Main neurophysiologic findings in multiple sclerosis in children may reflect altering membrane excitability of motor neurons and demyelinating lesions. Axonal damage in children with multiple sclerosis are less apparent.",
          "beginSection": "abstract",
          "offsetInBeginSection": 604,
          "endSection": "abstract",
          "offsetInEndSection": 824
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15938672",
          "text": "The onset of multiple sclerosis is being increasingly recognized in children and adolescents. There are now approved immunomodulatory therapies for adults with multiple sclerosis. Treatment early in the disease course appears to have a greater impact on disease outcome, an issue of particular importance for children who face decades of multiple sclerosis disease activity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 374
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24640729",
          "text": "Main neurophysiologic findings in multiple sclerosis in children may reflect altering membrane excitability of motor neurons and demyelinating lesions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 604,
          "endSection": "abstract",
          "offsetInEndSection": 755
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15938672",
          "text": "The onset of multiple sclerosis is being increasingly recognized in children and adolescents. There are now approved immunomodulatory therapies for adults with multiple sclerosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 179
        }
      ],
      "ideal_answer": "Yes, children can be affected by multiple sclerosis. The onset of multiple sclerosis is being increasingly recognized in children and adolescents, and there are now approved immunomodulatory therapies for adults with multiple sclerosis that can be used in this population.",
      "exact_answer": "yes"
    },
    {
      "id": "661d4aa3eac11fad33000019",
      "type": "list",
      "body": "What are the current approaches for gene therapy for Phenylketonuria (PKU)?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37401651",
        "http://www.ncbi.nlm.nih.gov/pubmed/14728985",
        "http://www.ncbi.nlm.nih.gov/pubmed/32524084",
        "http://www.ncbi.nlm.nih.gov/pubmed/8828602",
        "http://www.ncbi.nlm.nih.gov/pubmed/7766948",
        "http://www.ncbi.nlm.nih.gov/pubmed/25375236",
        "http://www.ncbi.nlm.nih.gov/pubmed/1677790",
        "http://www.ncbi.nlm.nih.gov/pubmed/31364419",
        "http://www.ncbi.nlm.nih.gov/pubmed/35782620",
        "http://www.ncbi.nlm.nih.gov/pubmed/21659675"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7766948",
          "text": "Classical phenylketonuria (PKU) is an autosomal recessive disorder caused by a deficiency of hepatic phenylalanine hydroxylase (PAH). Three different vector systems have been developed to examine the potential of somatic gene therapy for the treatment of PKU. Recombinant retroviral vectors and DNA/protein complexes can efficiently transduce PAH-deficient hepatocytes in vitro, but their present application is limited by their low transduction efficiency in vivo.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 465
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7766948",
          "text": "Classical phenylketonuria (PKU) is an autosomal recessive disorder caused by a deficiency of hepatic phenylalanine hydroxylase (PAH). Three different vector systems have been developed to examine the potential of somatic gene therapy for the treatment of PKU.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 259
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37401651",
          "text": "Phenylketonuria (PKU) or hyperphenylalaninemia is considered a paradigm for an inherited (metabolic) liver defect and is, based on murine models that replicate all human pathology, an exemplar model for experimental studies on liver gene therapy. Variants in the PAH gene that lead to hyperphenylalaninemia are never fatal (although devastating if untreated), newborn screening has been available for two generations, and dietary treatment has been considered for a long time as therapeutic and satisfactory. However, significant shortcomings of contemporary dietary treatment of PKU remain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 591
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25375236",
          "text": "New Strategies for the Treatment of Phenylketonuria (PKU).",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 58
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37401651",
          "text": "Phenylketonuria (PKU) or hyperphenylalaninemia is considered a paradigm for an inherited (metabolic) liver defect and is, based on murine models that replicate all human pathology, an exemplar model for experimental studies on liver gene therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 246
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8828602",
          "text": "Gene therapy for phenylketonuria.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 33
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7766948",
          "text": "Gene therapy for phenylketonuria.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 33
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37401651",
          "text": "Phenylketonuria (PKU) or hyperphenylalaninemia is considered a paradigm for an inherited (metabolic) liver defect and is, based on murine models that replicate all human pathology, an exemplar model for experimental studies on liver gene therapy. Variants in the PAH gene that lead to hyperphenylalaninemia are never fatal (although devastating if untreated), newborn screening has been available for two generations, and dietary treatment has been considered for a long time as therapeutic and satisfactory.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 508
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32524084",
          "text": "Prospects for Cell-Directed Curative Therapy of Phenylketonuria (PKU).",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 70
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8828602",
          "text": "Classical phenylketonuria (PKU) is an autosomal recessive disorder caused by a deficiency of hepatic phenylalanine hydroxylase (PAH). Limitations of the current dietary treatment for PKU have led to the development of potential treatments based on somatic gene transfer. Three different vector systems have been examined.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 321
        }
      ],
      "ideal_answer": "Current approaches for gene therapy for Phenylketonuria (PKU) include the use of retroviral vectors and DNA/protein complexes, which have shown to efficiently transduce PAH-deficient hepatocytes in vitro but are limited by their low transduction efficiency in vivo. Somatic gene transfer is also being explored as a potential treatment.",
      "exact_answer": [
        [
          "retroviral vectors"
        ],
        [
          "DNA/protein complexes"
        ],
        [
          "somatic gene transfer"
        ]
      ]
    },
    {
      "id": "65d134bd1930410b13000037",
      "type": "factoid",
      "body": "What disease can be treated with Trofinetide?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37191913",
        "http://www.ncbi.nlm.nih.gov/pubmed/37291210",
        "http://www.ncbi.nlm.nih.gov/pubmed/37568516",
        "http://www.ncbi.nlm.nih.gov/pubmed/37635789",
        "http://www.ncbi.nlm.nih.gov/pubmed/28964591",
        "http://www.ncbi.nlm.nih.gov/pubmed/35149233",
        "http://www.ncbi.nlm.nih.gov/pubmed/38017349",
        "http://www.ncbi.nlm.nih.gov/pubmed/30918097",
        "http://www.ncbi.nlm.nih.gov/pubmed/38024580",
        "http://www.ncbi.nlm.nih.gov/pubmed/32660869"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38017349",
          "text": "BACKGROUND AND OBJECTIVE\nTrofinetide is the first drug to be approved for the treatment of Rett syndrome, a neurodevelopmental disorder.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 136
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37191913",
          "text": "Trofinetide (DAYBUE™), an oral, small molecule, synthetic analog of glycine-proline-glutamate [GPE; the N-terminal tripeptide derivative of insulin like growth factor-1 (IGF-1)], is being developed by Neuren Pharmaceuticals and Acadia Pharmaceuticals for the treatment of rare childhood neurodevelopmental disorders. Trofinetide was approved in March 2023 in the USA for the treatment of Rett syndrome in adult and pediatric patients 2 years of age and older. This article summarizes the milestones in the development of trofinetide leading to this first approval for Rett syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 582
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37191913",
          "text": "Trofinetide (DAYBUE™), an oral, small molecule, synthetic analog of glycine-proline-glutamate [GPE; the N-terminal tripeptide derivative of insulin like growth factor-1 (IGF-1)], is being developed by Neuren Pharmaceuticals and Acadia Pharmaceuticals for the treatment of rare childhood neurodevelopmental disorders. Trofinetide was approved in March 2023 in the USA for the treatment of Rett syndrome in adult and pediatric patients 2 years of age and older.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 459
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37291210",
          "text": "Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 75
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37191913",
          "text": "Trofinetide was approved in March 2023 in the USA for the treatment of Rett syndrome in adult and pediatric patients 2 years of age and older.",
          "beginSection": "abstract",
          "offsetInBeginSection": 317,
          "endSection": "abstract",
          "offsetInEndSection": 459
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37191913",
          "text": "Trofinetide was approved in March 2023 in the USA for the treatment of Rett syndrome in adult and pediatric patients 2 years of age and older. This article summarizes the milestones in the development of trofinetide leading to this first approval for Rett syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 317,
          "endSection": "abstract",
          "offsetInEndSection": 582
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37191913",
          "text": "Trofinetide (DAYBUE™), an oral, small molecule, synthetic analog of glycine-proline-glutamate [GPE; the N-terminal tripeptide derivative of insulin like growth factor-1 (IGF-1)], is being developed by Neuren Pharmaceuticals and Acadia Pharmaceuticals for the treatment of rare childhood neurodevelopmental disorders.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 316
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38017349",
          "text": "BACKGROUND AND OBJECTIVE\nTrofinetide is the first drug to be approved for the treatment of Rett syndrome, a neurodevelopmental disorder. The purpose of the study is to fully characterize the metabolic and excretion profiles of trofinetide in humans.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 249
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37291210",
          "text": "Trofinetide is a synthetic analog of glycine-proline-glutamate, the N-terminal tripeptide of the insulin-like growth factor 1 protein, and has demonstrated clinical benefit in phase 2 studies in Rett syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 62,
          "endSection": "abstract",
          "offsetInEndSection": 271
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37191913",
          "text": "Trofinetide: First Approval.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 28
        }
      ],
      "ideal_answer": "Rett syndrome.",
      "exact_answer": [
        "Rett syndrome"
      ]
    },
    {
      "id": "65f7789dc4010b4d78000034",
      "type": "factoid",
      "body": "Which is the most reliable liquid biopsy technique after complete resection of  colorectal cancer metastases?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32628360",
        "http://www.ncbi.nlm.nih.gov/pubmed/33667566",
        "http://www.ncbi.nlm.nih.gov/pubmed/19672932",
        "http://www.ncbi.nlm.nih.gov/pubmed/15997444",
        "http://www.ncbi.nlm.nih.gov/pubmed/22939863",
        "http://www.ncbi.nlm.nih.gov/pubmed/20544397",
        "http://www.ncbi.nlm.nih.gov/pubmed/29621772",
        "http://www.ncbi.nlm.nih.gov/pubmed/21443115",
        "http://www.ncbi.nlm.nih.gov/pubmed/7676517",
        "http://www.ncbi.nlm.nih.gov/pubmed/26007322"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33667566",
          "text": "BACKGROUND\nLiquid biopsies are increasingly tested in patients with colorectal cancer to assess tumor burden, response to therapy, and prognosis. The significance of liquid biopsy results after resection of colorectal liver metastases (CLMs) is not well-defined. STUDY DESIGN\nSixty-three patients undergoing CLM resection between 2016 and 2018 had plasma drawn postoperatively for liquid biopsy evaluation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 408
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33667566",
          "text": "BACKGROUND\nLiquid biopsies are increasingly tested in patients with colorectal cancer to assess tumor burden, response to therapy, and prognosis. The significance of liquid biopsy results after resection of colorectal liver metastases (CLMs) is not well-defined.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 262
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33667566",
          "text": "The significance of liquid biopsy results after resection of colorectal liver metastases (CLMs) is not well-defined. STUDY DESIGN\nSixty-three patients undergoing CLM resection between 2016 and 2018 had plasma drawn postoperatively for liquid biopsy evaluation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 146,
          "endSection": "abstract",
          "offsetInEndSection": 408
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33667566",
          "text": "The significance of liquid biopsy results after resection of colorectal liver metastases (CLMs) is not well-defined.",
          "beginSection": "abstract",
          "offsetInBeginSection": 146,
          "endSection": "abstract",
          "offsetInEndSection": 262
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15997444",
          "text": "CONCLUSION\nNeedle-track deposits are common after biopsy of suspected colorectal liver metastases. Biopsy of metastases confers poorer long-term survival on patients after liver resection and cannot be justified in patients with potentially resectable disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1057,
          "endSection": "abstract",
          "offsetInEndSection": 1317
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33667566",
          "text": "The significance of liquid biopsy results after resection of colorectal liver metastases (CLMs) is not well-defined. STUDY DESIGN\nSixty-three patients undergoing CLM resection between 2016 and 2018 had plasma drawn postoperatively for liquid biopsy evaluation. Next-generation sequencing analysis was performed to detect somatic mutations in 70 genes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 146,
          "endSection": "abstract",
          "offsetInEndSection": 499
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19672932",
          "text": "METHODS\nData on 113 patients who underwent R0 resection of pulmonary metastases from colorectal cancer were reviewed.",
          "beginSection": "abstract",
          "offsetInBeginSection": 292,
          "endSection": "abstract",
          "offsetInEndSection": 409
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33667566",
          "text": "Preliminary Analysis of Liquid Biopsy after Hepatectomy for Colorectal Liver Metastases.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 88
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15997444",
          "text": "5.5) per cent in group 1, compared with 46.7 (2.8) per cent in group 2 (P = 0.008). CONCLUSION\nNeedle-track deposits are common after biopsy of suspected colorectal liver metastases. Biopsy of metastases confers poorer long-term survival on patients after liver resection and cannot be justified in patients with potentially resectable disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 971,
          "endSection": "abstract",
          "offsetInEndSection": 1317
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19672932",
          "text": "METHODS\nData on 113 patients who underwent R0 resection of pulmonary metastases from colorectal cancer were reviewed. Overall median follow-up was 49 (range 1-140) months.",
          "beginSection": "abstract",
          "offsetInBeginSection": 292,
          "endSection": "abstract",
          "offsetInEndSection": 463
        }
      ],
      "ideal_answer": "Next-generation sequencing analysis of liquid biopsies is a reliable technique after complete resection of colorectal cancer metastases, as it can detect somatic mutations in 70 genes.",
      "exact_answer": [
        "next-generation sequencing analysis"
      ]
    },
    {
      "id": "65f59e46c4010b4d78000015",
      "type": "factoid",
      "body": "Where is the tumor of follicular infundibulum usually found?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26143173",
        "http://www.ncbi.nlm.nih.gov/pubmed/28550716",
        "http://www.ncbi.nlm.nih.gov/pubmed/25761672",
        "http://www.ncbi.nlm.nih.gov/pubmed/26170707",
        "http://www.ncbi.nlm.nih.gov/pubmed/11401679",
        "http://www.ncbi.nlm.nih.gov/pubmed/1769423",
        "http://www.ncbi.nlm.nih.gov/pubmed/30809409",
        "http://www.ncbi.nlm.nih.gov/pubmed/25387502",
        "http://www.ncbi.nlm.nih.gov/pubmed/9082365",
        "http://www.ncbi.nlm.nih.gov/pubmed/19377761"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30809409",
          "text": "Tumor of the follicular infundibulum or infundibuloma is a relatively rare benign adnexal tumor usually solitary and located in the head, neck, and trunk.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 154
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30809409",
          "text": "Tumor of the follicular infundibulum or infundibuloma is a relatively rare benign adnexal tumor usually solitary and located in the head, neck, and trunk. Here we present a 70-year-old woman with a tender vulvar lesion.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 219
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30809409",
          "text": "Tumor of the follicular infundibulum or infundibuloma is a relatively rare benign adnexal tumor usually solitary and located in the head, neck, and trunk. Here we present a 70-year-old woman with a tender vulvar lesion. Histopathologic exam shows a well-circumscribed lesion with a subepidermal horizontally oriented, plate-like proliferation of pale appearing squamous epithelial cells with numerous points of connections with the overlying epidermis and peripheral palisading.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 478
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25387502",
          "text": "Tumor of the follicular infundibulum is a rare benign cutaneous adnexal neoplasm with variable clinical presentation. In most cases the diagnosis is made with the help of histopathology, due to lack of a characteristic clinical presentation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 241
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1769423",
          "text": "Tumor of follicular infundibulum.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 33
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25387502",
          "text": "Tumor of the follicular infundibulum is a rare benign cutaneous adnexal neoplasm with variable clinical presentation. In most cases the diagnosis is made with the help of histopathology, due to lack of a characteristic clinical presentation. The most common form is a solitary lesion, but it can be multiple or eruptive, then called infundibulomatose.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 351
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25387502",
          "text": "Tumor of follicular infundibulum with unique features.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 54
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11401679",
          "text": "BACKGROUND\nTumor of the follicular infundibulum (TFI) is a relatively rare tumor which clinically presents as a solitary keratotic papule usually on the head and neck which on microscopic examination typically reveals a plate-like fenestrated epithelial tumor composed of pale staining cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 292
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19377761",
          "text": "Tumor of the follicular infundibulum is an uncommon cutaneous lesion with different forms of clinical presentation, namely solitary and multiple/eruptive variants.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 163
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19377761",
          "text": "Tumor of the follicular infundibulum is an uncommon cutaneous lesion with different forms of clinical presentation, namely solitary and multiple/eruptive variants. The former shows predilection for head and neck and presents as a papulonodular scaly tumor.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 256
        }
      ],
      "ideal_answer": "The tumor of follicular infundibulum is usually found in the head and neck.",
      "exact_answer": [
        "head"
      ]
    },
    {
      "id": "6616576afdcbea915f000050",
      "type": "summary",
      "body": "Mechanisms that explain irritable bowel syndrome.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28404070",
        "http://www.ncbi.nlm.nih.gov/pubmed/27159638",
        "http://www.ncbi.nlm.nih.gov/pubmed/21957758",
        "http://www.ncbi.nlm.nih.gov/pubmed/21537540",
        "http://www.ncbi.nlm.nih.gov/pubmed/1483881",
        "http://www.ncbi.nlm.nih.gov/pubmed/11284772",
        "http://www.ncbi.nlm.nih.gov/pubmed/16500602",
        "http://www.ncbi.nlm.nih.gov/pubmed/26155376",
        "http://www.ncbi.nlm.nih.gov/pubmed/23279011",
        "http://www.ncbi.nlm.nih.gov/pubmed/12182741"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28404070",
          "text": "Underlying mechanisms that could lead to irritable bowel syndrome include genetic factors (most notably an identified mutation of SCN5A); post-infectious changes, chronic infections and disturbances in the intestinal microbiota; low-grade mucosal inflammation, immune activation, and altered intestinal permeability; disordered bile salt metabolism (in 10-20% of cases with diarrhoea); abnormalities in serotonin metabolism; and alterations in brain function, which could be primary or secondary factors. Identical irritable bowel syndrome symptoms are probably due to different disease processes; grouping patients with this disorder into either diarrhoea-predominant or constipation-predominant subtypes promotes heterogeneity. An approach based on the underlying pathophysiology could help to develop therapies that target causes and ultimately provide a cure for patients with irritable bowel syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 626,
          "endSection": "abstract",
          "offsetInEndSection": 1532
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21957758",
          "text": "Irritable bowel syndrome is a frequent functional disorder of gastrointestinal tract.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 85
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1483881",
          "text": "Irritable bowel syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 25
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28404070",
          "text": "Pathophysiology of irritable bowel syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 44
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21957758",
          "text": "[Irritable bowel syndrome].",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 27
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28404070",
          "text": "Underlying mechanisms that could lead to irritable bowel syndrome include genetic factors (most notably an identified mutation of SCN5A); post-infectious changes, chronic infections and disturbances in the intestinal microbiota; low-grade mucosal inflammation, immune activation, and altered intestinal permeability; disordered bile salt metabolism (in 10-20% of cases with diarrhoea); abnormalities in serotonin metabolism; and alterations in brain function, which could be primary or secondary factors. Identical irritable bowel syndrome symptoms are probably due to different disease processes; grouping patients with this disorder into either diarrhoea-predominant or constipation-predominant subtypes promotes heterogeneity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 626,
          "endSection": "abstract",
          "offsetInEndSection": 1355
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1483881",
          "text": "The irritable bowel syndrome is a common disorder of gastrointestinal motility.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 79
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28404070",
          "text": "Underlying mechanisms that could lead to irritable bowel syndrome include genetic factors (most notably an identified mutation of SCN5A); post-infectious changes, chronic infections and disturbances in the intestinal microbiota; low-grade mucosal inflammation, immune activation, and altered intestinal permeability; disordered bile salt metabolism (in 10-20% of cases with diarrhoea); abnormalities in serotonin metabolism; and alterations in brain function, which could be primary or secondary factors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 626,
          "endSection": "abstract",
          "offsetInEndSection": 1130
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28404070",
          "text": "Underlying mechanisms that could lead to irritable bowel syndrome include genetic factors (most notably an identified mutation of SCN5A); post-infectious changes, chronic infections and disturbances in the intestinal microbiota; low-grade mucosal inflammation, immune activation, and altered intestinal permeability; disordered bile salt metabolism (in 10-20% of cases with diarrhoea); abnormalities in serotonin metabolism; and alterations in brain function, which could be primary or secondary factors",
          "beginSection": "abstract",
          "offsetInBeginSection": 626,
          "endSection": "abstract",
          "offsetInEndSection": 1129
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28404070",
          "text": "Traditionally, irritable bowel syndrome has been considered to be a disorder with no known underlying structural or biochemical explanation, but this concept is likely to be outdated.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 183
        }
      ],
      "ideal_answer": "",
      "exact_answer": "n/a"
    },
    {
      "id": "661d4c2eeac11fad3300001a",
      "type": "factoid",
      "body": "What is the cause of Rett Syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37408271",
        "http://www.ncbi.nlm.nih.gov/pubmed/2729788",
        "http://www.ncbi.nlm.nih.gov/pubmed/16225827",
        "http://www.ncbi.nlm.nih.gov/pubmed/2475669",
        "http://www.ncbi.nlm.nih.gov/pubmed/2133757",
        "http://www.ncbi.nlm.nih.gov/pubmed/12212921",
        "http://www.ncbi.nlm.nih.gov/pubmed/15070486",
        "http://www.ncbi.nlm.nih.gov/pubmed/8484399",
        "http://www.ncbi.nlm.nih.gov/pubmed/3434734",
        "http://www.ncbi.nlm.nih.gov/pubmed/23481597"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15070486",
          "text": "Rett syndrome, one of the leading causes of mental retardation and developmental regression in girls, is the first pervasive developmental disorder with a known genetic cause. The majority of cases of sporadic Rett syndrome are caused by mutations in the gene encoding methyl-CpG-binding protein 2 (MeCP2). MeCP2 binds methylated DNA and likely regulates gene expression and chromatin structure.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 395
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16225827",
          "text": "In 1999, mutations in the MECP2 gene were identified as the primary cause of Rett syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 91
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15070486",
          "text": "Rett syndrome, one of the leading causes of mental retardation and developmental regression in girls, is the first pervasive developmental disorder with a known genetic cause. The majority of cases of sporadic Rett syndrome are caused by mutations in the gene encoding methyl-CpG-binding protein 2 (MeCP2).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 306
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2133757",
          "text": "Rett syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 14
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2475669",
          "text": "Rett syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 14
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15070486",
          "text": "Rett syndrome, one of the leading causes of mental retardation and developmental regression in girls, is the first pervasive developmental disorder with a known genetic cause.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 175
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15070486",
          "text": "The majority of cases of sporadic Rett syndrome are caused by mutations in the gene encoding methyl-CpG-binding protein 2 (MeCP2).",
          "beginSection": "abstract",
          "offsetInBeginSection": 176,
          "endSection": "abstract",
          "offsetInEndSection": 306
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16225827",
          "text": "Molecular diagnosis of Rett syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 37
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2133757",
          "text": "Rett Syndrome is probably not an uncommon cause of severe progressive neurological disability in girls.",
          "beginSection": "abstract",
          "offsetInBeginSection": 462,
          "endSection": "abstract",
          "offsetInEndSection": 565
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2475669",
          "text": "Rett Syndrome is probably not an uncommon cause of severe progressive neurological disability in girls.",
          "beginSection": "abstract",
          "offsetInBeginSection": 462,
          "endSection": "abstract",
          "offsetInEndSection": 565
        }
      ],
      "ideal_answer": "Rett Syndrome is caused by mutations in the MECP2 gene.",
      "exact_answer": [
        "mutations in the MECP2 gene"
      ]
    }
  ]
}